Non-Communicable Disease Prevention by unknown
Non-communicable diseases (NCDs) are the leading cause of death worldwide, 
contribu� ng to over 73% of all deaths annually. Each day NCDs cause more than 100,000 
deaths, 80% of which occur in low- and middle-income countries. NCDs, however, are 
largely preventable, and a great deal of technical knowledge exists about how to prevent 
and manage them. Why, then, have we, as a global community, not been more successful 
at reducing this NCD burden? Does a universal problem not have a universal solu� on?
Created by an interna� onal consor� um of experts, this informa� ve and accessible book 
provides prac� cal guidelines, key learning points, and dynamic, real-world case studies 
to aid NCD program managers, policy offi  cers and decision-makers in low- and middle-
income countries, so that they can assess interven� ons for the preven� on and control of 
NCDs.
The book comprises ten chapters, which collec� vely explore the reasons behind, and 
strategies for, preven� ng and managing the NCD burden. It spans key themes such as 
poli� cal economy, the transferability of economic evidence, the role of cross-sectoral 
policies, the importance of delibera� ve processes, and health technology assessment.
NCD Preventi on is wri� en for the benefi t of the global health community, and is primarily 
targeted at those individuals who are involved in NCD programs. This book will also be of 
interest to NCD champions, policy advocates, and educators spearheading the movement 
for increased visiblity of NCDs.
As with all Open Book publica� ons, this en� re book is available to read for free on the 
publisher’s website. Printed and digital edi� ons, together with supplementary digital 
material, can also be found at  www.openbookpublishers.com
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The ultimate purpose of the Prince Mahidol Award Foundation under 
Royal Patronage, according to my interpretation, is to pursue the 
ideology of Prince Mahidol of Songkla in serving the benefit of mankind. 
The Foundation has three activities: the Prince Mahidol Award, the 
PMAC (Prince Mahidol Award Conference) and the Prince Mahidol 
Award Youth Program. The theme of PMAC 2019 was ‘The Political 
Economy of NCDs: A Whole of Society Approach’. The idea to publish 
this book, Non-communicable Disease Prevention: Best Buys, Wasted Buys 
and Contestable Buys, was proposed during the PMAC 2019 preparation 
meeting and has been partially funded by PMAC. 
PMAC is proud to have supported the development and dissemination 
of this book. In fact, it is more than just a book. We hope that it will 
be a collective learning tool for NCD managers and stakeholders, 
together with health economists or health intervention and technology 
assessment specialists. The ultimate goal of the learning process is ‘good 
health at reasonable cost’ with emphasis on NCDs. Taking a broader 
perspective, this learning process aims to help strengthen universal 
health coverage (UHC) schemes. 
NCDs and their root causes are very complex; addressing or 
preventing them is even more complex. A policy or intervention which 
is thought to be Best Buy can turn out to be Wasted Buy. Even when 
there is evidence of high cost-effectiveness in one country, when the 
intervention is transferred directly to another country, it can become a 
Wasted Buy. 
This is a book of evidence management and utilization in NCD 
prevention, which can be applied to the development of health 
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systems as a whole. The key proposal is the SEED Tool (Systematic 
thinking for Evidence-based and Efficient Decision-making). To me, 
it is a framework or conceptualization tool that can handle complex 
situations. The decision-making process proposed is not linear, but a 
learning loop to guide deliberation. The book helps the target audience 
scrutinize evidence, mainly cost-effectiveness analyses, to be applied in 
local contexts with involvement. 
PMAC is proud to present this high-quality commissioned work. We 
hope it will help to change the paradigm from communicable-disease-
oriented health systems to more NCD-oriented systems, which is a 
much more complex paradigm. 
Prof. Vicharn Panich 
Chairperson of PMAC International Organizing Committee
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Since 2007, the Prince Mahidol Award Conference (PMAC) has been 
organized as an annual international conference focusing on policy of 
global significance related to public health. For over a decade, PMAC 
has provided opportunities for debate, discussion and deliberation 
on priority global health policy and systems, and it has contributed 
to the exchange of knowledge and experience on global health 
between participants from across the world. In 2018, PMAC initiated 
commissioned work to provide a body of evidence to facilitate the 
sharing of experience at country level and among country and regional 
networks, in order to influence the implementation of global health 
and/or national policies and to enhance PMAC’s capacities to deliver its 
knowledge and experiences to a wider spectrum of people. 
Non-Communicable Disease Prevention: Best Buys, Wasted Buys and 
Contestable Buys is the first PMAC-commissioned work. This book 
provides evidence-informed insights to help understand which non-
communicable disease (NCD) interventions work and which don’t, 
so that program managers, policy officers and decision-makers in 
low- and middle-income countries (LMICs) can assess and implement 
interventions for the prevention and control of NCDs. It is a gold mine 
of very informative, easy to read and extremely helpful guidelines for 
those who wish to implement or reassess their strategies for preventing 
the NCD burden in their settings. 
Non-Communicable Disease Prevention will augment PMAC’s 
contribution in terms of changing health policy and improving health 
systems in different settings in relation to NCDs. It will continue the 
momentum of the PMAC 2019 theme on ‘The Political Economy of 
NCDs: A Whole of Society Approach’, enable the contributions from 
PMAC to reach a wider audience and sustain PMAC work into the 
future. This sharing of real-world case studies, practical guidelines and 
key learning points will truly benefit all relevant stakeholders and the 
global health community and help accelerate the global progress in 
NCD prevention and control. 
Prof. Churnrurtai Kanchanachitra 
PMAC Secretariat
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Demographic change, like climate change, proceeds slowly. National 
populations — starting from very different positions — exhibit a 
steady, usually predictable, but always slow increase in the number of 
individuals at older ages. The risks of stroke, heart disease, cancers and 
chronic respiratory illness increase sharply with age. Thus demography 
drives increases in incidence and mortality from these conditions. 
These changes — like the consequences of climate change — often 
remain below the threshold of visibility. Until they don’t. Almost all 
middle-income countries (and many low-income ones) have crossed 
a threshold where the major non-communicable diseases (NCDs) 
have become highly salient in public discourse and, more practically, 
in the budgetary demands on health systems. Yet only recently — in 
many countries — have the medical, public health and public policy 
communities begun to assess critically how best to respond to the 
inexorable rise in NCDs.
Thailand achieved unusually early success in reducing child 
mortality and infectious disease mortality more generally with one 
consequence being the aging of its population and concomitant rise 
in NCDs. Also unusually, Thailand invested early and substantially 
to create the analytic capacity to identify and develop approaches to 
NCD prevention and management. The Thai Health Ministry’s Health 
Intervention and Technology Assessment Programs (HITAP), as well 
as closely associated efforts at Mahidol University, have provided 
world leadership in developing and applying techniques of economic 
evaluation to help ensure that public money spent on health buys the 
greatest possible reduction in premature mortality and morbidity. 
This timely volume — Non-Communicable Disease Prevention: Best 
Buys, Wasted Buys and Contestable Buys — brings to a global audience a 
distillation of much of HITAP’s experience. An international editorial 
team was formed to match authors to topics. Then a broadly inclusive 
and iterative process of chapter development, described in Chapter 1, 
led to a volume that will become required reading for two important 
audiences: one concerned with implementation of strategies for NCD 
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control and, significantly, the community of economists and others 
seeking an up-to-date account of how best to apply economic methods 
in practice.
Three important characteristics contribute to making this book 
an unusually informative resource. First, the volume results from an 
extensive international collaboration of individuals and institutions. This 
collaboration enriches the book’s content and facilitates communication 
with diverse audiences. Second and closely related, the volume relies 
heavily on case studies to convey its main message — a total of fifty-
eight case studies from thirty countries. The case studies ground the 
lessons of the book in operational experience and should prove of 
particular salience to NCD program managers, an audience the volume 
particularly tries to reach. Finally, this book develops and present a 
practical guide to the assessment of intervention attractiveness — the 
‘Systemic thinking for Evidence-based and Efficient Decision-making 
(SEED)’ tool. SEED provides a valuable framework both for the book 
itself and for its application in practice.
It is not my purpose in this brief forword to overview this rich 
a volume. Nonetheless, I would like to touch on three points that 
resonated with my own experience working on the Disease Control 
Priorities (DCP) Project and, in particular, on issues that various 
iterations of DCP have had to deal with over many years.1 One concerns 
the quality and transferability of evidence. A second persistent issue 
concerns economic evaluation when an intervention has significant 
non-health consequences (what the volume’s authors call cross-
sectoral intervention). Third, the volume’s title points to consideration 
of Wasted Buys as well as Best Buys, a topic too often neglected in 
the literature. On each of these issues the authors provide valuable 
insights.
Two of the volume’s chapters discuss evidence: one focuses on the 
synthesis of evidence of varying degrees of quality; and another on 
transferring findings from one setting or population to another and 
perhaps to very different settings or populations. The volume concurs in 
the general observation that randomized-controlled trials (RCTs) provide 
the highest quality evidence, but it is equally insistent in pointing out 
1 Dean T. Jamison et al., Disease Control Priorities: Improving Health and Reducing 
Poverty (Washington, DC: World Bank, 2017), 3rd edition, IX.
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that an RCT must be supplemented by judgement about transferability 
if the results are to be applied outside of the original setting. ‘Hard’ 
evidence can become soft very quickly and the DCP approach has been 
to acknowledge the ever-present need for informed judgement about 
the relevance and transferability of evidence. The explicit objective 
of the DCP’s approach has been to balance concerns about accepting 
that an intervention is attractive when it is not — unfortunately the 
dominant concern of the medical community — with apprehension 
about rejecting an intervention that might be appropriate. The approach 
advocated in this book provides a welcome, systematic approach 
to facilitate judgement in this necessary search for balance. This 
approach can be applied equally to two other areas where judgement is 
required: evaluating the effect of a combined intervention (multi-drug 
approaches to secondary prevention of vascular disease, for example, 
when trials have been undertaken only on single-drug regimens); and 
deciding whether two different interventions (two health promotion 
campaigns or two anti-hypertensive drugs, for examples) can be viewed 
as essentially the same in terms of efficacy.
Reducing behavioral and environmental risk often involves action 
outside the health sector. Issuing and enforcing controls on air quality, 
for example, could result in significant reductions in mortality in 
many cities. Health ministries lack money and mandates to issue such 
regulations and, even if they did, there are likely to be significant 
benefits that derive from such investments that are unrelated to 
health. An economic evaluation of air quality regulation that relies 
on a standard incremental cost-effectiveness assessment — cost per 
death averted, say — will fail to capture all relevant benefits. On the 
other hand, an economic evaluation from the perspective of an energy 
ministry may simply neglect to consider health benefits. This book 
includes a thoughtful chapter on how to approach this problem within 
a cost-effectiveness framework. DCP authors assessing cross-sectoral 
intervention have tended either to report ‘dashboards’ of outcomes, 
without aggregation into a single figure of merit, or to use monetary 
metrics within a benefit-cost analysis (BCA) framework. I don’t see an 
approach that is obviously best (although I lean toward BCAs). This 
book very much contributes to the thinking on this topic and national 
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experience with the methods explained here will, over time, provide 
insight into what is practical and useful.
Separating economic evaluation from advocacy can prove difficult. 
Groups that work on immunization (or any other interventions you 
can name) often do so from a laudable commitment to the value of 
what they are doing. Likewise, because of their interest, these groups 
often commission or participate in economic evaluations. It requires no 
conscious bias to have results lean toward the favorable. Thus, this book’s 
explicit argument for the importance of also considering Wasted Buys is 
very much to be welcomed. My own experience in DCP was that asking 
authors to identify interventions of low priority met with little success. 
Most DCP authors — there were important exceptions — simply avoided 
doing this. It appears that the authors of this book experienced similar 
problems. They report that of the fifty-eight case studies received, forty-
seven were of Best Buys, seven were Contestable Buys and only four 
were Wasted Buys. This simply underscores this volume’s contribution 
to generating sustained and serious consideration of what not to do (or 
to do only later). The inclusion of Wasted Buys in the title of the book 
and in the analysis sends a good message.
******
Analysts often neglect the political economy of implementation. One 
could argue that there is a natural division of labor between analysis 
and the politics of implementation (and in the past I have so argued). 
This book takes the perspective that considerations of political economy 
need inclusion from the outset. It is reasonable to predict that this 
explicit approach will combine with the book’s analytic strength to give 
it enduring value.
Prof. Dean T. Jamison
Institute for Global Health Sciences 
University of California, San Francisco
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1. Introduction
Wanrudee Isaranuwatchai, Rachel A. Archer 
and Anthony J. Culyer
1.1 Non-Communicable Disease
Non-communicable diseases (NCDs) are the leading cause of death 
worldwide and contribute to over 73% of all deaths annually.1 Each day, 
NCDs cause more than 100,000 deaths; 80% of which occur in low- and 
middle-income countries (LMICs).2 Over the last 30 years, NCDs have 
replaced communicable diseases (CDs) as the cause of greatest health 
burden.3 This trend is evident in the risk factors for NCDs. According 
to the World Health Organization (WHO), obesity has tripled since 
1975;4 while the International Diabetes Federation estimates that the 
global prevalence of diabetes, 8.8% in 2017, will increase by 48% by 
2045, with an additional 204 million people living with diabetes.5 Much 
of this burden could be completely avoided because NCDs are largely 
preventable.6 Approximately 40% of all cancers and three-quarters 
1  Our World In Data, What Do People Die From?, 2018, https://ourworldindata.org/
what-does-the-world-die-from
2  World Health Organization, Non-communicable Diseases, 2018, https://www.who.
int/news-room/fact-sheets/detail/noncommunicable-diseases
3  Institute for Health Metrics and Evaluation, Global Burden of Disease (GBD), 2019, 
http://www.healthdata.org/gbd
4  World Health Organization Newsroom, Obesity and Overweight: Key Facts, 2018, 
https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
5  International Diabetes Federation, IDF Diabetes Atlas — 8th Edition, 2017, https://
diabetesatlas.org/resources/2017-atlas.html
6  World Health Organization, 10 Facts on Non-communicable Diseases, 2019, https://
www.who.int/features/factfiles/noncommunicable_diseases/facts/en/index4.html
© W. Isaranuwatchai, R. A. Archer and A. J. Culyer, CC BY 4.0  https://doi.org/10.11647/OBP.0195.01
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of the incidence of heart disease, stroke and type 2 diabetes could be 
prevented by addressing tobacco use, unhealthy diet, physical inactivity 
and harmful use of alcohol. A great deal of technical knowledge exists 
about how to prevent and manage NCDs, such as the WHO Package of 
Essential NCD interventions (WHO PEN),7 the SHAKE8 (the technical 
package for salt reduction) and HEARTS9 (the technical package for 
cardiovascular disease management in primary health care) packages. 
In addition to the NCD burden,10 there is an increasing demand on 
governments to address the health needs arising from NCDs through 
universal health coverage (UHC) policies, a direction that has been 
endorsed by the World Health Assembly11 and the United Nations 
General Assembly.12 NCDs are the result of various factors, for 
example genetic, physiological, and environmental and behavioral13 
individually or in combination. They frequently require a collective 
response. They are not contagious, unlike communicable or infectious 
diseases, which can be spread, directly or indirectly, from one person 
to another.14 CDs, accidents and injuries also often need collective 
actions (such as mass vaccination or health and safety legislation) for 
7  World Health Organization, Tools for Implementing WHO PEN (Package of Essential 
Non-communicable Disease Interventions), 2019, https://www.who.int/ncds/
management/pen_tools/en/
8  World Health Organization, The SHAKE Technical Package for Salt Reduction, 2016, 
https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.
pdf?sequence=1
9  World Health Organization, Hearts: Technical Package for Cardiovascular Disease 
Management in Primary Health Care., 2016, https://apps.who.int/iris/bitstream/han
dle/10665/252661/9789241511377-eng.pdf?sequence=1
10  David E. Bloom et al., From Burden to ‘Best Buys’: Reducing the Economic Impact of Non-
Communicable Diseases in Low-and Middle-Income Countries (Geneva, 2011), http://
apps.who.int/medicinedocs/documents/s18804en/s18804en.pdf; David E. Bloom et 
al., The Global Economic Burden of Non-communicable Diseases, World Economic Forum: 
World Economic Forum and the Harvard School of Public Health (Geneva, 2011).
11  World Health Organization, World Health Assembly Resolution WHA67.23: Health 
Intervention and Technology Assessment in Support of Universal Health Coverage (World 
Health Organization, 2014), http://apps.who.int/medicinedocs/en/m/abstract/
Js21463en/
12  United Nations General Assembly, United Nations General Assembly Resolution 
A/67/L.36: Global Health and Foreign Policy (United Nations, 2012), https://documents-
dds-ny.un.org/doc/UNDOC/LTD/N12/630/51/PDF/N1263051.pdf?OpenElement
13  World Health Organization, ‘Non-communicable Diseases: Key Facts 2018’, 2019, 
http://www.who.int/news-room/fact-sheets/detail/non-communicable-diseases
14  Mauricio L. Barreto et al., ‘Infectious Diseases Epidemiology’, Journal of Epidemiology 
and Community Health, 60 (2006), 192–95, http://dx.doi.org/10.1136/jech.2003.011593
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effective treatment but can also be treated effectively on an individual 
basis. There are noticeable patterns in prevalence and mortality 
between CDs and NCDs. Figures 1.1 and 1.2 show the prevalence and 
mortality of CDs and NCDs in high-income countries (HICs), LMICs 
and around the globe.15 CDs are prevalent (~70%) in HICs compared to 
~45% in LMICs (Fig. 1.1). NCDs are more prevalent in LMICs (~55%) 
compared to HICs (~30%). From the 37 years of data examined for 
Global Burden of Disease Study 2016, NCDs now dominate premature 
death.16 Over 80% of the world’s premature deaths are attributable to 
NCDs in LMICs.17 The probability of premature death from NCDs is 
almost four times higher in LMICs compared to HICs.18 
Fig. 1.1 Prevalence of CDs and NCDs by World Bank country income categories.19
15  Institute for Health Metrics and Evaluation, Global Health Data Exchange, 2016, 
http://ghdx.healthdata.org/
16  Ibid.
17  UN Interagency Task Force on NCDs, Working Together for Health and Development: 
Prevention and Control of Non-Communicable Diseases, 2017, https://www.who.int/
ncds/un-task-force/working-together-adaptation.pdf?ua=1
18  Ibid. 
19  World Health Organization, 10 Facts on Non-communicable Diseases.
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Fig. 1.2 Deaths from CDs and NCDs by World Bank country income categories.20
NCDs represent a significant burden through both an epidemiological 
and an economic lens.21 They affect everyone regardless of sex and age.22 
The four main NCDs are cardiovascular disease, chronic respiratory 
disease, cancer and diabetes, which account for over 80% of NCDs 
deaths.23 A macroeconomic simulation model suggested a cumulative 
loss of USD $47 trillion over the next 2 decades due to NCDs.24 The 
Disease Control Priorities 3rd edition (DCP3) estimated that the number 
of deaths averted through prevention in LMICs could be between 2 to 4.2 
million by 2030.25 Additionally, mental health problems are the leading 
20  Ibid.
21  Catherine P. Benziger et al., ‘The Global Burden of Disease Study and the 
Preventable Burden of NCD’, Global Heart, 11.4 (2016), 393–97, https://doi.
org/10.1016/j.gheart.2016.10.024
22  World Health Organization, ‘10 Facts on Non-communicable Diseases’, https://
www.who.int/features/factfiles/non-communicable_diseases/facts/en/index4.html
23  World Health Organization, ‘Non-communicable Diseases: Key Facts 2018’, 2019, 
http://www.who.int/news-room/fact-sheets/detail/non-communicable-diseases
24  Bloom et al., The Global Economic Burden of Non-communicable Diseases, World 
Economic Forum: World Economic Forum and the Harvard School of Public Health
25  Dean T. Jamison et al., ‘Universal Health Coverage and Intersectoral Action for 
Health: Key Messages from Disease Control Priorities’, The Lancet, 11.4 (2018), 
1108–20, https://doi.org/10.1016/S0140-6736(17)32906-9
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cause of disability around the world.26 For example, approximately 
800,000 people commit suicide every year and about 75% of those 
occur in LMICs.27 Mental health problems represent risk factors for 
other diseases such as cardiovascular diseases and diabetes including 
unintentional and intentional injury. There is significant inequity in the 
support (e.g., health services) for mental health around the world.
In an ideal world, it would be easy to prioritize interventions and 
allocate resources to have the maximum impact on health and its fair 
distribution, while simultaneously minimizing the risk to families of 
serious financial hardship from out-of-pocket payments. These are 
generally seen as the main concerns of cost-effectiveness analysis.
Systems are, however, faced with a diversity of investment options, 
inescapable limits on resources, evidence that is at best sporadic, many 
other political, financial and social constraints, and a host of other 
additional28 considerations; all of which make identifying good value-
for-money interventions challenging. The question naturally arises: why 
have we, the global community, not been more successful at reducing this 
NCD burden? Does a universal problem not have a universal solution? 
Is resource scarcity the fundamental culprit? Is cost-effectiveness really 
the answer? Are there better ways of using the resources that countries 
already have? Do countries have the essential human capital required 
to develop and roll out the right policies? Are there higher priorities for 
public spending against which the NCDs simply cannot compete? We 
try to answer these questions and make some suggestions for future 
actions in this book.
1.2 Best, Wasted and Contestable Buys
One response by the WHO to the NCD crisis was the idea of ‘Best Buys’. 
WHO defines Best Buys almost solely by their cost-effectiveness, that 
is, interventions which achieve best value for money in comparison 
to all comparators.29 More precisely, Best Buys for LMICs are 
26  World Health Organization, 10 Factors on Mental Health, 2019, https://www.who.
int/features/factfiles/mental_health/mental_health_facts/en/index1.html
27  Ibid.
28  See Chapter 4.
29  Bloom et al., From Burden to ‘Best Buys’: Reducing the Economic Impact of Non-
Communicable Diseases in Low-and Middle-Income Countries.
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interventions with an incremental cost-effectiveness ratio (ICER) under 
100 International United States dollars per disability-adjusted life-year 
(DALY) averted.30 
Some Wasted Buys are easy to define: they are interventions that 
have no beneficial effect. Others are slightly harder to specify, for they 
are interventions that do have a beneficial effect (with NCDs, the effect 
almost always lies in the more distant future) but ones that require too 
great a sacrifice of resources. That is, those resources would have a more 
beneficial effect used elsewhere on other health interventions or elsewhere 
in the economy. In other words, their opportunity cost is too high. 
We suggest the addition of the category ‘Contestable Buys’ when 
there are suggestions that an intervention and its associated attributes 
may be a Best Buy but there is no direct evidence of cost-effectiveness 
in the local setting in which the intervention might be implemented. 
Thus, interventions in the WHO’s Best Buys list may be better classed 
as Contestable Buys if there is no demonstrative evidence of cost-
effectiveness for the particular setting in question. The main distinction 
between Best and Contestable Buys is thus the availability of context-
specific evidence.
1.3 Definitions and Central Ideas
Box 1.1 contains the definitions of central ideas that are used throughout 
the book. The reader will find these definitions to vary slightly from 
the many that lie elsewhere in the literature, though we are confident 
that any differences are minor and more questions of emphasis than of 
substance. We — all the authors here represented — have sought to be 
consistent in the way we have used these terms. 
We refer frequently to ‘interventions’. This word is intended as an all-
embracing term to capture a package of care over a relevant time period as 
applied to a particular condition or combination of morbidities. It may be 
restorative, maintenance or preventive. It may be provided in part from a 
health service program and partly from another like childcare or primary 
education. This is especially significant in the field of NCDs, with which 
30  The DALY is one of several frequently met measures of the effectiveness of health 
care interventions. It stands for ‘Disability-Adjusted Life-Year’ where the Life-Year 
is a year of life gained and an adjustment is then made for the quality of life in terms 
of presence or absence of disabilities. A measure of health gain is therefore a DALY 
averted.
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this book is concerned. An intervention should not be seen as merely 
the purchase and use of a medicine, or any other single input, but rather 
as the planned or usual combination of human and physical resources 
required for the delivery of a service at a chosen standard. Some of these 
inputs may not be what we customarily think of as ‘healthcare’.
A critical starting point in determining the value of an intervention 
is its cost-effectiveness — if an analysis establishes empirical evidence 
of cost-effectiveness in the context of the location in which it is intended 
to be used, the intervention will be categorized as a ‘Best Buy’. If it 
establishes empirical evidence of its cost inefficiency, it will essentially 
be categorized as a ‘Wasted Buy’ or if it confers very little effectiveness, 
that is, the costs are not proportional to effectiveness, then it will again 
be categorized as a Wasted Buy.
Box 1.1 Definitions of Basic Terminology Used in 
Economic Evaluation
Economic evaluation is the comparative analysis of two or more 
alternatives in terms of their costs and outcomes. There are 
different types of economic evaluation, namely cost-benefit 
analysis, cost-minimization analysis, cost-utility analysis 
and cost-effectiveness analysis. They differ primarily in the 
measurement of consequences or outcome; however, each 
approach entails value judgements that should be explicitly 
considered in terms of their appropriateness in the decision 
context.
Cost-effectiveness analysis (CEA) is a form of economic evaluation 
that uses monetary units to measure/value costs and (usually) 
a single effect of interest that is common to the alternatives in 
consideration. The effect is measured in terms of clinical natural 
units (e.g., life-years gained). Often, cost-effectiveness analyses 
are interchangeable with cost-utility analysis that uses generic 
outcome measures such as the quality-adjusted life-year (QALY) 
or disability-adjusted life- year (DALY) instead of clinical natural 
effects. The advantage of the cost-utility analysis approach over 
cost-effectiveness analysis is that the former allows comparison 
of value in health investment between different health problems 
such as diabetes and mental health. 
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Disability-adjusted life-year (DALY) is a measure of overall 
disease burden, expressed as the total number of years of life 
lost due to ill-health, disability, or premature death. One DALY 
is equal to one year of healthy life lost.
Quality-adjusted life-year (QALY) is a measure of the state of 
health of a person or group, which is a function of the length 
and quality of life. One QALY is equal to one year of life in 
perfect health.
Incremental cost-effectiveness ratio (ICER) is calculated as the 
difference in cost between two possible interventions, divided 
by the difference in their outcomes. It is a standard measure 
representing marginal cost per marginal benefit from health 
investment. 
Health Technology Assessment (HTA) is a form of evaluation that 
includes CEA but goes beyond its categories by including non-
financial constraints and local environmental, organizational, 
social and political factors that may affect the costliness, 
effectiveness and feasibility of interventions.
Sources: adapted from Drummond et al., 2015 and Briggs et al., 2006.31
1.4 The Cost-Effectiveness Plane
31  Michael F Drummond et al., Methods for the Economic Evaluation of Health Care 
Programmes (Oxford: Oxford University Press, 2015); Andrew Briggs, Mark Sculpher 
and Karl Claxton, Decision Modelling for Health Economic Evaluation (Oxford: Oxford 
University Press, 2006).
These ideas are illustrated by what is called a Cost-Effectiveness Plane. 
In Fig. 1.3, the health effects of an intervention are measured in terms 
of lives saved, QALYs, DALYs averted, or other suitable indicators on 
the horizontal axis (positive effects to the right and negative ones to the 
left). Its relative costliness is shown by the vertical axis. A comparator 
intervention can be understood to be at the origin where the two axes 
cross, so the health gain and the cost are both relative to a comparator. 
The distances along the axes measure the difference between the 
intervention under investigation and the comparator. The slope of the 
dashed line labelled ‘threshold’ indicates the willingness of the payer 
(usually an insurer or the government) to pay for additional health 
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Fig. 1.3 Cost-effectiveness plane.
(ΔC/ΔE): the ICER. This threshold is also known as the cost-effectiveness 
threshold or willingness-to-pay (WTP) threshold and is expected to be 
different for each country setting.32 That being so, what is regarded as 
cost-effective will also differ according to country.
The area lying in quadrant D clearly identifies a Best Buy — the 
intervention is both more effective and less costly than a relevant 
comparator. The area lying in quadrant A is clearly a Wasted Buy. D and 
A are areas in which an intervention dominates or is dominated by the 
comparator in terms of cost-effectiveness and its position relative to the 
threshold. This analysis is a development of the approach taken by the 
Institute of Medicine’s (IOM) famous book Crossing the Quality Chasm.33 
In discussing efficiency as one of the six specific aims for improvement 
in health care, the book asserts that ‘the opposite of efficiency is waste, 
the use of resources without benefit to the patients a system is intended 
to help’.34
32  Hilary F. Ryder et al., ‘Decision Analysis and Cost-Effectiveness Analysis’, Seminars 
in Spine Surgery, 21.4 (2009), 216–22, https://doi.org/10.1053/j.semss.2009.08.003
33  Institute of Medicine (U.S.), Committee on Quality of Health Care in America: Crossing 
the Quality Chasm: A New Health System for the 21st Century (Washington, DC: 
National Academy Press, 2001).
34  Jaqueline Zinn and Ann Barry Flood, ‘Commentary: Slack Resources in Health 
Care Organizations-Fat to Be Trimmed or Muscle to Be Exercised?’, Health Services 
Research, 44.3 (2009), 812–20, https://doi.org/10.1111/j.1475-6773.2009.00970.x
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What of areas B and C? An intervention falling in B could be either 
a Best Buy or a Wasted Buy. In quadrant B, the intervention is more 
expensive but it is also more effective, so the question become whether 
the additional effectiveness is ‘worth’ the additional expense. Here, the 
dashed line comes into play because cost-effectiveness will depend on 
the maximum amount the payer is willing to spend for additional health 
outcomes. When the intervention is located above the dashed line, the 
additional or incremental cost (ΔC) exceeds the payer’s willingness to 
pay for the additional or incremental health (ΔE), and the intervention 
will be judged to be cost-ineffective by the payer and therefore a Wasted 
Buy. Conversely, an intervention falling below the threshold line will be 
deemed cost-effective and therefore a Best Buy.
Quadrant C brings up some counter-intuitive possibilities. In this 
quadrant, the intervention is definitely less effective than the comparator. 
However, it is also less costly. Again, whether it would be a Wasted Buy 
depends on whether the cost savings of using it sufficiently compensate 
for using this intervention rather than its more effective comparator. 
How can this be? Only if the cost savings, if realized, can be used to 
generate more health elsewhere. In quadrant B, the threshold line 
indicates the maximum willingness of the payer to pay for additional 
units of health. In quadrant C, the line indicates the minimum the payer 
is willing to accept to forgo a marginal health benefit. If the threshold 
genuinely indicates the payer’s judgment of value, then an intervention 
located below the dashed line will indicate a larger cost saving than 
the minimum indicated as acceptable by the dashed line. Paradoxically, 
then, a less effective intervention need not be a Wasted Buy — as long as 
it is also sufficiently cheaper than the comparator it will replace. It may 
even be a Best Buy!
Various techniques have been used to define thresholds. The three 
most popular methods35 are: 
• deriving the threshold from previous decisions or other 
jurisdictions, 
• the willingness to pay of the payer (‘demand-side method’), or
• value of displaced services (‘supply-side method’). 
35  Anthony J. Culyer, ‘Cost-Effectiveness Thresholds in Health Care: A Bookshelf 
Guide to Their Meaning and Use’, Health Economics, Policy and Law, 11.4 (2016), 
415–32, https://doi.org/10.1017/s1744133116000049 
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The latter two have gained popularity and are the most cited approaches. 
However, each has limitations. The demand-side approach requires the 
society’s or the government’s willingness to pay (WTP) for healthcare 
to determine the threshold that would guide expenditures from the 
healthcare budget accordingly. In most cases, society’s willingness to 
pay will be set explicitly or implicitly by the government. The chosen 
threshold will inevitably be controversial, so the methods used to 
determine it should be well-founded, clear and transparent. Where 
experts are consulted, they should be of appropriate distinction and 
independence. Calculating an aggregate social willingness to pay by 
asking citizens is also fraught with difficulties and can be controversial. 
The WHO previously adopted the approach of the first bullet in the 
list above. It generated a global threshold ratio taking the form that 
interventions costing less than three times the average per capita income 
per disability-adjusted life-years (DALY) averted were considered to be 
cost-effective and those exceeding this level were considered to be cost-
ineffective.36 Subsequently, there was an updated suggestion that the 
threshold could be between one to three Gross Domestic Product (GDP) 
per capita.37 This approach in both cases implicitly assumed that there 
is fixed relationship between GDP and the appropriate magnitude of 
expenditure on healthcare, despite this being a policy decision that can 
legitimately vary depending on local priorities. Context and additional 
considerations38 are matters that should be considered prior to the 
implementation of any threshold. A global threshold for all countries 
is an average (which may be generally too high or too low) but will 
rarely exactly fit the conditions in any particular country and may lead 
countries into committing themselves to merely Contestable Buys or, 
worse, to Wasted Buys.39 
The threshold, though potentially useful, is not itself a decision rule. 
It is only a guide. There may be circumstances under which a country 
36  Tessa-Tan-Torres Edejer et al., ‘Making Choices in Health: WHO Guide to Cost-
Effectiveness Analysis’, (Geneva: World Health Organization, 2003), https://www.
who.int/choice/publications/p_2003_generalised_cea.pdf
37  World Health Organization, World Health Organization, Cost-Effectiveness Thresholds, 
2012, http://www.who.int/choice/costs/CER_thresholds/en/index.html
38  See Chapter 4.
39  Melanie Y. Bertram et al., ‘Cost-Effectiveness Thresholds: Pros and Cons’, Bulletin 
of the World Health Organization, 94.12 (2016), 925–30, https://doi.org/10.2471/
blt.15.164418
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may rationally choose to admit interventions that have ICERs above 
the threshold or reject some that lie below it. For analyses that try to 
take account of factors other than cost-effectiveness in deciding whether 
an intervention is a Best Buy, one may turn to Health Technology 
Assessment (HTA).
Cost-saving and cost-effectiveness are not synonyms. Depending on 
the context, it is possible, especially in a highly resource-constrained 
setting, that a less expensive and slightly less effective strategy is 
preferable, and vice-versa; interventions that are expensive may be 
cost-effective if they result in significant health outcomes and the cost-
effectiveness threshold is sufficiently high. 
These, then, are the basic ideas around which this book is built. 
What initially seems clear, and even obvious, turns out to be complex, 
controversial and may require the tools of Health Technology Appraisal 
(HTA) rather than those of CEA alone.
1.5 The Story of This Book
The Prince Mahidol Award Conference (PMAC) was first convened in 
2007 and has continued annually since. This global health forum honors 
the memory of Prince Mahidol of Songkla, who dedicated his life’s 
work to advancing public health and medical practice in Thailand and 
is respectfully regarded as the Father of Modern Medicine and Public 
Health of Thailand. Further information about PMAC is available via 
this link: https://pmaconference.mahidol.ac.th/site.
At a preparatory meeting for PMAC 2019, the slow progress towards 
global NCD targets was a major topic for discussion, particularly 
how the inadequate implementation of effective NCD prevention 
interventions contributes to this failure. Dr. Yot Teerawattananon, the 
founding leader of the Health Intervention and Technology Assessment 
Program (HITAP), emphasized that inefficiency in healthcare hinders 
progress. Working in collaboration with the International Decision 
Support Initiative (iDSI) (https://www.idsihealth.org/), which is a 
network of priority-setting organizations, HITAP has found that low-
value health interventions are a significant contributor to wasteful 
spending in health. 
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With the financial support from PMAC, the Thai Health Promotion 
Foundation and iDSI, and in collaboration with several other global 
partners, HITAP developed a concept note for a practical guide to assist 
program managers in identifying good solutions (Best Buys) and avoid 
poor choices (Wasted Buys) for the prevention of NCDs. The concept 
note was accepted by the PMAC Scientific Committee in Tokyo in May 
2018 and the initiative ‘Non-Communicable Disease Prevention: Best 
Buys, Wasted Buys and Contestable Buys’ was born.
1.6 The Project and Its Output
The project brought together experts from various disciplines in health 
economics, health policy, political economy, public health practice and 
NCDs. HITAP, which served as the project’s secretariat, invited various 
organizations and individuals in its wider network to join the authorship 
team. In total, we have 20 authors from 14 organizations in 8 countries. 
Authors were assigned a chapter from the concept note according to 
their expertise; some chapters were co-authored by members of several 
organizations. The output was always conceived as something much 
more than a book. Our findings were to be disseminated through 
knowledge translation materials such as videos, blogs, animations and 
interactive seminars. The project aimed to create an evidence package 
to support health program managers when thinking about NCD 
prevention. The evidence package as finalized includes the printed 
book, the online book, online appendices (which include further 
details on the project, such as additional descriptions on methods), 
interview clips with policy-makers on the topic of NCD prevention, and 
a website.40 More details can be found on the project website: https://
www.buyitbestncd.health.
1.7 The Project Journey
An initial in-person meeting was held in August 2018 for 12 members of 
the project team. This meeting enabled the project team members to meet 
40  The printed, digital and online editions of this book, together with the online 
appendices, can be found on the Open Book Publishers website, https://www.
openbookpublishers.com/product/1113 
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one another and enabled the authors to present and receive comments 
on the outlines they had developed. Additionally, discussions prompted 
modifications to the form and structure of the book. 
It was recognized that the work needed to be relevant to the target 
audience of NCD managers, that it should be written in comprehensible 
language and that it should draw whenever possible on managers’ 
perceptions and experience. HITAP subsequently put out a call for 
LMIC-focused case studies on experiences of Best Buys, Wasted Buys 
or Contestable Buys in the prevention of NCDs. The call was circulated 
through various channels including: PMAC, iDSI, HTAsiaLink and 
WHO. In total, 58 case studies were received from thirty countries 
(https://www.buyitbestncd.health/about). Out of the fifty-eight cases 
submitted, forty-seven case studies that were deemed relevant were 
analyzed (see Chapter 4 on Best Buys). 
A second, two-day, in-person meeting was convened in November 
2019 with chapter leads, the editorial team, project organizers and 
observers. The preliminary drafts of the findings for  each chapter were 
circulated with authors beforehand and systematically discussed. The 
concept note originally had the title Best Buys, Wasted Buys and ‘Do-It-
Yourselves’ (DIYs) in NCD Prevention. The DIY term was dropped after 
much discussion, mainly because of its apparent endorsement of an 
individualistic approach to NCDs, and was replaced by ‘Contestable 
Buys’ to cover the many cases where Best and Wasted Buys could not be 
identified unambiguously. 
Our initial ideas and some draft chapters were presented in 
January 2019 at PMAC 2019 (http://pmac2019.com/site) through two 
side-meetings and one main parallel session. The first side-meeting 
took the form of a closed meeting where eighteen external reviewers 
commented on the work to date. A second side-meeting was convened 
privately for authors to discuss how best to move forward following 
the feedback received in the previous side-meeting. This discussion 
resulted in some changes to the proposed content structure of the book 
and a commitment as far as possible to draw on real-world cases to 
illustrate points of principle and their practical application. A main 
parallel session at PMAC 2019 was open to the entire conference. 
Lead authors presented their chapters for five minutes followed by 
interactive questions and answers. This session was the best attended 
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parallel session at PMAC 2019 and provided the basis for the final 
shape and content of the book.
After further draft revisions and editing, chapters and book were sent 
to ten experts for external review: each of the eight main chapters were 
assigned a reviewer, and two reviewers were entrusted with evaluating 
the book as a whole. After further revisions, the chapters were shared 
with the editorial team for final edits. 
1.8 Target Audience 
This book is written mainly with individuals who coordinate and/or 
have decision-making authority over NCD programs in mind. While 
their official job titles vary, we used the term ‘NCD program managers’ 
to encompass chronic disease or NCD managers, policy officers, project 
managers, scheme managers, implementers and evaluators operating in 
(non-)governmental organizations. Some of the common characteristics 
of the job roles and the managers’ working environments are as follows. 
They:
• work in (non-)governmental ‘NCD units’ or ‘sub units’ 
dedicated to one or more of the main diseases (cardiovascular 
disease, diabetes, chronic lung disease, cancers and mental 
health) under the NCD umbrella, or to NCD risk factors;
• implement NCD health plans to the community;
• operate at the national, provincial, district or local level; and/
or 
• work on the integration of NCDs into existing service delivery 
platforms.
The target audience of this book thus consists of individuals who work 
in spheres of implementation. The work is, however, also intended to 
aid NCD champions, policy advocates and educators who spearhead 
the movement for increased visibility of NCDs and a reduction in the 
occurrence of these diseases.

2. Non-Communicable Diseases,  
NCD Program Managers and the 
Politics of Progress
Sumithra Krishnamurthy Reddiar and Jesse B. Bump
2.1 Background 
Non-communicable diseases (NCDs) are a defining problem of the 
twenty-first century,1 with an estimated economic loss of 7 trillion 
US dollars (USD) and counting to low- and middle-income countries 
(LMICs) between 2011 and 2025.2 By 2020, NCDs are expected to cause 
seven out of every ten deaths in developing countries.3 This challenge 
raises many questions, including how to raise the priority of NCDs on 
national policy agendas, augment capacities and identify resources to 
overcome it. Over the last decade, international agreements and three 
high-level meetings on NCDs held by the United Nations (UN) General 
Assembly (in 2011, 2014 and 2018)4 have outlined the tolls NCDs 
1  Sara Glasgow and Ted Schrecker, ‘The Double Burden of Neoliberalism? Non-
communicable Disease Policies and the Global Political Economy of Risk’, Health 
and Place, 39 (2016), 204–11, https://doi.org/10.1016/j.healthplace.2016.04.003
2  World Health Organization and United Nations Development Programme, What 
Legislators Need to Know: Non-communicable Diseases, 2018, https://www.undp.org/
content/dam/undp/library/HIV-AIDS/NCDs/Legislators%20English.pdf
3  Samira Humaira Habib and Soma Saha, ‘Burden of Non-Communicable Disease: 
Global Overview’, Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 4.1 
(2010), 41–47, https://doi.org/10.1016/j.dsx.2008.04.005
4  World Health Organization, ‘United Nations High-Level Meeting on Non-
communicable Disease Prevention and Control’, 2011, https://www.who.int/
nmh/events/un_ncd_summit2011/en/; World Health Organization, ‘High-Level 
Meeting of the UN General Assembly to Undertake the Comprehensive Review 
and Assessment of the 2011 Political Declaration on NCDs’, 2014, https://www.
who.int/nmh/events/2014/high-level-unga/en/; World Health Organization, ‘Third 
© S. Reddiar and J. B. Bump, CC BY 4.0  https://doi.org/10.11647/OBP.0195.02
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take on individual and collective health outcomes and affirmed that 
preventing and controlling NCDs is essential to national, regional and 
global development. These political actions have been supported and 
reinforced by substantive technical guidance. For example, following the 
UN’s Political Declaration on NCDs in 2011, WHO developed a global 
monitoring framework5 and identified sixteen Best Buy interventions 
as part of the 2013 Global Action Plan for Prevention and Control of 
NCDs.6 UN Member States now also receive support to collect and 
analyze surveillance data on NCDs.7 
However, the continued rise of NCDs shows that increased political 
attention and knowledge of prevention strategies has yet to translate into 
effective policy implementation at national and local levels. For example, 
the cost-effectiveness of prevention has been demonstrated broadly, 
including in the WHO 2018 ‘Saving lives, spending less’ report.8 The 
United Nations Development Programme (UNDP), in collaboration with 
WHO, has also developed briefs on how multiple sectors can engage in the 
prevention of NCDs.9 Yet, NCDs receive less than 2% of all health funding 
globally,10 and less than 1% in LMICs.11 Additionally, as we explore in 
this chapter and has been shown in the Caribbean region,12 NCD funding 
United Nations High-Level Meeting on NCDs’, 2018, https://www.who.int/ncds/
governance/third-un-meeting/en/
5  World Health Organization, NCD Global Monitoring Framework, 2017, https://www.
who.int/nmh/global_monitoring_framework/en/
6  World Health Organization, Tackling NCDs: Best Buys, 2017, http://apps.who.int/
iris/bitstream/handle/10665/259232/WHO-NMH-NVI-17.9-eng.pdf?sequence=1
7  World Health Organization, STEPwise Approach to Surveillance (STEPS), 2019, 
https://www.who.int/ncds/surveillance/steps/en/
8  World Health Organization, Saving Lives, Spending Less: A Strategic Response to 
Non-communicable Diseases, 2018, https://apps.who.int/iris/bitstream/handle/10665/ 
272534/WHO-NMH-NVI-18.8-eng.pdf?ua=1
9  United Nations Development Programme, What Government Ministries Need to 
Know about Non-Communicable Diseases, 2019, https://www.undp.org/content/undp/
en/home/librarypage/hiv-aids/what-government-ministries-need-to-know-about-
non-communicable-diseases.html
10  World Health Organization, Non-communicable Diseases and Their Risk Factors, 2019, 
https://www.who.int/ncds/management/ncds-strategic-response/en/
11  World Health Organization, Saving Lives, Spending Less: A Strategic Response to Non-
communicable Diseases. 
12  W. Andy Knight and Dinah Hippolyte, Keeping NCDs as a Political Priority in 
the Caribbean: A Political Economy Analysis of Non-Communicable Disease Policy-
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has been concentrated on ensuring political commitment, as opposed 
to implementation activities. In part, this gap reflects the challenge of 
the many contextual factors that affect NCDs. Universally applicable 
solutions for NCDs are in short supply because these diseases and their 
related risk factors are strongly influenced by cultures, habits, lifestyles 
and other circumstances, which have an impact on the distribution of 
NCDs observed at local level. Implementing global recommendations 
also requires investment in data capture and management, governance 
structures, political buy-in and other capacities that may not be present 
in many settings. These contextual challenges impede efforts to advance 
NCD policy and action at national levels. Understanding the constellation 
of activities required to address NCDs, and then adapting them 
appropriately to address local circumstances, requires deft political and 
technical negotiation as well as action. 
In this chapter, we identify reasons why global policy 
recommendations to address NCDs have not translated easily into 
effective programs and action. We focus our research on the experiences 
of national NCD managers and their reflections on local capacity and 
challenges. NCD managers are typically located in a Ministry of Health 
and responsible for an NCD unit, with a mandate focused on NCDs. 
We reasoned that their position within ministries of health would 
give them insights into the institutional arrangements, interests and 
ideas involved in advancing or challenging NCD action. The chapter 
begins by presenting our methods, followed by an explanation of 
NCD units and the NCD manager position. We used the ‘Three-I’s’ 
framework (institutions, ideas and interests), to structure our findings 
and concluded with recommendations for NCD program managers and 
others for advancing progress against NCDs. 
2.2 Methods for Interviews and Analysis
We gathered data by conducting semi-structured interviews with 
national NCD managers, representatives from WHO and civil 
society organizations and urban-level implementers. The interview 
guide (available in the Online Appendix 2)13 was organized around 
three themes: priority-setting, work patterns and context. First, we 
asked about prioritization and allocation of resources for NCDs 
13 Available at https://hdl.handle.net/20.500.12434/09617d51
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(including staffing, money and political attention). Second, we 
elicited descriptions of how NCD managers and others in related 
positions work, including how they organized their own work and 
engaged other stakeholders within the Ministry of Health and other 
ministries, as well as patient groups and civil society groups. Third, 
we asked about successes achieved and challenges faced in order to 
gather information about factors and conditions that had influenced 
their outcomes. Throughout, we sought to understand how and why 
actions by NCD managers and units were (or were not) translated into 
NCD prevention and control. 
Informants were identified by several means. We consulted NCD 
experts at the Health Intervention and Technology Assessment Program 
(HITAP) of the Ministry of Public Health of Thailand. In connection 
with Chapter 4, HITAP had solicited case studies from NCD managers 
on Best Buys, Wasted Buys and Contestable Buys; we issued interview 
invitations to the authors of approximately one-quarter of the cases. We 
also networked with contacts at the Harvard T. H. Chan School of Public 
Health and WHO to reach other possible interviewees. 
In total, seventeen NCD experts agreed to an interview. We began 
each interview with an explanation of the project and pledged not to 
report personally identifying information without obtaining express 
permission. Of the interviewees, five were women and twelve were 
men. Eight were from the Asia/Pacific region (Bangladesh, Bhutan, 
China, Myanmar, Philippines (x2), Sri Lanka and Thailand); three 
from the Americas (Ecuador, Mexico and the Pan-American Health 
Organization regional office); three from Europe (Finland, Georgia and 
the WHO European Regional Office); and three from Africa (Ethiopia, 
Guinea and Kenya). Among our respondents were one NCD program 
implementer (Asia/Pacific region) and two who commented on regional 
considerations. A large majority (fourteen) of the interviewees were 
physicians. The others had backgrounds in health-related academia, 
consulting, or research positions. Fourteen interviews were carried out 
in English and three in Spanish. The interviews lasted for approximately 
twenty to forty minutes and were conducted via the internet and 
telephone. 
To structure our findings, we chose the 3-I’s framework: Institutions, 
Interests and Ideas. This analytical framework from the field of political 
science uses the 3-I’s to describe processes involved in public policy 
 212. NCD Program Managers and the Politics of Progress
development14. According to the framework, ‘Institutions’ represent the 
structures and norms that influence political behavior. These include 
issues of governance, mandates, mechanisms of accountability and 
hierarchical structures. We use the ‘Institutions’ category to describe and 
analyze the NCD unit structure, its position within national ministries 
of health and its relationships with other ministries and relevant 
stakeholders. The ‘Interests’ component represents stakeholders affected 
by the policies in question and their respective agendas. Taking account 
of interests also requires sensitivity to power dynamics among and 
between stakeholders, and the successes and failures the stakeholders 
may experience. For the purposes of this chapter, we interpret interests 
as incorporating the various sectors involved in NCD action, including 
those that are not formal health services, with their own particular 
influences and preoccupations. ‘Ideas’, lastly, represents evidence, 
knowledge and the values of all policy makers, stakeholders and the 
public. ‘Ideas’ also includes ways to represent NCD policies and global 
recommendations for the advancement of NCDs at national level.
2.3 Institutions: NCD Managers, NCD Units  
and Ministries of Health
We were told that NCD units (and also NCD Divisions or NCD 
Programs) are recent bodies in national ministries of health.15 Over 50% 
14  National Collaborating Centre for Health Public Policy, Understanding Policy 
Developments and Choices Through the ‘3-i’ Framework: Interests, Ideas, and Institutions, 
2014, http://www.ncchpp.ca/docs/2014_procpp_3iframework_en.pdf; N. Bashir 
and W. Ungar, The 3-I Framework: A Framework for Developing Policies Regarding 
Pharmacogenomics (PGx) Testing in Canada. Genome., 2015, https://tspace.library.
utoronto.ca/bitstream/1807/70678/1/gen-2015-0100.pdf
15  Interview 1, ‘Consultant, Ministry of Health, Asia-Pacific Region,’ Skype interview, 
29 November 2018; Interview 2, ‘Advisor, Ministry of Health, European Region,’ 
WhatsApp interview, 20 December 2018; Interview 3, ‘NCD Manager, Ministry 
of Health, African Region,’ WhatsApp interview, 18 December 2018; Interview 4, 
‘NCDs Program Advisor, Ministry of Health, African Region,’ Skype interview, 
18 December 2018; Interview 5, ‘NCD Program Manager, Ministry of Health, 
African Region,’ WhatsApp interview, 18 December 2018; Interview 6, ‘Former 
Director of Technical Support Body, Ministry of Health, Asia-Pacific Region,’ Skype 
interview, 24 January 2019; Interview 7, ‘Program Officer, Ministry of Health, 
Asia-Pacific,’ Skype interview, 8 March 2019; Interview 8, ‘Advisor for NCDs, 
Regional Organization,’ Skype interview, 12 March 2019; Interview 9, ‘Senior 
Official, Ministry of Health, Americas Region,’ Skype interview, 18 February 
2019; Interview 10, ‘Senior Official, Ministry of Health, Americas Region,’ Skype 
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of the NCD units and programs whose managers and representatives we 
interviewed had been established in the early 2010s,16 and all informants 
reported that attention to NCDs had increased in the past five to ten 
years in their countries. They cited various reasons for this, beginning 
with the rising NCD burdens brought on by aging populations and 
increased exposure to risk factors, noting that ‘risk factors are easier to 
identify and target [with vertical mechanisms]’.17 Tools, guidelines and 
frameworks produced over this period such as the Package of Essential 
NCD interventions (WHO PEN)18 and the STEPswise approach to 
surveillance (STEPs) surveys19 by WHO were also referenced as 
influential in increasing the attention paid to NCDs. On average, NCD 
managers had worked in their positions for close to nine years, with 
many having been appointed when the unit was established or shortly 
thereafter. The average number of employees in the NCD units or 
related programs in our sample was seventeen, with a range of nine to 
fifty (excluding front-line providers and implementers). All respondents 
reported having between one and three people working on NCDs at a 
managerial level. We were not able to learn exactly how this compares 
with the number of staff dedicated to communicable diseases, although 
our interviewees indicated that it was higher than for NCDs.
interview, 12 April 2019; Interview 11, ‘Officer, Multilateral Organization, Asia-
Pacific Region,’ in-person interview, 1 February 2019; Interview 12, ‘Former Officer, 
Multilateral Organization, Asia-Pacific Region,’ in-person interview, 1 February 
2019; Interview 13, ‘NCD Department Head, Ministry of Health, European Region,’ 
Skype interview, 12 April 2019; Interview 14, ‘Country Representative, Multilateral 
Organization, Asia-Pacific Region,’ Skype interview, 15 March 2019; Interview 15, 
‘NCD Division Director, Regional Organization,’ Skype interview, 15 March 2019; 
Interview 16, ‘NCD Program Coordinator, City-Level, Ministry of Health, Asia-
Pacific Region,’ Skype interview, 28 March 2019; Interview 17, ‘Senior Official, 
Ministry of Health, Asia-Pacific Region,’ Facebook Messenger interview, 8 May 
2019. 
16  Interview 1; Interview 3; Interview 4; Interview 5; Interview 7; Interview 8; 
Interview 9; Interview 10; Interview 15.
17  Interview 15.
18  World Health Organization, Tools for Implementing WHO PEN (Package of Essential 
Non-communicable Disease Interventions), 2019, https://www.who.int/ncds/
management/pen_tools/en/
19  World Health Organization, STEPwise Approach to Surveillance (STEPS).
Interviewees reported that ministries of health were generally 
organized in two broad divisions: one was responsible for public health 
and health promotion, and the other had a mandate for service delivery 
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Fig. 2.1 Ministry of Health Organization and consequences for NCD Units.
and disease control. In over 40% of our cases, the NCD units (inclusive 
of two NCD divisions, one national and one regional)20 were located 
in the service delivery and disease control division or directorates. In 
these cases, respondents explicitly noted that the NCD units did not 
oversee the management of risk factors, such as tobacco smoking, 
alcohol use and dietary improvement; these were instead addressed 
either in the Ministry’s health promotion or public health directorates, 
or in separate units. Two countries21 in our sample had no specific NCD 
units or program, three had NCD units or programs that sat in the 
disease prevention and control directorates,22 two sat in public health 
or prevention and promotion directorates23 and one division sat under 
20  Interview 3; Interview 5; Interview 6; Interview 8; Interview 11; Interview 12; 
Interview 14.
21  Interview 2; Interview 10.
22  Interview 4; Interview 9; Interview 16; Interview 17.
23  Interview 7; Interview 13.
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direct regional administration.24 As shown in Figure 2.1, the placement 
of the NCD unit inside a larger directorate has consequences for its 
influence — strong within the directorate but relatively limited in other 
directorates, which was also mentioned by interviewees in relation to 
authority over NCD risk factors and preventive action. 
We were told that the mandates of the NCD units were reflected in 
national NCD policies and action plans. These task NCD units with 
responsibility for diseases that vary according to the country that 
was reporting. Some NCDs were common to all countries, such as 
cardiovascular diseases, diabetes, hypertension and cancers. Others, for 
example, rheumatic disease,25 sickle cell disease26 and eye health,27 were 
mentioned in only one or two countries. Other cited NCDs addressed 
by the NCD units and national plans included chronic kidney disease,28 
mental health,29 neurological diseases,30 asthma,31 genetic diseases32 
and renal diseases.33 Interviewees also mentioned NCD policies 
encompassing elderly care,34 injury prevention,35 urgent care,36 palliative 
care37 and drug and substance abuse.38 Commenting on the breadth 
of NCDs covered, one manager suggested that ‘even the concept of 
“NCDs” is a problem […] it is not easy to understand […] it seems 
too large’.39 In turn, because of this large scope ‘the challenges [NCD 
managers] have [are] on coordination’.40 Figure 2.2 below summarizes 
the frequency with which particular NCDs were mentioned as a 
proportion of interviews in which they were cited.
24  Interview 15.
25  Interview 4.
26  Interview 5.
27  Interview 4; Interview 17.
28  Interview 1; Interview 4; Interview 7; Interview 8.
29  Interview 2; Interview 4; Interview 5; Interview 6; Interview 8; Interview 12; 
Interview 13; Interview 14; Interview 15; Interview 16; Interview 17.
30  Interview 4; Interview 14.
31  Interview 4; Interview 9; Interview 16.
32  Interview 15.
33  Interview 1; Interview 16.
34  Interview 3; Interview 16.
35  Interview 8; Interview 13; Interview 14; Interview 15; Interview 16.
36  Interview 14; Interview 15.
37  Interview 7.
38  Interview 17.
39  Interview 5.
40  Interview 5.
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Fig. 2.2 NCDs ranked by proportion of interviews in which they were mentioned.
Nearly 40% of respondents reported that cancers were dealt with 
differently from other NCDs.41 Reasons included the high funding 
demands for cancer and the need for stronger health system capacity 
to address cancer incidence. Respondents also noted that cancer 
management requires control over risk factors, such as air pollution, 
that cannot be addressed by NCD units or ministries of health alone, 
requiring the engagement and support of other ministries and 
stakeholders — the Ministry of Environment and polluting industries 
were cited, among others. 
The NCD units included in our sample were engaged in a broad set 
of activities, ranging from raising awareness about NCDs to designing 
NCD policies and programs. In nearly 90% of the country cases in our 
sample, NCD units were responsible for technical coordination, capacity 
41  Interview 3; Interview 7; Interview 9; Interview 10; Interview 14; Interview 17.
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building and training of health personnel, advocacy and awareness-
raising. Most respondents also described undertaking activities such 
as the creation of tools and recommendations for training front-line 
providers in provincial centers and integrating NCD screening into 
health services. Data collection and monitoring, through STEPS surveys, 
Burden of Disease Studies42 and Disease Control Priorities Project43 
(DCP3), were also cited as key responsibilities of nearly all NCD units in 
our sample. However, no national or regional NCD units were directly 
involved in implementation efforts, as these were responsibilities carried 
out by other stakeholders, including other ministries, local health 
officers and civil society organizations.44 Additionally, in most of the 
sampled countries, legislative processes precede the implementation of 
NCD efforts operationally and in priority. 
2.4 Interests: Stakeholders and Power
The complex multiple causal pathways of NCDs are influenced by 
many sectors beyond health care,45 including trade, agriculture and 
education, making multisectoral coordination especially important. All 
of our respondents recognized that, for NCD prevention in particular, 
approaches often fall outside the scope of ministries of health, with one 
interviewee reflecting that tobacco and alcohol industries ‘are tackled 
with the muscle of other institutions.’46 All respondents similarly 
emphasized the importance of multisectoral engagement and political 
buy-in for implementation efforts. Examples of stakeholders with whom 
NCD managers and units work, particularly for the implementation of 
NCD policy, include other national ministries, the private sector and 
42  Global Burden of Disease Collaborative Network, Global Burden of Disease Study 
2017 (Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 
2019), http://ghdx.healthdata.org/gbd-results-tool
43  Disease Control Priorities: Economic evaluation for health, DCP3, 2019, http://
dcp-3.org/
44  Interview 1; Interview 2; Interview 3; Interview 4; Interview 5; Interview 6; Interview 
7; Interview 8; Interview 9; Interview 10; Interview 11; Interview 12; Interview 13; 
Interview 14; Interview 15; Interview 17.
45  World Health Organization; Regional Office for the Eastern Mediterranean, 
Non-communicable Diseases, 2019, http://www.emro.who.int/noncommunicable-
diseases/publications/questions-and-answers-on-the-multisectoral-action-plan-to-
prevent-and-control-noncommunicable-diseases-in-the-region.html
46  Interview 3.
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civil society. Respondents also acknowledged receiving funding and 
technical support from international organizations such as WHO, NCD 
Alliance, Partners in Health, PATH (the global health nonprofit), the 
United States Agency for International Development (USAID), Japan 
International Cooperation Agency (JICA) and the World Bank. WHO 
was cited by all respondents as an active contributor to the advancement 
of NCDs in national policy agendas and as helping to raise awareness 
of NCD burdens. More than one-third of interviewees reported that 
their countries had adopted the WHO PEN47 and had begun at least 
partial implementation. The WHO’s recommendations on restrictions 
on tobacco and alcohol through the Framework Convention on Tobacco 
Control (FCTC)48 and the Global Strategy to Reduce the Harmful Use of 
Alcohol49 had also been considered, with nearly 60% of the countries in 
the sample having enacted legislation in at least one of these areas50 and 
the remaining countries working to do so. 
NCD managers and units engaged with vested stakeholders in 
several different ways across our sample countries, and no two countries 
reported having the same multi-stakeholder engagement model. Some 
respondents used roundtable discussions, focus groups and research 
collaborations. Nearly one-quarter of the respondents reported that 
NCD action in their countries was overseen by multisectoral committees 
in which authority and decision-making was rotated and shared among 
members;51 this structure was specifically cited for the oversight of key 
risk factors such as unhealthy diets and tobacco use. Two interviewees 
reported participating in parliamentary procedures including voting 
and proposing policy motions, with the Ministry of Health holding 
ultimate authority.52 Other examples of multi-stakeholder collaborations 
included working with the Road Safety Ministry to introduce alcohol 
47  Interview 5; Interview 7; Interview 11; Interview 12; Interview 16; Interview 17; 
World Health Organization, Tools for Implementing WHO PEN (Package of Essential 
Non-communicable Disease Interventions).
48  World Health Organization, Framework Convention on Tobacco Control, 2003, https://
apps.who.int/iris/bitstream/handle/10665/42811/9241591013.pdf?sequence=1
49  World Health Organization, Global Strategy to Reduce the Harmful Use of Alcohol. 
World Health Organization, 2010, https://apps.who.int/iris/handle/10665/44395
50  Interview 1; Interview 2; Interview 4; Interview 6; Interview 11; Interview 13; 
Interview 14; Interview 15; Interview 16, Interview 17.
51  Interview 2; Interview 6; Interview 10; Interview 13.
52  Interview 2; Interview 13.
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breathalyzers,53 the introduction of food labeling requirements with 
the Ministry of Agriculture,54 the promotion of physical activity and 
healthier diets with and in schools,55 and engaging with the media for 
mass health promotion campaigns.56 
In terms of institutional arrangements for action on NCDs, our 
respondents reported that decision-making authority usually sat with 
Ministers of Health or political leaders, stipulating that their role and units 
‘[have] little authority’,57 ‘are weak’58 and ‘are not in [a] strong position’.59 
Almost all of our interviewees suggested that political leaders were in 
charge of both funding allocation and priority-setting in national agendas; 
in these cases, NCDs were competing with other health priorities, and the 
Ministry of Health was competing with other ministries for attention and 
resources. As a result, NCD managers reported resorting to knowledge-
building and awareness-raising about NCDs, specifically targeted at 
politicians and Ministers of Health. Ultimately, NCD managers reported 
that the NCD units alone hold little authority or oversight over setting 
priorities or making decisions at a national level.
While our respondents recognized the importance of multi-
stakeholder engagement, it was cited as a challenge by nearly half of 
them. About 30% (five out of seventeen respondents) mentioned a 
lack of coordination of multi-stakeholder meetings and strategies,60 
and three managers suggested that NCD action appears daunting 
and/or confusing to non-experts.61 Some respondents suggested that 
further guidance and models could help improve multi-stakeholder 
engagement. 
2.5 Ideas: Evidence, Knowledge and Values
How countries engage in NCD action arguably reflects how NCDs 
are perceived in that setting. Some NCD managers noted that ‘ten 
53  Interview 7.
54  Interview 7; Interview 10; Interview 17.
55  Interview 1; Interview 2; Interview 5; Interview 9.
56  Interview 1; Interview 6; Interview 10; Interview 13.
57  Interview 6.
58  Interview 5.
59  Ibid. 
60  Interview 1; Interview 4; Interview 5; Interview 14; Interview 17.
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The decade of 2000–2010 was ‘marked by a rebellion against the 
neglect of the NCDs in the MDGs’,63 and our interviewees held a mixed 
assessment of how NCDs were currently being prioritized in their 
countries. Five respondents judged that NCDs were considered a low 
priority64 with one reporting that ‘NCDs don’t get the attention they 
deserve considering [the] deaths and morbidity they cause’.65 In contrast, 
six believed that their countries gave them high priority.66 Across our 
sample, prioritization among NCDs also varied; cardiovascular disease 
was cited as the top priority NCD by six interviewees.67 Within the 
NCD agenda, mental health,68 injury prevention,69 palliative care70 and 
kidney issues71 were reportedly gaining increasing attention. Some 
respondents underscored the poor attention given to chronic respiratory 
diseases.72 In dealing with NCDs at a broader level, seven respondents 
reported that service provision was, or should be, a higher priority than 
prevention.73 Service provision examples mentioned included coverage 
at district level, capacity building and training of service providers, 
drug procurement, early detection and integration of NCD services with 
primary care and universal health coverage and, as already reported, 
63  Interview 15.
64  Interview 3; Interview 4; Interview 5; Interview 13; Interview 16.
65  Interview 3.
66  Interview 1; Interview 2; Interview 7; Interview 9; Interview 10; Interview 17.
67  Interview 4; Interview 8; Interview 12; Interview 13; Interview 14; Interview 15.
68  Interview 2; Interview 4; Interview 6; Interview 8; Interview 12; Interview 13; 
Interview 14; Interview 15; Interview 16; Interview 17.
69  Interview 8; Interview 13; Interview 14; Interview 15; Interview 16.
70  Interview 7.
71  Interview 1; Interview 4; Interview 6; Interview 7; Interview 8.
72  Interview 9; Interview 14; Interview 15.
73  Interview 1; Interview 3; Interview 5; Interview 6; Interview 13; Interview 16; 
Interview 17.
years ago, we [at the national level] did not have any official interest 
in NCDs,’62 and that attention to risk factors preceded attention to the 
burden of NCDs, as evidenced by historical efforts. To illustrate the 
changes in attention to NCDs over the last few decades, we developed a 
timeline (Fig. 2.3) which highlights international agreements, data and 
monitoring methods and key milestones that were cited as particularly 
important by interviewees in achieving national NCD action from 
legislation to implementation.
62  Interview 5.
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service provision received larger budget allocations than prevention in 
nearly half the units in our sample. 
Regarding the prioritization of risk factors, all interviewees 
highlighted the importance of interventions to promote healthy diets 
and exercise. Efforts to promote diet and exercise included advertising,74 
taxation,75 and educational campaigns.76 One interviewee described 
an effort to establish outdoor gyms.77 Actions against tobacco and/or 
alcohol use were cited in nearly 65% of interviews,78 typically in relation 
to legislation and surveillance. Other risk factors mentioned were air 
pollution,79 chewing tobacco80 and salt consumption.81 Generally, 
action for salt reduction lags behind the more common measures for 
addressing alcohol and tobacco use. 
Interviewees described the importance of perception of NCDs in 
relation to the implementation and uptake of interventions. Factors 
affecting public perception cited by managers included the influence 
of politicians in two decision-making settings,82 social networks in 
five,83 and media in four.84 These factors reportedly influenced attitudes 
towards screening, healthier diets and health literacy. 
In nearly 60% of our interviews, concerns were expressed that the 
implementation of NCD action lacked buy-in from politicians and 
stakeholders,85 with some respondents suggesting that NCDs were 
‘not a real priority, only a priority on paper’.86 For example, seven 
interviewees mentioned problems in enforcing legislation.87 Although 
74  Interview 1; Interview 3; Interview 5; Interview 13; Interview 16; Interview 17.
75  Interview 2; Interview 6; Interview 9; Interview 10; Interview 11; Interview 17.
76  Interview 1; Interview 2; Interview 4; Interview 5; Interview 10.
77  Interview 7.
78  Interview 1; Interview 2; Interview 4; Interview 6; Interview 8; Interview 10; 
Interview 13; Interview 14; Interview 15; Interview 16; Interview 17.
79  Interview 2; Interview 4; Interview 9; Interview 13; Interview 14.
80  Interview 4; Interview 11.
81  Interview 4; Interview 6; Interview 7; Interview 8; Interview 11; Interview 13; 
Interview 14; Interview 16.
82  Interview 3; Interview 4.
83  Interview 1; Interview 2; Interview 5; Interview 7; Interview 13.
84  Interview 1; Interview 6; Interview 10; Interview 13.
85  Interview 2; Interview 3; Interview 4; Interview 5; Interview 6; Interview 9; 
Interview 14; Interview 15; Interview 16; Interview 17.
86  Interview 6.
87  Interview 3; Interview 4; Interview 5; Interview 6; Interview 12; Interview 15; 
Interview 17.
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all countries in our sample had cited the adoption of legislation for 
controlling tobacco and most other risk factors, four respondents88 noted 
that there had been limited follow-through, little or no enforcement and 
few dedicated human or financial resources. Other challenges that were 
mentioned as impeding action on NCDs included the inability to control 
the inflow and outflow of potentially harmful substances,89 and weak 
advocacy efforts.90 Six interviewees cited cultural and behavioral inertia 
as a challenge.91 This inertia was related in some cases to links between 
religious practices and carbohydrate consumption,92 perceptions of 
junk-food consumption as a sign of modernization and prosperity,93 or 
reliance on neighbors and family members for health information.94 It 
was also suggested that the delegation of responsibilities outside the 
NCD unit and Ministry of Health created challenges.
Reflections from respondents were mixed in terms of effective 
and successful implementation of Best Buys. This finding is relevant 
because Best Buy recommendations are predominantly focused on risk 
factor action, which underscores the focus on service delivery by NCD 
units and the challenges in relation to multisectoral coordination that 
have already been highlighted. While all respondents reported that 
the recommended alcohol and tobacco legislation was in place, only 
five respondents95 mentioned implementation of the salt consumption 
recommendation and a mere two96 mentioned vaccination against 
human papillomavirus. In one country, drug therapy and counselling 
services were reported to be available for individuals with diabetes, 
hypertension, or a history of heart attack or stroke.97 Smoke-free public 
spaces were cited by four interviewees,98 health information and 
warnings about tobacco by five,99 and bans on alcohol advertising and 
88  Interview 3; Interview 4; Interview 5; Interview 6.
89  Interview 2.
90  Interview 5; Interview 13.
91  Interview 1; Interview 4; Interview 5; Interview 9; Interview 13; Interview 14.
92  Interview 1.
93  Interview 5.
94  Interview 13.
95  Interview 4; Interview 6; Interview 7; Interview 11; Interview 17.
96  Interview 13; Interview 16.
97  Interview 16; Interview 17.
98  Interview 6; Interview 10; Interview 16; Interview 17.
99  Interview 6; Interview 10; Interview 12; Interview 16; Interview 17.
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restricted access to retail alcohol by two.100 Trans fats were cited by three 
respondents,101 but with no implementation. Mass-media campaigns 
relating to diet and physical activity were reported by six interviewees.102 
Some suggested that the implementation of Best Buys would benefit 
from detailed recommendations for implementation at the local level.103 
Five respondents also suggested that the Best Buys need to be more 
sensitive to context.104 Noting that ‘Best Buys are useful to define national 
priorities, but are not automatic’,105 some interviewees felt that Best Buys 
are too ‘broad’106 and should consider context-specific capacity and 
needs, especially as ‘what works in one country is not transferable’.107 
Respondents also cited other policies as Best Buys, such as the PEN108 and 
HEARTS109 (technical package for cardiovascular disease management in 
primary health care) packages, as well as school meals, though these are 
not officially designated as Best Buys by the WHO.110 
2.6 Discussion
Why have global recommendations and guidance on how to advance 
action on NCDs not been easily translated into improvements in local 
health outcomes? Understanding the reasons behind the generally 
reported difficulties involves examining institutional arrangements of 
NCD units within ministries, the varied interests of relevant stakeholders 
and the diverse ideas shaping perceptions of NCDs. Overall, our 
findings highlight many positive improvements in the recognition of 
NCDs in national agendas. The informants attributed this development 
to the combination of emphasis placed on NCDs by global bodies and 
100  Interview 6; Interview 13.
101  Interview 7; Interview 9; Interview 16.
102  Interview 1; Interview 5; Interview 6; Interview 10; Interview 13; Interview 16.
103  Interview 2; Interview 4; Interview 9; Interview 14; Interview 15.
104  Ibid.
105  Interview 9.
106  Ibid.
107  Interview 2.
108  World Health Organization, Tools for Implementing WHO PEN (Package of Essential 
Non-communicable Disease Interventions).
109  World Health Organization, Hearts: Technical Package for Cardiovascular Disease 
Management in Primary Health Care, 2016, https://apps.who.int/iris/bitstream/han
dle/10665/252661/9789241511377-eng.pdf?sequence=1
110  Interview 7; Interview 10; Interview 16; Interview 17.
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advocates, changes in population profiles and growing epidemiological 
evidence of the burden of NCDs. National developments, such as the 
establishment of NCD units, the adoption of frameworks and policies 
based on internationally determined good practices, and expanding 
efforts to collect data on NCDs, were increasingly evident. Furthermore, 
the types of NCD policies adopted by national governments were 
largely guided by global-level leadership from WHO. We see these 
developments as positive examples of global recommendations and 
stakeholders influencing local agendas and action on NCDs. However, 
according to NCD managers, many challenges remain, which expose 
the need for increasing the adaptability of global recommendations to 
local levels. 
The institutional arrangements of NCD units, like service provision 
divisions of ministries of health, may not be adequate for the 
adaptation and adoption of global recommendations. For example, 
many of these recommendations and guidelines, including Best Buy 
recommendations, address both service delivery and prevention, 
some aspects of which are outside the mandate of service providers. 
Moreover, NCDs tend not to have single-cause origins or etiologies and 
thus cannot be interrupted directly, as is possible with many infectious 
diseases.111 In some instances, the distinction between prevention and 
service delivery is not clear, as when addressing diabetes incidence and 
prevalence by promoting exercise,112 or cases in which chemotherapy 
is used preventively for certain cancers.113 Some institutional 
arrangements further limit how global recommendations can support 
the coordination of prevention efforts. Locating NCD units in service 
provision strengthens the service delivery components of NCD action. 
While useful, this structure can, however, separate NCD managers from 
the overall scope of multisectoral preventive efforts in their own views 
and the views of other stakeholders. 
111  Center for Disease Control, Overview of Non-communicable Diseases and Related Risk 
Factors, 2013, https://www.cdc.gov/globalhealth/healthprotection/fetp/training_
modules/new-8/Overview-of-NCDs_PPT_QA-RevCom_09112013.pdf
112  Igor P. Briazgounov, ‘The Role of Physical Activity in the Prevention and Treatment 
of Noncommunicable Diseases’, World Health Statistics Quarterly, 41.3–4 (1988), 
242–50.
113  Science Direct, Adjuvant Chemotherapy, 2017, https://www.sciencedirect.com/topics/
medicine-and-dentistry/adjuvant-chemotherapy
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The institutional mandates of NCD units often require engaging with 
a broad range of risk factors and activities. Global recommendations 
do not fully recognize the multitude of tasks that fall to NCD units. 
For example, the HEARTS114 and SHAKE technical package for salt 
reduction115 target individual diseases and risk factors; they do not 
include activities that address the overall mandates of NCD units. The 
heterogeneity (among countries) and diversity (within countries) of the 
challenges that contribute to NCDs make it difficult for global actors to 
promote consistently compelling messages and effective policies. 
Grouping all NCDs in one unit within a ministry contrasts starkly 
with the prevailing practice for addressing infectious diseases. A ministry 
generally comprises many units, some responsible for a single disease 
(such as malaria or tuberculosis) and some presiding over a group of 
related diseases (such as sexually transmitted infections). The breadth 
of diseases designated for the NCD unit creates operational challenges. 
One of our informants mentioned that ‘there’s a lot of debate about what 
NCDs are’,116 which we interpret to underscore the difficulty of developing 
technical competence and strategic partnerships across a large portfolio 
of NCDs, which vary from country to country. Furthermore, it generates 
challenges in the ways in which NCDs are perceived by stakeholders, 
potentially exacerbating confusion and frustration in the time-frame 
required to see results. Political influence and buy-in to address the 
full range of NCDs is also especially difficult, given the complexities 
involved and the inherent competing priorities. A similar challenge 
arises from trying to address an array of diseases without duplicating 
efforts, which could be particularly difficult for NCDs located within 
disease-prevention-and-control directorates. Finally, the funding and 
staffing allocations for NCD units were generally low, especially when 
compared with communicable disease units.
The difficulties engendered by the institutional arrangements and 
mandates of NCD units are underscored by a lack of evidence on 
114  World Health Organization, Hearts: Technical Package for Cardiovascular Disease 
Management in Primary Health Care.
115  World Health Organization, The SHAKE Technical Package for Salt Reduction, 2016, 
https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.
pdf?sequence=1
116  Interview 14.
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best practices for coordinating the interests of multiple stakeholders. 
Although we found it encouraging that all interviewees reported 
that NCD units work with various stakeholders on implementation, 
prevention and risk reduction, among other activities, the effectiveness 
of such engagements has not been well documented. One manager 
suggested that ‘the NCD community […] are not yet embracing health 
systems components’117 and others expressed a need for frameworks 
or other guidance on how to engage stakeholders successfully for 
coordinated action. Existing efforts, including available tools118 and 
documents,119 have not yet been widely mainstreamed nor have they 
been especially relevant in national settings. 
The diversity of stakeholders with whom NCD units sought to engage 
reflects the breadth of concerns and risk factors connected with NCDs. 
For a unit with just one, two, or three managerial positions, coordination 
across the full range of stakeholders for NCDs represents a monumental 
task. We identified a need for further research to develop guidance on 
organizing a bureaucracy for effective NCD action. This also highlights 
a gap in the existing global recommendations: identifying best practices 
for multi-stakeholder action to mainstream NCD action in recognition 
of the multiple demands NCD unit mandates have. 
Respondents also stated that there was nearly always a strong focus 
on upstream action, such as legislative efforts or the development of 
national strategies. Relatively little focus was placed on downstream 
activities such as multisectoral coordination, with one interviewee 
noting that ‘the solution is there, we just need to do it’.120 An 
emphasis on upstream action could possibly be interpreted as a weak 
commitment to NCDs—after all, implementation is typically more 
resource-intensive than policy making. It could also indicate that the 
international guidelines and frameworks have focused too much on 
securing mandates rather than on supporting operational activities, 
which is underscored by one of our respondents reflecting that ‘the time 
117  Interview 14.
118  World Health Organization, Toolkit for Developing, Implementing and Evaluation the 
National Multisectoral Action Plan (MAP) for NCD Prevention and Control, 2019, http://
apps.who.int/nmh/ncd-map-toolkit/index.html
119  World Health Organization, Approaches to Establishing Country-Level Multisectoral 
Coordination Mechanisms for the Prevention and Control of Non-communicable Diseases’, 
2015.
120  Interview 1.
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is now for implementation, not further standards and norm-setting’.121 
This is also reflected in our interviewees frequently discussing Best 
Buy recommendations in relation to legislative efforts with relatively 
low enforcement capacity. Poor enforcement of policies may result 
from a lack of focus on operational aspects or capacity, resulting in a 
lack of designated responsibility and corresponding accountability for 
implementation and enforcement. If the consequences of not enforcing 
a policy, including a lack of clarity about who is responsible, have not 
been clearly outlined, policies will not be effectively implemented. 
Ultimately, NCD managers might, in addition to their current roles, 
also be forced to take on responsibility for enforcement. Alternatively, 
they could develop strong liaisons with those delegated to implement 
in order to ensure buy-in and attention to NCD action. Incidentally, 
these interviewees reminded us that beyond the FCTC,122 global action 
against commercial and environmental determinants of health has, as 
of yet, been modest.
Finally, the interviews revealed clearly that, while international 
advocacy and recommendations have successfully raised the level of 
attention given to NCDs in at least some countries, ‘the challenge has 
now reduced itself to implementation, [requiring] a different set of 
skills’123 to assist countries in contextualizing recommended approaches 
and adapting priorities to their specific needs. A major obstacle to such 
downstream actions was the limited knowledge and engagement that 
national political leaders demonstrated in relation to NCDs, as well 
as general ideas and perceptions of NCDs among government and 
population as a whole. To a large extent, global movements, rather than 
domestic advocacy, promoted NCDs within national policy agendas. 
Limited implementation of NCD policies at national level could also be 
interpreted as an indication of a disconnect between global and local 
perceptions of NCDs. NCD units and other advocates for NCD action 
need to build domestic support more systematically, including by 
educating national and local politicians. Additionally, the WHO should 
consider developing regionally contextualized recommendations that 
are easier for countries to use and adapt. 
121  Interview 15.
122  World Health Organization, Framework Convention on Tobacco Control. 
123  Interview 14.
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2.7 Limitations
The research that informed this chapter had several limitations. First, 
despite extensive efforts over eight months to recruit interviewees, we 
received fewer positive responses than we wanted. A larger sample 
could have generated more, and more generalizable, conclusions. 
Second, although the interviewees represented a variety of countries 
and regions, the sample was skewed towards Asia, which made regional 
comparisons difficult. Third, the breadth and diversity of NCDs and 
settings encompassed in the interviews made it hard to investigate 
specific themes consistently. Fourth, the interview guide and the time 
allocated for interviews allowed for a high-level exploratory approach, 
as distinct from an exhaustive study of NCD efforts in the countries 
in our sample. Fifth, our interviews were not always conducted in the 
interviewees’ first languages. This may have resulted in some confusion 
and limited the nuances of some responses. Finally, low-quality internet 
connections made some interviews especially difficult.
2.8 Conclusions and Recommendations
NCDs remain a key health-system challenge for virtually every 
country in the world.124 Global NCD recommendations are rarely 
directly relevant and applicable to local settings. NCD units in national 
ministries of health face challenges in adopting and adapting global 
best practices to advance NCD action. These challenges arise from the 
mandates given to and institutional arrangements made for the units, 
the necessity of engaging with relevant stakeholders with diverse ideas 
and the difficulties inherent in prioritizing NCDs in relation to other 
national health and development plans. Nevertheless, encouraging 
developments are evident, particularly in the form of national legislation 
and other upstream actions. The WHO also has an important presence 
in local settings. 
In our interviews with national NCD managers and similar actors, 
two needs were clearly revealed: first, support for stronger action 
124  Ala Alawan, The NCD Challenge: Progress in Responding to the Global NCD Challenge 
and the Way Forward, 2017, https://www.who.int/nmh/events/2017/discussion-
paper-for-the-ncd-who-meeting-final.pdf
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downstream from the NCD unit; and second, improved frameworks 
for multi-stakeholder engagement and multisector coordination efforts. 
The implementation challenges reported by NCD managers revealed 
that additional leadership, resources and innovation were required. 
Meeting some of these needs lies beyond the remit and authority of 
either the NCD managers or ministries of health, outlining the ongoing 
role of global institutions and non-governmental organizations. 
We propose three action points, based on our findings and analysis, 
that could support the translation of global NCD recommendations into 
better NCD outcomes at the local level:
• Expand global support for engaging political leadership 
in NCD agendas. NCD managers reported that the limited 
knowledge and engagement among senior political leaders 
was a major obstacle to prioritizing action on NCDs. We 
recommend developing advocacy guidance and materials 
for use by NCD managers. Technical experts, such as NCD 
managers, need simplified tools for educating and discussing 
key NCDs and related policies with potential advocacy 
partners (such as professional associations, patient groups 
and influential individuals who have personal experience 
with an NCD). Additionally, global institutions should use 
their access to senior politicians to create opportunities to 
conduct joint outreach and advocacy efforts. We recommend 
that global NCD advocates and experts collaborate with health 
ministers and NCD managers to identify one or more NCDs 
to emphasize and generate interest and action for relevant 
policies and programs.
• Expand the managerial and institutional structures 
responsible for NCDs to reflect operational requirements 
and realities. Most NCD units are not fully equipped or 
resourced to take on the complete range of NCDs and 
relevant activities. The placement of NCD units in either the 
public health or the service delivery division of the Ministry 
of Health represents a serious limitation. Even the attempt 
to narrow the programmatic approaches to pragmatic 
dimensions by identifying Best Buys still leaves NCD units 
with an extraordinarily wide range of activities to oversee. We 
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recommend that NCD units, ministries and global institutions 
consider expanding or creating parallel managerial structures 
aligned with the capacities needed to execute NCD programs. 
Alternatively, a simplification of the mandates of NCD units 
to target country-specific needs could facilitate managerial 
structures. 
• Generate effective guidance and support to stimulate 
multisectoral coordination, collaboration and action. The 
NCD unit has little control or authority over the causes of 
and contributors to the vast majority of NCD risk factors. 
Although ‘multisectoral action’ has become a prominent 
buzzword of late, our interviews revealed that NCD managers 
neither had guidance on how to do it nor knew with precision 
what it was. However, NCD units are a natural focal point for 
discussing many multisectoral issues, such as tax policies for 
discouraging tobacco, alcohol and other harmful substances, 
and environmental protections to improve nutrition 
and food security. We recommend that NCD managers 
immediately begin pursuing informal relationships to foster 
such discussions, while global institutions develop specific, 
actionable and context-sensitive guidance for NCD managers 
on this topic.
3. Framework for Implementing  
Best Buys and Avoiding Wasted Buys
Yot Teerawattananon, Alia Luz, Manushi Sharma  
and Waranya Rattanavipapong
Best Buys and Wasted Buys are two sides of the same coin. If every 
healthcare system invested only in Best Buys, then Wasted Buys are 
automatically avoided. Therefore, if we understand the features of 
Best Buys, it is straightforward to understand the etiology of Wasted 
Buys. Best Buy policies are normally based on good intentions, rigorous 
evidence and efficient management and coordination; by contrast, 
Wasted Buy policies tend to be formulated with a weak rationale or 
self-interested motivation, absent or poor-quality evidence, inadequate 
management and weak coordination. Having a framework of step-by-
step practical considerations to implementing Best Buys and avoiding 
Wasted Buys is consequently to have something of value. With this in 
mind, we propose the SEED Tool (Systematic thinking for Evidence-
based and Efficient Decision-making) as shown in Figure 3.1. 
The SEED Tool can be understood broadly in two parts: the 
inner circle and outer boxes. The inner circle is a set of fundamental 
questions that NCD policy managers and/or other decision-makers 
ought to ask themselves. NCD policy managers can increase the 
likelihood of implementing Best Buys and avoiding Wasted Buys if 
they systematically take account of each of these considerations. Each is 
numbered in a normative logical order. Interventions should ideally be 
assessed sequentially in the following order: sound theoretical basis (1), 
good quality evidence (2), transferability to the implementation setting 
(3), reasonable cost (4) and sufficient political investment (5). In practice, 
© Chapter’s authors, CC BY 4.0  https://doi.org/10.11647/OBP.0195.03
42 Non-Communicable Disease Prevention
however, NCD policy managers may order them differently, depending 
on their local and political contexts (e.g., starting from five, continuing 
on to three and then two, etc.). Provided that there are affirmative 
answers to each consideration, different orderings can still result in a 
Best Buy. To support this, the outer semi-circle has recommendations 
on how to incorporate and/or improve evidence support for each of 
the major considerations. It is important to note that this tool requires 
political commitment to using evidence for decision-making, which 
is separate from the political commitment to the intervention under 
scrutiny (see Consideration 5).
3.1 Consideration One 
The first step questions the rationale or the theoretical background for 
the implementation of the intervention. Unlike curative interventions, 
where the effect can be observed early, NCD prevention interventions, 
as with most health-promotion and disease-prevention programs, have 
indirect effects on disease burdens. They aim to reduce health risks 
and therefore need a longer timeline to have any measurable impact 
on disease prevention. If programs do not use tested theories, they 
may not produce the desired improvements in health.1 The strongest 
preventative programs have a clear conceptual basis that is built on good 
evidence. They guide the actual process of planning, implementation 
and evaluation. Understanding the purpose, history, constructs and 
context of the situation helps in selecting the most appropriate theory 
to guide the program. Preventive interventions also generally require 
commitment from individuals. For example, a mass media campaign 
to reduce obesity through healthy eating will be effective only if the 
target population understands and is responsive to the message. 
Governments can only promote the message but are unable to police 
healthy eating in the target population. As such, these policies require 
cultural understanding and should ideally be based on repeated proven 
experience in the field. This may involve a qualitative rather than a 
quantitative judgement but should nonetheless be one for which there 
is persuasive evidence.
1  Carl I. Fertman and Diane D. Allensworth, Health Promotion Programs — From 
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3.2 Consideration Two
The second question underlines the need to have good-quality evidence 
on the effectiveness of any intervention. It is highly desirable that the 
evidence on intervention efficacy/effectiveness2 should have been 
tested on the same (or at least very similar) population groups with 
the same dosage, frequency and other clinical and implementation 
characteristics — this homogeneity can reduce the risk of bias. There are 
many excellent appraisal tools for determining the quality of evidence. 
They are highlighted in an online resource called Enhancing the QUAlity 
and Transparency of Healthcare Research (EQUATOR) Network.3 
This online resource recommends different quality appraisal tools for 
different type of research. These include: the Consolidated Standards 
of Reporting Trials (CONSORT) for randomized control trials; the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA); the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE); and the Consolidated Health Economic 
Evaluation Standards (CHEERS). 
Alternatively, the quality of evidence on intervention effectiveness 
could be evaluated based on the hierarchy of evidence, which ranks 
different types of studies according to their ‘academic rigor’ (see Fig. 3.2 
below and Chapter 7). In this pyramid, the evidence is strongest (lowest 
potential bias) for systematic reviews and meta-analyses of randomized 
control trials, followed by randomized control trials, cohort studies, 
case control studies and case series/reports (and some pyramids also 
include expert opinion below these other study designs). This hierarchy 
of evidence exists in various forms in the literature even though most 
of them have the same general format, with the validity and strength 
of the evidence based on the risk of bias (also called internal validity).4 
While it is helpful to use the hierarchy of evidence, it has limitations in 
2  Efficacy = intervention performance under ideal and controlled circumstances; 
effectiveness = intervention performance under ‘real-world’ conditions.
3  Enhancing the QUAlity and Transparency Of Health Research (EQUATOR) 
Network, The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement: Guidelines for Reporting Observational Studies, 2019, http://
www.equator-network.org/reporting-guidelines/strobe/
4  Health Intervention and Technology Assessment Program (HITAP), Guide to Health 
Economic Analysis and Research (GEAR) Online Resource: Guidelines Comparison, 2019, 
http://www.gear4health.com/gear/health-economic-evaluation-guidelines
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application, especially in LMICs where there is often a lack of quality 
data or resources to conduct more rigorous study designs. 
Fig. 3.2 Hierarchy of evidence. Source: Modified from New Evidence Pyramid.5
3.3 Consideration Three 
The third question explores whether the studies’ results can be applied to 
the population of interest and whether the intervention can be transferred 
to other settings (also called the external validity of the studies). This 
consideration requires examination of the external or contextual factors 
that may alter the effect of the intervention from the studies’ settings to 
the implementation setting. This point is important since many countries 
(especially LMICs with limited resources for research) use evidence from 
other countries. An intervention with strong evidence from high-income 
countries might have less of an effect in more resource-constrained 
countries due to different population characteristics or a lack of supportive 
5  M. Hassan Murad et al., ‘New Evidence Pyramid’, Evidence Based Medicine, 21.4 
(2016), 125–27, https://doi.org/10.1136/ebmed-2016-110401; Health Intervention 
and Technology Assessment Program (HITAP).
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factors (e.g., infrastructure or social norms). Even transferring the study 
results of an intervention within a country with vastly different regional 
contexts, such as applying the results of studies set in urban areas to 
sparsely populated remote areas, can change the intervention effect 
drastically. The local context, including environmental factors, should 
therefore always be considered for any studies used for policy-making. 
NCD managers and policymakers ought to scrutinize the evidence with 
professional care and ensure that the evidence is reasonably transferable 
to their context. If this is not the case, then investing in additional measures 
to address the potential changes in effect, such as training sessions, 
incentive structures, communications campaigns and awareness raising, 
should be considered. 
3.4 Consideration Four
The fourth question addresses issues related to the cost of the 
intervention and its budget impact, i.e., cost-effectiveness, affordability 
and other cost outcomes. When considering a policy, especially 
preventive interventions where the health harvest is reaped in the 
future, NCD managers and decision-makers are confronted with higher 
early healthcare spending from the date of implementation onwards, 
whereas beneficial health outcomes will come later. Potential Best Buy 
interventions could be therefore be excluded from the NCD program. 
In this case, NCD managers should also consider how best to achieve 
the intervention within the budgetary constraints of the government 
or health provider; and, specifically to explore whether there are 
modifiable factors contributing to the high cost of the intervention, 
such as whether additional capital investment and human resource 
training will be needed and how they could affect the overall cost or the 
affordability. Governments, with the benefit of information provided 
from costing, cost-effectiveness, feasibility and budget impact studies 
can identify such factors, evaluate the long-term costs and benefits 
of the intervention and act to reduce the costs, thereby making them 
affordable and increasing the likelihood of a Best Buy.6
6  Adun Mohara et al., ‘Using Health Technology Assessment for Informing Coverage 
Decisions in Thailand’, Journal of Comparative Effectiveness Research, 1.2 (2012), 137–
46, https://doi.org/10.2217/cer.12.10
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3.5 Consideration Five
The last question asks whether there is political and professional 
support for the intervention in question. This consideration has 
different requirements compared to the previous questions, given that 
it is dependent on factors such as stakeholder consensus and buy-in, 
social and cultural influences and the governmental structure of the 
country. This issue is important because a Best Buy might be forgone 
if there is no political or professional support for it. ‘Policy-informed 
evidence’ might be deployed in response to high-level political 
pressures and influences instead of genuine evidence.7 Managing this is 
tricky, but failure results in the implementation of suboptimal options, 
especially if this consideration is the first to be addressed in the SEED 
Tool (one reason for our recommendation to follow the logical order). 
For example, one of the case studies in this book discusses Thailand’s 
implementation of a diabetes mellitus and hypertension screening 
program for the entire population, which was a good political 
investment even though there was a lack of evidence to support the 
policy fully.8 An economic evaluation conducted later showed that 
targeted screening for high-risk groups was more cost-effective and 
led to a change in policy with the potential for reallocation of the 
budget to other NCD programs and a further improvement in health 
outcomes. This case was successful because of a commitment from all 
sectors. However, it is much better to ensure that policies are based on 
evidence from the outset and, where this is not established practice, to 
build a new culture in which it is expected. This implies making sure 
that professional and training institutions instill in students a clear 
understanding of evidence-informed decision-making processes and 
why they are important, and that the training of civil servants and 
other government officials and advisers likewise includes modules on 
evidence and decision-making. 
7  Sarocha Chootipongchaivat et al., Factors Conducive to the Development of Health 
Technology Assessment in Asia: Impacts and Policy Options (Manila: World Health 
Organization, 2015), https://apps.who.int/iris/bitstream/handle/10665/208261/ 
9789290617341_eng.pdf?sequence=1&isAllowed=y
8  See Chapter 5.
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3.6 The SEED Tool in Practice
NCD prevention interventions are often complex and multi-faceted, 
requiring collective effort and time from both public and private players 
to implement. Consequently, they always come with a high opportunity 
cost for their introduction or maintenance within healthcare systems. 
The SEED Tool can be considered a framework or conceptualization 
that captures all necessary considerations to enhance the probability of 
implementing Best Buys and avoiding Wasted Buys. Each consideration 
in the tool has sub-considerations, which are discussed in other sections 
of this book — as such, the SEED Tool is the backbone of the book and 
the following chapters on Best Buys and Wasted Buys will illustrate 
the usefulness of applying it. This SEED Tool is also the starting point 
for in-depth discussion on technical and practical issues surrounding 
decision-making processes for health investment, such as the subjects of 
generalizability and transferability that will be described in Chapter 6 
(see the Consideration 3 discussion above) and political buy-in, which is 
discussed in Chapter 2 as part of its illustration of the political economy 
of NCD prevention. Governance and process are covered in Chapter 9 
(see the Consideration 5 discussion above). 
The SEED Tool summarizes not only all the types of evidence — such 
as those produced in health technology assessments, health systems 
research, policy studies, etc. — it also incorporates contextual issues 
such as local intervention costs and political buy-in among key decision 
makers. Further, given the intricacies of NCD prevention interventions, 
there are many stakeholders within and outside the health sector 
with their own perspectives and areas of concern. Having a common 
framework in the SEED Tool that allows these relevant stakeholders to 
deliberate and/or prioritize all competing policy options can be crucial 
for the success of NCD prevention, which requires commitment and 
ownership at all levels of policy implementation. 
This book benefits from using case studies to examine how NCD 
programs have been implemented in the past; this was an input in 
developing the SEED Tool. It is designed to be used for considering both 
new and existing interventions, whether it be for vertical programs or as 
part of broader public health systems. Specifically, the tool can be helpful 
in evaluating: 1) the impact of an existing program that will continue to 
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be implemented, and exploring any changes necessary to improve the 
program; 2) a new program in consideration for implementation; 3) the 
effect of a program that was completed, to determine lessons learned; 
and, 4) an ongoing program for continuation. As such, it can be used to 
evaluate the impact of current or past programs retrospectively as well 
as to determine whether proposed interventions should be implemented 
in the future. The authors hope to use and also to test this framework, 
with the aim of avoiding Wasted Buys and increasing the likelihood of 
investing in Best Buys.
The tool has the potential to be applied not only for NCDs but 
also for other public health programs, or even as a system-wide 
mechanism for priority-setting (for example, as part of the inclusion of 
health technology or services in the benefits package or the essential 
medicines list). This tool can also be helpful when used together with 
priority-setting institutions and appropriate policy processes. This is 
because the authors believe that together evidence and process can be 
impactful, generating a loop of better evidence for better processes and 
vice versa, which eventually leads to better decisions with a greater 
impact on health.9
9  Rob Lloyd et al., International Decision Support Initiative (IDSI) Theory of Change 
Review Report’, F1000Research, 7.1659 (2018).

4. Best Buys




Because decision-makers need to prioritize policy options that bring 
the greatest possible health benefits from limited available resources, 
the World Health Organization (WHO) introduced Best Buys and other 
recommended cost-effective policy interventions to prevent and control 
NCDs.1 The work, based on a rigorous process of review and selection, 
generated a menu of medical and public health interventions to reduce 
modifiable NCD risk factors in respect of diet, smoking, alcohol and 
physical activity, and to control and manage better the four major types 
of NCDs that contribute to 80% of global premature mortality from 
NCDs:2 cardiovascular disease, diabetes, cancer and chronic respiratory 
disease, as summarized in Table 4.1.3
1  World Health Organization, Tackling NCDs: Best Buys, 2017, http://apps.who.int/
iris/bitstream/handle/10665/259232/WHO-NMH-NVI-17.9-eng.pdf?sequence=1
2  World Health Organization, Non-communicable Diseases: Key Facts 2018, 2019, http://
www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
3  World Health Organization, Assessing National Capacity for the Prevention and Control 
of Noncommunicable Diseases, ed. by Report of the 2017 Global Survey (Geneva: 
World Health Organization, 2017).
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Table 4.1 WHO’s list of Best Buys on NCD preventions.
Risk factor and diseases Interventions
Tobacco use • Tax increases
• Plain/standardized packaging
• Smoke-free workplaces and public places
• Public awareness through mass media 
about the harms
• Ban on tobacco advertising, promotion and 
sponsoring
Harmful alcohol use • Tax increases
• Restricted access to retailed alcohol
• Bans on alcohol advertising
Unhealthy diet and 
physical inactivity
• Reduce salt intake in food through: 
◊ Product reformulation 
◊ Low salt options
◊ Food labelling
◊ Campaigns
• Public awareness through mass media 
about physical activity
Cardiovascular disease and 
diabetes
• Counselling and multi-drug therapy 
(including glycemic and blood pressure 
control) for people with a high risk of 
developing cardiovascular events
Cancer • Vaccination against human papillomavirus
• Screening and treatment of pre-cancerous 
lesions to prevent cervical cancer
Buys.4 An intervention is a Contestable Buy if there are only aspirations 
for, and hence no direct evidence of, cost-effectiveness in the country 
setting in which the intervention is being considered. Interventions in 
the WHO’s Best Buys list may still be Contestable Buys if there is no 
demonstrative evidence of cost-effectiveness in the particular setting in 
question. The main distinction between Best and Contestable Buys is 
thus the availability of context-specific evidence. The reason why the 
distinction is important is that local context strongly influences the cost-
effectiveness of an intervention. 
4  See Chapter 5 for full discussion of Wasted Buys.
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Data reviews confirm the scarcity of evidence of cost-effective 
Best Buys. Our analysis of the current evidence base in LMICs, based 
on the Global Health Cost Effectiveness Analysis Registry, identified 
very limited local evidence of Best Buys or of cost-effective preventive 
policies even for widely popular interventions such as taxation on 
tobacco and sugar-sweetened beverages (see Online Appendix 4A 
for an analysis of evidence by interventional type (Table 4A.1) and by 
country (Table 4A.2). We found country-specific evidence of Best Buy 
tobacco control policies in two countries only: Tanzania and Vietnam. 
Similarly, evidence of Best Buy alcohol control policies was found only 
in four relatively high-income countries: Australia, Denmark, Mexico 
and the Netherlands. Lack of local evidence creates uncertainty for 
decision-makers, who often have to rely on evidence transferred from 
other settings.5 
A recent country capacity survey by WHO demonstrated that their list 
of Best Buys and other cost-effective interventions was ‘underutilized’ 
and that progress on NCDs globally was insufficient to meet 2030 
goals.6 There were many reasons for this, including but not limited to: 
1) public health interventions are less likely than clinical interventions 
to have been subjected to cost-effective analyses for resource allocation 
decisions; 2) the evidence of the cost-effectiveness of those Best Buys 
as defined by the WHO report often does not come from their local 
decision context;7 3) a lack of adequate local capacity in implementing 
a Health Technology Assessment (HTA); 4) a limited awareness or 
demand for Cost-Effectiveness Analysis (CEA) from policy-makers 
in NCD prevention; and 5) the general absence of guidance either as 
to how to implement the recommended interventions on the Best 
Buys list or how to draw credible conclusions from the transfer of 
evidence between settings that have different disease burdens, different 
decision-making and managerial capacities, different institutional and 
5  See Chapter 6 for assessing the transferability of economic evidence.
6  World Health Organization, Assessing National Capacity for the Prevention and 
Control of Noncommunicable Diseases, 2017, https://apps.who.int/iris/bitstream/han
dle/10665/276609/9789241514781-eng.pdf
7  Luke. N. Allen et al., ‘Evaluation of Research on Interventions Aligned to WHO 
‘Best Buys’ for NCDs in Low-Income and Lower-Middle-Income Countries: A 
Systematic Review from 1990 to 2015’, BMJ Global Health, 3 (2018), e000535, https://
doi.org/10.1136/bmjgh-2017-000535
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delivery frameworks and different cultural and historical inheritances. 
Consequently, NCD policies are largely implemented without evidence 
of, or only with implicit assumptions about, cost-effectiveness. 
4.1.2 What This Chapter Offers
Achieving Best Buy status largely depends on cost-effectiveness data, but 
there are many issues to settle if cost-effectiveness evidence is to be used 
for making decisions in real-world settings. These include the quality of 
the design and execution of the research on which the evidence is based, 
the extent to which cost and health outcomes observed elsewhere are 
likely to apply in a different context and the methodological challenges 
involved in comparing cost and health outcomes elsewhere with those 
of alternative interventions locally, as well as the practical challenges 
involved in introducing and sustaining the intervention. In this chapter 
we draw on real-world experiences in NCD policies and show how an 
intervention that is a Best Buy in ex-ante aspiration is compromised 
when implemented within a specific local context, turning it therefore 
into a Contestable Buy. This alteration is at least partly because real-
world policies need to respond to the local context, such as culture, 
politics, history, market and law, within which they are implemented, 
and partly because of a common need to involve various stakeholders 
with vested interests who may be threatened by a novelty. There may 
also be important value judgements, such as judgements about equity, 
which might count in making decisions and which are locally specific. 
Furthermore, policies are not implemented in a vacuum but have 
synergistic and cumulative effects along with other policies, which in 
turn effect their potency. Prevention of NCDs is not just about addressing 
modifiable lifestyle risk factors but linking this to the social determinants 
of health, such as living and working environments, or economic policy 
and broader social policy.8 We use the analysis of real-world case studies 
on NCD prevention to develop a list of considerations to help guide NCD 
managers and policy-makers through the design of the implementation 
process. This is not an alternative to the WHO’s list of Best Buys, which 
can provide policy-makers with a useful starting point for planning NCD 
8  See Chapter 2 for the discussion from the political aspect.
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prevention interventions that potentially offer best value for money. The 
list is a secondary step to assist NCD managers in identifying a true local 
Best Buy and ensuring that it remains so during implementation, i.e., not 
remaining Contestable or even becoming Wasted. 
To give an example of how local context can affect the impact and 
reach of an intervention, bike-sharing schemes, although not listed 
as a WHO Best Buy, are now popular in many countries, as they 
can encourage active commuting, hence physical activity,9 as well as 
reducing congestion and potentially improving air quality. In Tehran, 
such a bike-sharing scheme is thriving, but only for men and not for 
women, due to the cultural and religious contexts that prevent women 
from taking part in the scheme.10 This does not necessarily mean that the 
scheme in Tehran is a Wasted Buy. The scheme is successful, at least for 
men, and it may be deemed a Best Buy within this specific context. In 
this example, culture and religion are not modifiable factors, but need to 
be considered when making policy. There are other types of contextual 
factors that policy-makers can potentially modify, which are discussed 
in the following section. 
4.2 Determining Important Contextual Factors 
 in NCD Prevention
Why does context matter so much, which contextual factors matter most 
and how can we measure their effect? 
Local contextual factors are often not subject to formal quantification 
in the same way as they are in cost-effectiveness analyses performed in 
high-income contexts. Real-world experiences are potentially useful and 
thought-provoking sources of information that can be used to identify 
which and how contextual factors interact with the implementation 
process. To gain some appreciation of real-world experience, we 
invited policy-makers and researchers from across the globe to share 
case studies of local implementations of NCD preventive policies. We 
9  James Woodcock et al., ‘Health Effects of the London Bicycle Sharing System: 
Health Impact Modelling Study’, BMJ, 348 (2014), g425, https://doi.org/10.1136/bmj.
g425
10  Russell Meddin, Tehran’s ‘Bike House’ Shines Green, 2010, http://bike-sharing.
blogspot.com/2010/03/tehrans-bike-house-shines-green.html
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collected forty-seven case studies on the implementation of Best or 
Contestable Buys and summarize them in Table 4.2.11 
Table 4.2 Summary of the collected case studies.
No. of case 
studies
Type of intervention Country
Risk-factor prevention
5 • Reduce tobacco use India, Iran Philippines, 
Uganda
4 • Reduce the harmful use 
of alcohol and other 
substance misuse
Bhutan, Democratic Republic 
of the Congo, Philippines
1 • Reduce tobacco use & 
harmful use of alcohol 
Kenya
12 • Reduce unhealthy diet Bangladesh, Chile, China, 
Hungary, India, Iran, 
Philippines, South Africa, 
Zambia
2 • Increase physical activity Bhutan, Rwanda
1 • Reduce unhealthy diet & 
increase physical activity
Haiti
Reduce disease through screening or immunization
7 • Prevent diabetes or 
cardiovascular diseases 
India, Kyrgyzstan, 
Philippines, Sri Lanka, 
Turkey, Uzbekistan
3 • Prevent cancer Bangladesh, Cambodia, 
Honduras
5 Improve health literacy Bangladesh, India, Philippines
1 Increasing awareness and 
health literacy
Indonesia
6 Other — strengthen health 
system response
Bangladesh, Iran, Ireland, 
Nepal, Slovenia
Although the forty-seven case studies do not necessarily represent 
successful NCD preventive policies, they provide useful insights into 
the reality of policy implementation. Twenty-five cases were specific to 
risk-factor modification: reducing tobacco use and sweetened beverage 
consumption were the most frequent. Ten cases were interventions to 
11  See Online Appendix 4B for more detailed information and our analyses.
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reduce disease through immunization or screening for risk or early 
disease. Six cases describe policies to increase public awareness and 
health literacy. The remaining six concerned strengthening the health 
system response to NCDs. We analyzed the case studies and then 
triangulated the findings with the existing literature on Best Buys 
and best practices in public health12 to reveal factors that seem to be 
significant in the processes of policy formation and implementation in 
various contexts. The results are summarized in Table 4.3 and form a 
list of considerations. We propose that these considerations are used 
to supplement, but not to replace, cost-effectiveness when deciding 
whether and how to implement an NCD prevention intervention. 
We call them ‘additional considerations’ to emphasize that they are a 
supplementary step between the global list of NCD preventive policies 
and implementation in local settings, in order to ensure that a Best Buy 
when implemented is really a Best Buy — although this can be tested 
only through robust monitoring and evaluation. 
In principle, whether an additional consideration is applicable is of 
course likely to be context-dependent, so what factors matter could differ 
by context. Although we applied the list of considerations to the forty-
seven case studies as a score card (Online Appendix 4B), this list has not 
gone through the necessary testing to validate it as a tool, a quantitative 
measure, or a score for each of the considerations. At this stage, it is 
a summary of wisdom drawn from real-world experiences, or a set of 
prompts or questions to ask when implementing and evaluating NCD 
preventive policies — hence why we call them considerations and not 
prerequisite steps. Likewise, the list is not a checkbox tool to identify a 
Best Buy that substitutes for local evidence of cost-effectiveness. Rather, 
the list should be used to assess proposed interventions and predict 
critical stumbling blocks that stem from local contexts, in particular 
when there is a desire to acquire a particular Best Buy, but its suitability 
needs testing. The considerations can be used to complement the SEED 
Tool (in particular consideration 3, 4 and 5) in Chapter 3, to give the 
intervention a better chance of being a Best Buy in the specific context of 
its possible implementation.
12  Eileen Ng and Pierpaolo de Colombani, ‘Framework for Selecting Best Practices in 
Public Health: A Systematic Literature Review’, Journal of Public Health Research, 4.3 
(2015), https://doi.org/10.4081/jphr.2015.577  
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4.3 Policymaking Challenges  
and Cost-Effectiveness Data
In this section, we apply cost-effectiveness and the additional 
considerations in Table 4.3 as a score card to assess policies for NCD 
prevention in LMICs and highlight those contextual factors that are 
critical; we also set out why and how these contextual factors make 
the implementation of NCD preventive policies complicated and 
challenging.
When the set of questions in Table 4.3 was applied to the forty-
seven case studies submitted by policy-makers and researchers,13 the 
most striking finding was that in the real world many of the Best Buys 
became Contestable Buys because of the nature of the evidence and 
implementation issues within the specific context. We give examples 
of this below. In fact, only three out of the forty-seven cases were 
explicitly informed by local cost-effectiveness data, suggesting that 
such data are probably rarely available and highly unlikely to be used 
by policy-makers in the decision-making process. We hypothesized in 
the introduction that cost-effectiveness evidence alone was in any case 
insufficient to determine which interventions should be prioritized 
and indicated the other considerations that might apply. This set of 
case studies suggests that cost-effectiveness evidence is rarely used to 
prioritize interventions. Further, fewer than half of the cases (seventeen 
out of forty-seven) were even informed by local data on effectiveness. 
Table 4.3 (fourth column) shows the number of case studies that 
mentioned each consideration, as judged by the chapter authors. The 
local relevance of NCDs was addressed in most of the case studies. They 
described the burden of disease, its magnitude and the awareness of the 
problem, but fewer than half the cases described the relevance of the 
chosen intervention in terms of the local culture, traditions and behavior, 
or in relation to other interventions already being implemented. Only 
half of the case studies explored the potential acceptability of their 
proposed approaches or the sustainability of the intervention in terms 
of financial or human resources. The case studies that described the 
implementation of a fiscal measure, for example taxation on tobacco or 
on sugar-sweetened beverages, particularly emphasized the importance 
13  See Online Appendix 4B.
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of political economy issues, including industry and other stakeholders’ 
opposition to implementation. 
The literature discusses the importance of effective public engagement 
and the need to ensure equitable representation of all groups in the 
composition of participation. Health equity and distributional justice 
are offered as critical issues given that an approach that seeks to 
maximize health benefits for a population can conflict with efforts to 
achieve equity.14 Despite this, community engagement or health equity 
were rarely considered or explicitly mentioned in our cases. 
4.4 Investigating Case Studies
The case studies gave a rich description of contextual challenges and 
enablers. We feature and investigate the forty-seven case studies15 and 
share examples of NCD prevention policies that faced challenges in 
implementation.
Case Study 4.4.1 Cardiovascular screening in Sri Lanka16
Sri Lanka is estimated to have the highest death rates due to NCDs 
in South Asia17, with many patients presenting late in the disease 
progression. A national survey reported that 36% of all patients with 
diabetes were undetected.18 In response, the government formulated a 
National Policy and Strategic Framework for prevention and control 
of chronic non-communicable disease which included implementation 
of a CVD risk screening program at community level.19 This policy 
was implemented nationally through the establishment of ‘Healthy 
14  Ng and Colombani.
15  In Appendix 4B you can see the detailed analysis of the forty-seven case studies.
16 Authors of this case study: Rohan Jayasuriya (University of New South Wales, 
Australia), Sumudu Karunaratne (Ministry of Health, Sri Lanka) and Amala de 
Silva (University of Colombo, Sri Lanka).
17  World Health Organization, ‘Global Health Estimates 2016: Deaths by Cause, Age, 
Sex, by Country and by Region, 2000-2016’ (Geneva: World Health Organization, 
2016).
18  Prasad Katulanda et al., ‘Prevalence and Projections of Diabetes and Pre-Diabetes 
in Adults in Sri Lanka-Sri Lanka Diabetes, Cardiovascular Study (SLDCS)’, Diabetic 
Medicine, 25.9 (2008), 1062–69, https://doi.org/10.1111/j.1464-5491.2008.02523.x
19  Ministry of Healthcare and Nutrition Sri Lanka, The National Policy & Strategic 
Frame Work for Prevention and Control of Chronic Non- Communicable Diseases, 2009, 
http://www.health.gov.lk/enWeb/publication/Act/NCDPolicy-English.pdf
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Lifestyle Clinics’ (HLCs) in 2011, initially funded by the World Bank. 
At present, there are 800 HLCs functioning in Sri Lanka.20 Several pilot 
studies informed the decision including the NCD Prevention Project 
(NPP), which was funded by the Japan International Corporation 
Agency.21 The NPP study tested two approaches. Both approaches 
had similar criteria for inclusion, all individuals between 40–75 years 
of age, without a history of NCDs. The first approach (a two-step 
model) involved screening by body mass index and blood pressure in 
the community and then diagnostic testing (fasting capillary glucose 
and blood pressure) in a health clinic. The second approach (a one-
step model) implemented screening and diagnostic testing at the same 
time in hospital. They achieved similar detection rates for risk factors 
including high blood pressure and diabetes and coverage of population. 
However, the two-step model saw a significantly higher follow-up rate 
of 85%, compared to 19% in the one-step model, which is a crucial 
finding as chronic disease management resulting in glycaemic control 
and control of hypertension in moderately high-risk individuals is the 
motivation for screening. In the two-step model, the field staff (Public 
Health Midwives — PHMs) were able to trace those who were at risk, 
resulting in higher follow up. However, neither model evaluated the 
cost-effectiveness of the approaches. Policy makers felt unable to justify 
implementing the two-step model in the national rollout due to issues 
of feasibility (affordability, health system structure and workforce 
capacity). The PHMs could not be deployed on a national level as it 
would distract from their core midwifery functions. Donors and 
policy-makers therefore backed the expansion of the one-step model 
through HLC, accepting that compromises in implementation are often 
necessary.
The case study from Sri Lanka, featured in the box, describes one of the 
pilot studies undertaken and the review of evidence generated prior to 
designing a National Cardiovascular (CVD) Screening program. If they 
20  D.S. Virginie Mallawaarachchi et al., ‘Healthy Lifestyle Centres: A Service for 
Screening Non-communicable Diseases through Primary Health-Care Institutions 
in Sri Lanka’, WHO South-East Asia Journal of Public Health, 5.2 (2016), 89, https://doi.
org/10.4103/2224-3151.206258
21  Japan International Cooperation Agency, Project on Health Promotion and Preventice 
Care Measures of Chronic NCDs Final Report (Tokyo: Japan International Corporation 
Agency, 2013), http://open_jicareport.jica.go.jp/pdf/12112322.pdf
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had applied the list of additional considerations, Sri Lanka could have 
ticked many of the boxes. Relevance was established, local evidence was 
generated and political will and donor support were critical to realizing 
and determining the contents of this national program. Inadequate 
local capacity, however, became a stumbling block to implementing the 
preferred model of delivery. Evidence suggests that drug treatment for 
those at high risk of CVD (total risk of CVD event >30%) is a cost-effective 
intervention and a Best Buy,22 so by choosing the approach that yielded 
fewer follow-up visits and therefore chronic disease management the Sri 
Lankans may have undermined the effectiveness and cost-effectiveness 
of this program. Compromise and pragmatism are often required in the 
real world, but the consequences of decisions need to be captured. An 
evaluation of the program should capture not only the percentage of 
the eligible population that has been screened and identify modifiable 
risk factors like smoking and hypertension, but also outcomes such 
as the number of patients with controlled hypertension. This is a way 
of measuring the impact of the program as currently structured. The 
results may point to some constraints that could be easily addressed. 
For example, a recent review of the routine data for this CVD risk 
screening program showed that more than two thirds of the attendees 
were women. It was quickly realized that this was because the screening 
occurs during the official working week, i.e., Monday to Friday, which 
was preventing men from benefiting from the scheme and resulting in 
a rectifiable inequity. The Public Health Midwives or other primary 
health staff, as well as community representatives, should be invited to 
contribute to finding a solution for the workforce capacity issues and 
community participation in the screening program. Local areas may 
want to pilot different solutions.
Case Study 4.4.2 Prevention and control of cervical cancer in 
Cambodia
Another case study, authored by Koum Kanal, concerned prevention 
and control of cervical cancer in Cambodia. Cervical cancer in Cambodia 
is one of the most serious yet preventable health problems. Cambodia 
implemented a pilot study of a new cervical cancer program, which was 
22  World Health Organization, Tackling NCDs: Best Buys.
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based on the WHO’s guide to Comprehensive Cervical Cancer Control.23 
The program aimed to: 1) raise access to cervical cancer screening 
among factory workers; 2) improve gynecologic capacity for diagnosis 
and treatment of precancerous lesions; and 3) strengthen pathological 
capacity for cancer diagnosis. The implementation was supported 
by strong political will and involved ministries and donors, which 
facilitated international collaborations of professional associations. The 
cost of the new screening program was estimated to be less than 1 US 
dollar per person per year and was therefore financially sustainable. 
Although there is no direct cost-effectiveness evidence, the program 
was likely to be highly cost-effective and hence a Best Buy. However, 
the most striking barrier to nationwide implementation was again an 
inadequate local capacity to scale up the program nationally — there 
were only four pathologists in the country and built infrastructure was 
also needed. Cambodia started a new pathology residency program in 
the country in 2015, in which five residents are trained with support 
from Japanese and German universities. A technician-capacity-building 
program was also initiated. While these capacities are being developed, 
temporary measures could be explored and, wherever affordable, 
adopted to meet the needs of the screening and management, including 
outsourcing; e.g., contracting a pathology service with neighborhood 
countries or requesting international co-operation, which means 
setting up a program and guidelines for pathologists from outside of 
the country to effectively work in the Cambodian context with limited 
human resources and skills. 
Case Study 4.4.3 Sugar-Sweetened Beverage (SSB) taxes
The SSB tax to discourage sugar consumption is probably the approach 
currently being most tested, partly because of the popularity of SSBs 
across cultures, the worldwide increase in sales and their price-
sensitivity, especially in low and low-middle-income countries.24 South 
23  World Health Organization, Comprehensive Cervical Cancer Control: A Guide to 
Essential Practic (WHO Library Cataloguing-in-Publication Data, 2014), https://apps.
who.int/iris/bitstream/handle/10665/144785/9789241548953_eng.pdf?sequence=1
24  Yevgeniy Goryakin et al., ‘Soft Drink Prices, Sales, Body Mass Index and Diabetes: 
Evidence from a Panel of Low-, Middle- and High-Income Countries’, Food Policy, 
73 (2017), 88–94, https://doi.org/10.1016/j.foodpol.2017.09.002
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Africa, Zambia, Chile and Philippines all submitted case studies on SSB 
taxation (authored by Karen Hofman, Surgey et al., Cristóbal Cuadrado, 
Frances Claire Onagan, respectively). They described the policy process 
and the challenges faced when implementing an effective tax to improve 
health, as well as how the impact of these additional considerations can 
affect whether the intervention is a Best Buy for health or not.
SSB taxes are notably announced and led by Ministries of Finance (MoF) 
or Health (MoH) or in some instances by the Head of State and thus are 
a classic example of a multisectoral approach. When implementing SSB 
taxes, the MoF’s primary objective is not necessarily health improvement, 
but revenue creation. Implementation of an SSB tax tends to be subject 
to strong opposition by industry, which tries to limit its impact. Even 
when there is strong political leadership in tackling NCDs, such special 
interests can have implications for the level at which taxes are set and 
this is a challenge for the health sector. In many countries, SSB tax rates 
are moderate (for example at 5%), which may not significantly influence 
consumer purchasing in the long run, in which case the tax serves only as 
a revenue-raising mechanism.25 For example, Zambia is proposing a 3% 
tax that modelling has shown to have no benefit on health, but which will 
raise about $33,314 USD per annum in revenue. For the authors of this 
chapter, the Zambia SSB tax would be a Contestable Buy as it is unable 
to demonstrate health benefit, but it is not a Wasted Buy as it generates 
government revenue that could be used to fund other preventive or 
treatment interventions — hence the tax policy can be part of a Best Buy 
policy package and creates awareness of the risk of SSB consumption 
among the public which can lead to behavioral change. 
These case studies highlight the importance of conflict of interest 
and of taking account of the resulting powerful influence of industry 
in creating doubt, determining the rate of the tax and on mediating the 
impact of taxation on consumers, thus weakening the political will for 
action. They underline the importance of engaging with the public, the 
need for strong advocacy, the value of local evidence and the importance 
of publicly countering industry arguments. Where taxes have been 
implemented without strong public health messaging to encourage 
25  World Health Organization, Using Price Policies to Promote Healthier Diets. 
Copenhagen: WHO Regional Office for Europe, 2015, http://www.euro.who.int/__data/
assets/pdf_file/0008/273662/Using-price-policies-to-promote-healthier-diets.pdf
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consumer demand for healthier products, populations have interpreted 
the policy action as governments finding another way to extract money 
from them, which makes the intervention less acceptable to the public.26 
4.5 Discussion
We endorse the WHO Best Buys for tackling NCDs but recommend 
that NCD decision-makers use local, context-specific cost-effectiveness 
information where obtainable, as well as the additional considerations, 
to prioritize interventions and to undertake the effective implementation 
of their chosen intervention. The Best Buy list is a list of evidenced 
interventions that have been shown to be cost-effective in more than one 
setting. The list contains interventions that are indeed Best Buys in some 
places and times and it provides a strong resource for countries to draw 
on. Unfortunately, there is no ‘one size fits all’ and the user of the list 
should not generalize and passively expect the interventions to be cost-
effective in their setting just because they were in another; instead they 
should actively enquire whether the intervention is likely actually to 
be cost-effective in their setting. The user should assess any additional 
considerations that are of local relevance, given their specific country 
with its own constraints (budgetary and other), values, institutions 
and capacities. Users should also appreciate that contexts will require a 
different combination of policies to address a health challenge, that an 
intervention on its own might not be cost- effective, but in combination 
with others might form a cost-effective package. 
We have proposed a list of considerations for assessing the possible 
importance of locally contextual, additional considerations, covering 
relevant areas including: culture, religion and ethnicity; leadership, 
governance and compliance; sustainability; multisectoral collaboration; 
community and stakeholder involvement; ethics and values (Table 4.3). 
The case studies have demonstrated that, in the real world, compromises 
are often made in the implementation process. 
As a policy-maker, adviser or NCD manager using this list of 
additional considerations in your planning process, what do you 
26  Orly Tamir et al., ‘Taxation of Sugar Sweetened Beverages and Unhealthy Foods: 
A Qualitative Study of Key Opinion Leaders’ Views’, Israel Journal of Health Policy 
Research, 7.1 (2018), 43, https://doi.org/10.1186/s13584-018-0240-1
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do if there are unsatisfactory answers to some of questions posed in 
Table 4.3? How do you explore whether the consequence of these 
considerations is sufficiently serious to reject the proposed intervention 
or whether it is possible to take complementary steps to mitigate the 
consequences? One solution could be to conduct a workshop and/or 
set up an advisory group with experts and policy-makers to explore 
the issues and any potential controversies, and design the necessary 
monitoring and measurement programs for an evaluation. Constraints 
(especially political and professional ones) could be overcome in several 
ways, for example: through price negotiations to increase affordability 
of the more effective model; investment in training and human capital 
to strengthen the sustainability and infrastructure elements; involving a 
wider range of public and private stakeholders from other governmental 
departments, the universities, professions and industry; and facing up 
to ethical and cultural challenges, for example, by encouraging open 
public debate on the critical issues.
Sometimes a Buy may be deemed to be Contestable on the grounds of 
the quality of the evidence. This is not usually a matter of local context.27 
The problem will often lie in the design of the primary research or in the 
reviews and meta-analyses that underlie the case, or in the data used, 
which may raise significant questions of transferability. Again, one way 
forward might be to conduct workshops of experts and policy-makers 
at which the issues and possible solutions and compromises can be 
explored. The forty-seven case studies demonstrated that little local 
evidence of effectiveness or cost-effectiveness is currently being utilized, 
probably because it is not available, but possibly also because of a lack 
of awareness that workable tools exist. Therefore, another possibility 
might be to conduct further research to address data deficiencies either 
at a local level or regionally, to incorporate other criteria than cost-
effectiveness alone in the evaluation of the intervention in question and, 
in general, to raise awareness that will have consequential implications 
for training. All these will raise further questions of timing and funding. 
In all cases good judgment is called for, which underlines the 
importance of regarding cost-effectiveness analysis and related methods 
as aids to thought rather than substitutes for it. It is important for decision-
makers to understand the basics of the evaluative methodologies 
27  See Chapter 7.
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involved and their limitations, so that they can interrogate both the 
evidence and the experts intelligently and reach sound conclusions 
about the design and operation of the decision-making processes used 
in the country. 
Best Buys are not necessarily ‘quick fixes’. Modelling their return on 
investment involves projections over two to three decades. The fact that 
benefits from NCD prevention policies and interventions might not be 
felt until way into the future makes them politically difficult to justify, 
especially when the benefits accrue to one government department, 
but the spend falls on another. A significant number of the Best Buy 
policies need to be implemented by other sectors or with other sectors.28 
Even in the case of the revenue-generating fiscal policies where the costs 
of implementation and monitoring could be covered by the revenue 
generated, it was acknowledged that there were challenges with 
enforcing legislation or guidance. 
Policy-makers need to balance national spending priorities fairly 
and efficiently while at the same time safeguarding an individual’s 
right to health. Achieving equity can be costlier as it means reaching 
less accessible, often marginalized groups, thus potentially deeming the 
intervention, or some aspects of it, cost-ineffective. This emphasizes one 
of the challenges of applying CEA tools to public health interventions. 
Public health interventions are often more concerned with the 
distribution of health gains rather than maximizing health benefits 
or efficiency. The current economic evaluation methodology almost 
exclusively concerns the latter. In addition, due to the broad nature 
of the costs and benefits incurred, economists need an intersectoral 
approach to identify them and to measure health and social gain (see 
Chapter 8 on cross-sectoral policies to address NCDs). For example, a 
DALY may not be broad enough to identify all the benefits to society.29
4.6 Conclusion
In this chapter, we have made the case that cost-effectiveness data are 
generally scarce in NCD prevention in LMICs and that available data are 
28  See Chapter 8 for cross-sectoral policies to address NCDs.
29  Helen Weatherly et al., ‘Methods for Measuring Cost Effectiveness of Public Health 
Interventions: Key Challenges and Recommendations’, Health Policy, 93.2–3 (2009), 
85–92, https://doi.org/10.1016/j.healthpol.2009.07.012
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not always generalizable to different settings. A crucial element of cost-
effectiveness analysis is context sensitivity, meaning that a list of Best 
Buys generated at a global level cannot be assumed to be a Best Buy in a 
local setting unless there is local evidence of cost-effectiveness. Through 
a series of case study examples, we have sought to demonstrate the 
importance of context and developed a list of considerations in policy 
implementation to help NCD managers to judge whether a potential 
Best Buy intervention is effective and cost-effective in their own setting. 
In order to strengthen the effectiveness and cost-effectiveness of NCD 
prevention interventions, funders, national governments and technical 
agencies should consider investing in the following: 
1. Regional support units to assist in the generation of regional 
and local cost-effectiveness evidence with local academics and 
health economists. This collaboration can enable the sharing 
of experiences and insights both in implementing NCD 
preventive policies and conducting HTAs, and also build the 
capacities of junior researchers and policy-makers through 
experiences and knowledge exchanges.30
2. Prioritization and decision-making processes that are informed 
by cost-effectiveness evidence such as the Lancet NCDI (non-
communicable diseases and injuries) Commission31, which 
familiarizes NCD managers and policy-makers with cost-
effectiveness data and tools. This should increase the demand 
for such information and, hence, its production. 
3. Development of further tools to assist in implementation. The 
list of additional considerations is a starting point for guiding 
managers and policy-makers. Further efforts should be 
invested in designing and validating a tool that is user friendly 
with a quantitative measure and/or composite score. Tools 
such as the tobacco control playbook developed by WHO 
Europe, which supports NCD managers and policy-makers 
with evidence-based arguments to defend tobacco control 
30  Yot Teerawattananon et al., ‘Historical Development of the HTAsiaLink Network 
and Its Key Determinants of Success’, International Journal of Technology Assessment 
in Health Care, 34.3 (2018), 260–66, https://doi.org/10.1017/s0266462318000223
31  Gene Bukhman et al., ‘Reframing NCDs and Injuries for the Poorest Billion: A 
Lancet Commission’, The Lancet, 386.10000 (2015), 1221–22, https://doi.org/10.1016/
s0140-6736(15)00278-0
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policies in parliament, are useful guidance documents in that 
they prevent the weakening and subsequent ineffectiveness of 
such policies,32 but offer no assessment of the implementation 
process. Academics are currently working to develop a tool to 
explicitly incorporate the notion of context when implementing 
public policies, which could be used to steer this process.33
4. Monitoring and evaluation of existing NCD prevention 
policies and interventions with a view to strengthening 
implementation and impact.
5. Best practice pilots that can generate further evidence of 
implementation methods and pitfalls.
32  World Health Organization, Tobacco Control Playbook, 2019,  http://www.euro.who.
int/en/health-topics/disease-prevention/tobacco/policy/tobacco-control-playbook 
33  Politics and Ideas, Context Matters: A Framework to Support Knowledge into Policy, 
2016, http://cm.politicsandideas.org/homepage
5. Wasted Buys 
Yot Teerawattananon, Manushi Sharma, Alia Luz,  
Waranya Rattanavipapong and Adam G. Elshaug
5.1 Introduction
In 2011, approximately 6.9 trillion USD were spent globally on 
health, of which 20–40% were thought by the WHO to be wasted.1 
This evidence is corroborated by the Organization for Economic 
Co-operation and Development (OECD), which found that potentially 
one-fifth of total health spending in developed countries is wasted.2 
This observation is an example of inefficiency, and waste on this scale 
is far more serious in LMICs, where the overall burden of disease is 
so much higher and relatively small expenditures can have enormous 
impact (if spent wisely). The usual methods of controlling rising health 
expenditures have been either through structural reorganization or 
cost-cutting measures. The former is time-consuming and carries risks 
of missing the intended mark, an approach famously lampooned by 
Maynard in the UK as ‘redisorganization’,3 while the latter is a blunt 
instrument and may impinge indiscriminately on both cost-effective 
and cost-ineffective parts of the system. Often the missing piece of 
this conundrum is figuring out how to eliminate waste and/or low-
value health care. Efficiency gains from measures to improve health 
outcomes can be dispersed across sectors, but also have the potential 
to allow reallocation from poor value, low-impact interventions to 
1  World Health Organization, Global Health Expenditure Atlas (Geneva: WHO Press, 
2014), https://www.who.int/health-accounts/atlas2014.pdf
2  OECD, Tackling Wasteful Spending on Health, 2017, https://www.oecd.org/health/
tackling-wasteful-spending-on-health-9789264266414-en.htm
3  Alan Maynard, ‘What about Value for Money?’, BMJ, 342 (2011), https://doi.
org/10.1136/bmj.d1319
© Chapter’s authors, CC BY 4.0  https://doi.org/10.11647/OBP.0195.05
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high-value, high-impact ones: a rare win-win for healthcare. Low-
value resource allocation exists for a multitude of reasons: lack of 
evidence needed to create better health outcomes or to identify 
cheaper but equally effective procedures; poor management and weak 
coordination; social and political factors that may be of little general 
benefit to the community; the knowledge deficits and biases of the 
policy-makers and program managers; and governance-related waste 
such as fraud and corruption.4
This problem of low-value care is increasingly recognized in 
clinical medicine.5 Many countries are now promoting the use of 
generic medicines,6 seeking to prevent unnecessary interventions, 
avoiding adverse events and improving the targeting of tests and 
interventions to those most likely to benefit. However, much less is 
known about inefficient spending on the prevention and control of 
non-communicable diseases (NCDs) at the programmatic level. This 
chapter aims to fill this gap. 
Our objective is to show that tackling inefficient spending or ‘Wasted 
Buys’ is a value-enhancing agenda which acts as a catalyzer in achieving 
the ultimate goals of a healthcare system. We provide an operational, 
pragmatic definition of Wasted Buys which will help program managers 
and policy-makers to identify inefficient spending and initiate a 
constructive dialogue; explain the common characteristics of inefficient 
spending incurred in the prevention of NCDs with current examples; 
and show how inefficient spending can be avoided by substituting 
better care at the same cost, more efficient care (more benefit compared 
to incremental cost), or cheaper alternatives with the same or even better 
health outcomes.
5.1.1 What Are ‘Wasted Buys’?
The scalability of any intervention is subject to available evidence, which 
is often lacking, or is of variable quality, or is not context specific. What 
constitutes waste is often revealed in an implementation setting that is 
different from the study setting that generated the existing evidence, so 
4  Vikas Saini et al., ‘Addressing Overuse and Underuse around the World’, The 
Lancet, 390 (2017), 105–7, https://doi.org/10.1016/S0140-6736(16)32573-9
5  Shannon Brownlee et al., ‘Evidence for Overuse of Medical Services around the 
World’, The Lancet, 390 (2017), 156–68, https://doi.org/10.1016/S0140-6736(16)32585-5
6  OECD, ‘Pharmaceutical Spending Trends and Future Challenges’, in Health at 
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that what might be seen as wasted in one context might not be wasted 
in another. So how should a program manager identify a Wasted Buy?
The OECD defines ‘waste’ in a developed country context as: 
(i) services and processes that are either harmful or do not deliver 
benefits; and (ii) costs that could be avoided by substituting cheaper 
alternatives with identical or better benefits.7 Developed countries 
have well-established priority-setting mechanisms and data capture, 
which can be synthesized into relevant evidence to guide health 
policy. Developing countries pose a range of challenges in conducting 
a cost-effectiveness analysis, such as interpreting the poor-quality or 
non-contextual data used to estimate costs and effects, the choice of 
the comparator and whether subgroups of the target population are 
analyzed. There are therefore many uncertainties about how best to 
proceed. A comprehensive, pragmatic definition that fits the LMIC 
context is therefore required. 
Recalling the analysis of Chapter 1, we treat Wasted Buys as 
interventions that fall in the shaded area in Figure 5.1, while interventions 
falling in Section 2 of Quadrant B and the whole of Quadrant D are not 
Wasted Buys.
Fig. 5.1 Wasted Buys on a cost-effectiveness plane.




7  OECD, Tackling Wasteful Spending on Health.
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Wasted Buys include interventions that deliver no health benefits 
(Quadrant A); interventions that yield a higher cost per unit of health 
outcome gained than the cost-effectiveness threshold in that setting 
(Section 1 of Quadrant B); and interventions that have low efficacy or 
no significant positive impact on health outcomes albeit at a meagre 
cost (Section 3 in Quadrant C). Interventions falling in Section 4 in 
Quadrant C may need to be deliberated. For instance, interventions 
with a negative impact may be Contestable or even Best Buys if the cost 
reduction is sufficiently large to enable more health benefits to be gained 
elsewhere. Lastly, interventions that have a small cost or benefit impact, 
or about which there is substantial uncertainty, which fall in the ‘area 
of uncertainty’ should be carefully scrutinized before implementation 
(Section 5).
5.1.2 The ‘Area of Uncertainty’
The area of uncertainty (Section 5) has a fuzzy boundary. It has no 
sharp edges. The area of uncertainty includes interventions that have 
substantially uncertain benefits or cost-effectiveness. There are three 
reasons for this. The first is a lack of knowledge and information about 
the benefits and/or costs of an intervention, as when an intervention 
is still in the experimental phase or implemented with insufficient 
understanding of the context. The second is uncertainty around 
estimations of effect, cost and cost-effectiveness that may come from 
parameter uncertainty, model uncertainty and uncertainties concerning 
the assumptions used — for example, in modelling future streams of 
benefit beyond experimental periods, or in the use of a constant rate 
of disease incidence over time. Uncertainty afflicts both clinical and 
economic studies. Finally, generalizability issues occur with proposals 
to implement an intervention in a new setting with conditions that vary 
from the study setting. 
It is plainly important to note whether the radius of the circle 
is large or small or, indeed, whether it is a circle. This might remain 
unknown until further research has been conducted. The importance 
of understanding these different aspects of uncertainty may also 
vary across interventions, depending on several factors, such as the 
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infeasibility of some interventions in resource-limited settings. While 
the cost-effectiveness plane is useful in understanding the types of 
uncertainty that affect cost, benefit and cost-effectiveness, it does not 
account for the uncertainties that are unrelated to ex-ante evaluations 
(conducted prior to the implementation), such as those implicit in the 
implementation of the intervention itself.
5.2 Exploring Wasted Buys in Low-  
and Middle-Income Countries (LMICs)
While Best Buys are recognized and widely acknowledged, the existence 
of Wasted Buys and even Contestable Buys has only just started to gain 
traction in the health community. The concept of Wasted Buys is broad 
and examples abound in many countries. To better understand the 
nature of Wasted Buys, we reviewed the literature to identify studies 
that illustrated ineffective and cost-ineffective interventions. The 
review focused on economic evaluations of preventive interventions in 
non-communicable diseases. We searched the Cochrane Collaboration 
Database, the Global Health Cost-Effectiveness Analysis (GH CEA) 
Registry from the Tufts Medical Center and the Disease Control 
Priorities project.
A. Cochrane Collaboration Database 
Effectiveness is a necessary (but not sufficient) starting point to ensure 
the benefits of an intervention for the health system or to identify a Best 
Buy. If an ineffective intervention has been implemented, it counts as 
a low value or a ‘Wasted Buy’. The Cochrane Collaboration database8 
is a trustworthy resource and has curated content on the effectiveness 
of a variety of interventions. We reviewed interventions focusing on 
negative or inconclusive results. Cochrane reviews related to mass-
media campaigns for NCD preventions were selected and are discussed 
in detail in the next section.
8  ‘Cochrane | Trusted Evidence. Informed Decisions. Better Health’, 2019, https://
www.cochrane.org/
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B. The Global Health Cost-Effectiveness Analysis (GH CEA) Registry
We reviewed articles from the GH CEA Registry9 to establish the 
usefulness of the database and to understand the ‘cost-per-DALY 
averted’ approach to identifying Wasted Buy interventions. The review 
covered research conducted in LMICs; research on four specific NCDs: 
cancer, cardiovascular diseases (CVD), chronic respiratory diseases and 
diabetes; and intervention(s) for NCD prevention. Interventions were 
classified as Wasted Buys if the ICER was greater than three times the 
gross domestic product (GDP) per capita (which is referred to as a proxy 
for decision-making in LMICs that lack local research on thresholds) or if 
the ICER was negative, meaning that the intervention is costlier and less 
effective than the comparator(s). Nine studies were identified, of which 
one, a study on the cost-effectiveness of medical primary prevention 
strategies to reduce absolute risk of cardiovascular disease in Tanzania, 
was selected for review in detail. 
C. Disease Control Priorities (DCP)
The three editions of the DCP that have been published focus on 
cost-effective options according to current research: they highlight 
potential Best Buys, or interventions that yield the most benefits in 
terms of health outcomes compared to cost. We reviewed the DCP’s 
second edition and selected sections of the third to assess the project’s 
ability to shed light on Wasted Buys as well as Contestable Buys and 
Best Buys. The following chapters of DCP II were selected: Health 
Service Interventions for Cancer Control in Developing Countries; 
Diabetes: The Pandemic and Potential Solutions; Cardiovascular 
Disease; and Respiratory Diseases in Adults. From DCP III, Volume 
3 (Cancer) and Volume 5 (Cardiovascular, Respiratory and Related 
Disorders) were selected. The DCP authors conducted systematic 
reviews of high-burden diseases and economic evaluations, including 
diabetes in developing countries. They explored the interventions that 
9  Center for the Evaluation of Value and Risk in Health (CEVR)  Tufts Medical Center, 
‘Global Health CEA Registry’, 2019, http://healtheconomics.tuftsmedicalcenter.org/
ghcearegistry/
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were mentioned as being of lower priority due to cost-ineffectiveness, 
less clinical benefit, infeasibility and other relevant considerations. 
They are non-prescriptive and were published without the use of 
any specific threshold or willingness to pay for an intervention. In 
addition, many of the studies used different methods and had no 
standard outcome measures. Since performance of the interventions in 
the implementation setting is a major consideration in identifying Best 
or Wasted Buys, interventions from the DCP project require further 
study or research for their transferability across settings.10
To analyze context-specific factors that might lead to Wasted Buys 
and that capture the perspective of program managers, we placed a 
call for case studies (as described in Chapter 1). This was circulated 
through a variety of networks. Fifty-eight case studies from thirty 
countries were received. Case studies that were deemed relevant to 
the NCDs theme were then analyzed (see Online Appendix 4B). A 
considerable portion of the cases submitted as Best Buys were not 
based on any evidence other than international guidelines or other 
countries’ precedents. This is reflected in the case studies on diabetes 
screening in Indonesia and Thailand and drug testing among civil 
servants in Bhutan. 
Case Study 5.2.1 Leveling up: Mass-media campaigns  
for prevention of NCDs
Mass-media campaigns can change risk behavior by providing 
information with messages of warning, empowerment, or support, or 
offering incentives intended to correct erroneous normative beliefs, 
clarify social and legal norms, or set positive role models or social 
norms.11 Several behavioral theories explain the possible relationships 
through which mass-media interventions can influence health-related 
behavior by improving knowledge, attitudes and self-efficacy that 
contribute to a person’s motivation and competence to take appropriate 
10  K. M. Venkat Narayan et al., ‘Diabetes: The Pandemic and Potential Solutions’, 
in Disease Control Priorities in Developing Countries, 2nd Edition (Washington, DC: 
Oxford University Press, New York The International Bank for Reconstruction and 
Development/The World Bank, 2006).
11  Marica Ferri et al., ‘Media Campaigns for the Prevention of Illicit Drug Use in Young 
People’, Cochrane Database of Systematic Reviews, 5.6 (2013), CD009287, https://doi.
org/10.1002/14651858.CD009287.pub2
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actions.12 Given their potential for population reach, many governments 
often use mass media to deliver health messages with the intention of 
improving health literacy and mitigating risky health behavior. 
The WHO recommends several mass-media campaigns as Best Buys 
in NCD prevention.13 These include:
• mass-media campaigns that educate the public about the 
harms of smoking/tobacco use and second-hand smoke;
• mass-media campaigns to promote healthy diets (including 
social marketing to reduce the intake of total fat, saturated 
fats, sugars and salt) and the intake of fruits and vegetables;
• reduced salt intake through a mass-media campaign that aims 
to change behavior; or
• a mass-media campaign combined with other community-
based education, motivational and environmental programs 
aimed at supporting behavioral change in relation to physical 
activity levels.
But mass-media interventions might be Contestable Buys. These 
campaigns are often implemented at relatively high cost, especially 
when they are administered though newspapers or other printed 
materials, radio, television, billboards or social media. Our review 
of three Cochrane publications14 reveals that the available evidence 
is inadequate to conclude that mass-media campaigns alone can 
12  Jane T. Bertrand et al., ‘Systematic Review of the Effectiveness of Mass 
Communication Programs to Change HIV/AIDS-Related Behaviors in Developing 
Countries’, Health Education Research, 21.4 (2006), 567–97, https://doi.org/10.1093/
her/cyl036; Jeff Niederdeppe et al., ‘Media Campaigns to Promote Smoking 
Cessation among Socioeconomically Disadvantaged Populations: What Do We 
Know, What Do We Need to Learn, and What Should We Do Now?’, Social Science 
and Medicine, 67 (2008), 1343–53, https://doi.org/10.1016/j.socscimed.2008.06.037
13  David E. Bloom et al., From Burden to ‘Best Buys’: Reducing the Economic Impact of 
Non-Communicable Diseases in Low-and Middle-Income Countries (Geneva, 2011), 
http://apps.who.int/medicinedocs/documents/s18804en/s18804en.pdf
14  Malgorzata M. Bala et al., ‘Mass Media Interventions for Smoking Cessation 
in Adults’, Cochrane Database of Systematic Reviews, 2013, https://doi.
org/10.1002/14651858.CD004704.pub3; Malcolm P. Brinn et al., ‘Mass Media 
Interventions for Preventing Smoking in Young People’, in Cochrane Database of 
Systematic Reviews, ed. by Kristin V. Carson (Chichester, UK: John Wiley & Sons, 
Ltd, 2010), https://doi.org/10.1002/14651858.CD001006.pub2; Annhild Mosdøl et al., 
‘Targeted Mass Media Interventions Promoting Healthy Behaviours to Reduce Risk 
of Non-Communicable Diseases in Adult, Ethnic Minorities’, Cochrane Database 
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meaningfully change health behavior and/or reduce the burden of 
NCDs in the target population. Most studies related to mass-media 
campaigns that are focused on knowledge, attitude, awareness and 
short-term change in other outcomes (such as service utilizations) 
lack clear evidence about improvements in health outcomes (such as a 
reduction in the incidence or prevalence of NCDs).15 There is therefore 
a need for stringent evaluation of such mass-media campaigns, using 
studies with a before-and-after design that control for all factors 
affecting the campaign. They should include qualitative methods to 
demonstrate impact and unpack the most important elements of the 
campaigns.16 Mass-media campaigns may have become an established 
intervention by now, so it could be difficult for NCD managers to accept 
their failure in terms of evidenced direct health impact. Campaigns may 
also, however, have value to NCD managers because they generate 
social and political coverage and may open avenues to engage public 
support for more effective NCD policies. 
This case shows that while mass campaigns are not clear Wasted 
Buys, targeted mass-media campaigns on their own are inadequate to 
moderate the growth of NCDs. It is better for these campaigns to be 
implemented after careful research that supports their use rather than 
relying on well-meaning but essentially blind faith. This case study lies 
in Quadrant A (Fig. 5.1) in the area of uncertainty. 
Case Study 5.2.2 Overseas and over here: Cost-effectiveness 
of medical primary prevention strategies to reduce the risk of 
cardiovascular disease (CVD) in Tanzania
Following the publication of the WHO’s CVD preventive guidelines,17 a 
research team led by Tanzania’s Ministry of Health and Social Welfare 
of Systematic Reviews, 12.2 (2017), 200 https://doi.org/10.1002/14651858.CD011683.
pub2
15  Ruth G. Jepson et al., ‘The Effectiveness of Interventions to Change Six Health 
Behaviours: A Review of Reviews’, BMC Public Health, 10.1 2010, https://doi.
org/10.1186/1471-2458-10-538
16  Melanie A. Wakefield, Barbara Loken and Robert C. Hornik, ‘Use of Mass Media 
Campaigns to Change Health Behaviour’, The Lancet, 376.9748 (2010), 1261–1271, 
https://doi.org/10.1016/S0140-6736(10)60809-4
17  World Health Organization, Prevention of Cardiovascular Disease: Guidelines for 
Assessment and Management of Total Cardiovascular Risk, Nonserial Publication 
(Geneva, Switzerland: World Health Organization, 2011).
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conducted a study on the cost-effectiveness of medical preventive 
therapies for reducing the absolute risk of CVD.18 Although global 
evidence reflecting the benefits of preventive medicine in cardiology 
exists, variation in countries’ circumstances, including demographic, 
epidemiological, socio-economic and policy contexts, limits the 
transferability of findings. The Ministry therefore collaborated with 
academics to produce a local cost-effectiveness study using local data, 
age-specific background mortality rates and the provider cost of CVD 
treatment.
The study found that Losartan and Simvastatin, as a combination 
drug for all risk levels, was successful in averting DALYs. However, 
Tanzania’s willingness to pay (at that time 610 USD or 1 GDP per 
capita per DALY averted) was insufficient to warrant proceeding. 
A recommendation followed that medical treatment should not be 
provided for low-risk patients without diabetes. This combination drug 
seemed to be a Wasted Buy. In this case, the threshold was a major 
determinant in the decision-making process and was explicitly used to 
identify Wasted Buys. 
Tanzania’s study result lies in Section 1 of Quadrant B (Fig. 5.1) 
because primary prevention intervention is effective but the costs exceed 
the threshold. This is an example of an intervention that is effective but 
not cost-effective. If policy-makers were to increase the level of health 
investment, this would imply higher thresholds and the multi-drug 
combination may then prove to be good value for money (however, 
doing this would also increase the likely cost-effectiveness of other, 
possibly even more efficient, interventions).
Case Study 5.2.3 Streamlining health policy for health gains:  
Diabetes screening in Thailand and Indonesia
A large element of the NCD burden in Southeast Asia is attributed to 
diabetes. An estimated 96 million people have diabetes, 90% of whom 
have the preventable type 2 diabetes.19 Almost half this burden goes 
18  Frida N. Ngalesoni et al., ‘Cost-Effectiveness of Medical Primary Prevention 
Strategies to Reduce Absolute Risk of Cardiovascular Disease in Tanzania: A 
Markov Modelling Study’, BMC Health Services Research, 16.1 (2016), 1–29, https://
doi.org/10.1186/s12913-016-1409-3 
19  ‘Addressing Asia’s Fast Growing Diabetes Epidemic’, Bulletin of the World Health 
Organization, 95.8 (2017), 550–51, https://doi.org/10.2471/blt.17.020817
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undetected, especially among disadvantaged minorities. However, 
timely diagnosis eases diabetes management and ensures access to 
appropriate care. Several countries have implemented population-
based diabetic screening programs. One such program is the WHO 
Package of Essential Non-communicable Disease Interventions (WHO 
PEN). The tools in this package enable early detection and management 
of the major NCDs. Although screening is widely considered to be an 
effective strategy, program managers and policy-makers often fail to 
assess the transferability of the global guidelines. 
In Indonesia and Thailand, CVD and diabetes are significant disease 
burdens. Given the health and financial benefits of screening, these 
countries’ ministries adapted parts of the PEN guidelines for their 
primary care public health services. After three years of implementation, 
an economic evaluation of the PEN package in Indonesia compared to no 
screening was conducted.20 The findings revealed that implementation 
of the PEN program was indeed better than no policy, although it could 
have been improved through a targeted screening policy for high-risk 
groups aged forty and above, as opposed to the current entry level of 
fifteen years old. Screening for the fifteen-to-thirty-nine-year-old age 
category turned out to be a Wasted Buy. The savings from adopting 
the study recommendations could potentially be invested wisely and 
efficiently in other areas of priority. 
In 2012, Thailand introduced a policy for national diabetes 
screening annually for people aged fifteen years and above. The 
policy was solely based on a high-level decision-maker’s judgement 
following an analysis of the national epidemiological survey, but 
without considering other important factors such as infrastructure, 
feasibility, readiness assessment, or affordability. In 2015, an economic 
evaluation found that a targeted screening program for people aged 
thirty years and above would be more efficient.21 Here again, screening 
the fifteen-to-thirty-year-old segment of the population was found to 
be a Wasted Buy.
20  Waranya Rattanavipapong et al., ‘One Step Back, Two Steps Forward: An Economic 
Evaluation of the PEN Program in Indonesia’, Health Systems and Reform, 2.1 (2016), 
84–98, https://doi.org/10.1080/23288604.2015.1124168
21  Yot Teerawattananon et al., ‘Development of a Health Screening Package under the 
Universal Health Coverage: The Role of Health Technology Assessment’, Health 
Economics (United Kingdom), 25 (2016), 162–78, https://doi.org/10.1002/hec.3301
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The adoption of the new targeted screening policy in Thailand, 
despite its practicality and financial feasibility, posed a major challenge 
to policy-makers due to a potential negative public perception of the 
disinvestment. In Thailand, even though the evaluation was conducted 
in 2015, implementation took three years and received much resistance 
from policy-makers. In cases like these, an assessment of the key success 
factors, as well as the external factors influencing the intervention and 
their implications in the implementation context, should be considered. 
Using the SEED Tool detailed in Chapter 3, Considerations Two and 
Three would help address these points systematically.
Diabetes screening lies in the cost-ineffective region of Section 1 of 
Quadrant B (Fig. 5.1), because, although screening can be cost-effective, 
screening the entire population is not.22 
Case Study 5.2.4 Back to basics: Drug testing in Bhutan
Lifestyle choices contribute greatly to the burden of NCDs. Smoking, 
substance and alcohol abuse are notorious culprits. Some countries 
use workplace drug testing as a common intervention to mitigate the 
risk of substance abuse. The United States, one of the early adopters, 
first implemented it in the mid-1980s to ensure drug-free federal 
workplaces, initially for employees in safety and security jobs. Soon 
after, new laws allowed public and private companies to drug test 
their employees.23 Decades later, other countries, including the United 
Kingdom, Canada and several other European countries, introduced 
measures allowing drug testing using urine sampling. The reliability of 
this method is imperfect. Urine drug testing can involve samples that 
have been diluted; it is unable to differentiate between recreational and 
habitual use or uses on or without prescription. It is also found that 
urine samples contain metabolites and little of the parent drug.24
22  Rattanavipapong et al.; Teerawattananon et al.; Wangchuk Dukpa et al., ‘Is Diabetes 
and Hypertension Screening Worthwhile in Resource-Limited Settings? An 
Economic Evaluation Based on a Pilot of a Package of Essential Non-Communicable 
Disease Interventions in Bhutan’, Health Policy and Planning, 30.8 (2015), 1032–43, 
https://doi.org/10.1093/heapol/czu106
23  Michael R. Frone, Alcohol and Illicit Drug Use in the Workforce and Workplace, Choice 
Reviews Online (Washington, DC: American Psychological Association, 2013).
24  Michael R. Levine and W. P. Rennie, ‘Pre-Employment Urine Drug Testing 
of Hospital Employees: Future Questions and Review of Current Literature’, 
Occupational and Environmental Medicine, 61.4 (2004), 318–24, https://doi.org/10.1136/
oem.2002.006163
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There are often two main objectives in implementing a drug testing 
program: to reduce substance abuse in the workplace during working 
hours; or to ensure workplace safety. The effectiveness of workplace 
drug testing in meeting these objectives is unclear or may have 
unintended negative outcomes. Two systematic reviews examined the 
effectiveness of random drug testing aimed at determining whether it 
reduces injuries and accidents, of which one also examined whether it 
deterred employee drug use. The studies had methodological limitations 
and the evidence was insufficient to conclude that drug testing was 
effective.25 Several studies also found weaknesses in the reviews, such 
as lack of randomization and test result validation. Drug testing as 
an intervention should therefore be undertaken with caution.26 In the 
United States, research shows that employee drug testing often does not 
reduce employee substance abuse but may have the effect of excluding 
abusers from the workplace entirely.27 If the goal is to reduce substance 
abuse by individual employees and ensure that they are on the path 
to quitting, additional measures are needed to provide guidance and 
therapy for current drug users, whose cost-effectiveness would also 
of course require testing. Screening alone appears to have little to no 
bearing on quitting rates. 
These issues do not disappear when LMICs implement similar policies 
without thoroughly examining the evidence. Bhutan implemented 
a pre-employment drug-testing scheme for its Royal Civil Service 
25  C. M. Cashman et al., ‘Alcohol and Drug Screening of Occupational Drivers for 
Preventing Injury’, Cochrane Database of Systematic Reviews, 2.13 (2009), https://doi.
org/10.1002/14651858.cd006566.pub2; Timothy Christie, ‘A Discussion of the Ethical 
Implications of Random Drug Testing in the Workplace’, Healthcare Management 
Forum, 28.4 (2015), 172–74, https://doi.org/10.1177/0840470415581251; Michael 
T. French et al., ‘To Test or Not to Test: Do Workplace Drug Testing Programs 
Discourage Employee Drug Use?’, Social Science Research Academic Press, 2006, 33.1, 
45–63, https://doi.org/10.1016/s0049-089x(03)00038-3 
26  P. Homo et al., ‘Workplace Drug Testing: An Overview of the Current Situation’, 
Journal of Toxins, 3.1 (2016), https://doi.org/10.13188/2328-1723.1000013; Isabel 
Kazanga et al., ‘Prevalence of Drug Abuse among Workers: Strengths and Pitfalls 
of the Recent Italian Workplace Drug Testing (WDT) Legislation’, Forensic Science 
International, 215.1 (2012), 46–50, https://doi.org/10.1016/j.forsciint.2011.03.009; 
Hilde Marie Erøy Lund et al., ‘Results of Workplace Drug Testing in Norway’, 
Norsk Epidemiologi, 21.1 (2011), 55–59, https://doi.org/10.5324/nje.v21i1.1426; 
Michael T. French et al.; Shin Yu Lin et al., ‘Urine Specimen Validity Test for Drug 
Abuse Testing in Workplace and Court Settings’, Journal of Food and Drug Analysis, 
26.1 (2018), 380–84, https://doi.org/10.1016/j.jfda.2017.01.001
27  Christie, ‘A Discussion of the Ethical Implications of Random Drug Testing in the 
Workplace’.
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Commission (RCSC).28 The RCSC aimed to eliminate substance abuse in 
the government as well as to support the general national effort to deter 
abuse. The policy suffered some of the pitfalls mentioned above: 1) the 
tests were administered by human resource officers without adequate 
quality checks of the results; 2) while the twenty-four-hour notification 
to the employee prior to testing was a rule, the actual implementation 
was questionable; 3) of the 1,682 new employees in 2017, only two tested 
positive, so the positive test rate was low, which might be accurate or 
might be due to prevalent false negative test results; and 4) though the 
employees were sent to a Drugs Counselling Centre for guidance, there 
were no further measures. Further, there are no concrete interventions 
to address substance abuse by current employees. 
The SEED Tool recommends that one should first examine the 
theoretical grounds for implementation as well as the existing evidence 
to ascertain the policy’s a priori viability in meeting its aims. Given that 
there are clinical and implementation issues as well as weak evidence 
for this intervention, the NCD managers could choose to revise the 
policy or change it entirely. For example, other interventions, such as 
health promotion detailing the dangers of substance abuse and intensive 
therapy, could be implemented alongside the testing. This case lies in 
Quadrant A as a Wasted Buy near or in the area of uncertainty (Fig. 5.1).
5.3 Common Features of Wasted Buys
These case studies reveal common features of Wasted Buys. They often 
result from misguided motivations and beliefs, as well as from political, 
institutional, managerial, economic and social pressures and rigidities 
pervading the decision-making and implementation sphere of NCD 
management. The following summarizes some of the main features: 
1) the fallacy that prevention interventions are always Best Buys; 2) 
one size seldom fits all in international guidelines; 3) policy-based 
evidence versus evidence-based policy; 4) selective implementation of 
interventions; and 5) low CE threshold used for decision-making.
28  RCSC, ‘Notifcation-on-Drug-Test’, 2017, https://www.rcsc.gov.bt/wp-content/
uploads/2017/08/Notifcation-on-Drug-Test.pdf; RCSC, ‘Bhutan Civil Service Rules 
and Regulations’, 2018, https://www.rcsc.gov.bt/wp-content/uploads/2018/05/
BCSR2018.pdf
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5.3.1 The Fallacy that Prevention Interventions  
Are Always Best Buys 
The case studies show that NCD managers, decision-makers and 
stakeholders are vulnerable to an inaccurate generalization to the 
effect that preventive interventions are always both effective and cost-
effective and so can significantly reduce the burden of the disease (the 
‘prevention is better than cure’ mantra). Such beliefs persist because of a 
lack of reliable evidence about the true impact of prevention. Many also 
believe that national scaling-up of a preventive intervention increases 
the benefits gained. This may not always be the case, as was found in 
Indonesia and Thailand’s diabetic screening of a young population. 
5.3.2 One Size Seldom Fits All in International Guidelines
It is evident from the case studies in Indonesia, Tanzania and Thailand, 
as well as from many other countries not described here, that there 
is much uncritical adoption of international recommendations and 
guidelines in the belief that they are a gold standard. Even when they 
develop their own guidelines, countries tend to incorporate international 
recommendations without contextualization. Disease factors and 
incidence, health-system infrastructure and the cost of intervention 
often change the calculated cost-effectiveness of interventions. Uncritical 
acceptance of studies done in other, more developed countries imparts 
a systematic bias when applying results to LMICs. This is a problem of 
the transferability of prevention guidelines from one setting to another. 
International recommendations are rarely tailored to the economic 
levels of countries, whether low-income, upper/middle-income, or 
high-income. They are generally based on an analysis of all countries 
with a natural focus around the mean. In this case, recommendations 
may be applicable to half of all countries that require them, but not to 
the rest (see Fig. 5.2) — for example, in the case of evaluating an anti-
hypertensive medicine with a price range that varies globally. While 
this seems like a doom-and-gloom scenario for countries beginning the 
formulation of their NCD programs, international guidelines can still be a 
useful starting point for policy consideration and priority-setting — but 
they do require careful scrutiny of methods and evidence, and may 
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sometimes require detailed analysis of subgroups via a systematic 
review or, whenever feasible, further locally-focused research.
Fig. 5.2 Normal distribution of countries benefitting from international guidelines.
5.3.3 Policy-Based Evidence Versus Evidence-Based Policy
Policies can sometimes be developed without strong evidential support, 
because they are supported instead by the interests or passions of 
high-level decision-makers, or by pressures from stakeholder groups. 
Such policies are likely to result in Wasted Buys. For example, one 
case study demonstrated that a high-level politician was a zealous 
supporter of diabetes mellitus screening, for which they then sought 
evidence to support implementation. This selective use of evidence is a 
form of exclusion bias. While ‘political engagement and support’ is an 
extremely important part of the policy-making process and is required to 
implement the policy, the SEED Tool places it as a final check to prevent 
‘policy-based evidence’ and reduce the likelihood of a Wasted Buy. 
5.3.4 Selective Implementation of Interventions 
NCDs are complex diseases requiring multi-layered interventions. 
However, some case studies, such as the Bhutan drug-testing program 
and the mass-media campaign for NCD prevention, make it evident that 
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countries often implement an intervention, policy or technology that is 
untested or has conflicting or unconvincing evidence of effectiveness. 
This scenario may be due in part to the first common feature of Wasted 
Buys, which is a belief in preventive interventions as inevitable Best 
Buys. A related case is the implementation of interventions that have 
positive effects but have been shown to require additional interventions 
to ensure a more substantial impact relative to other interventions, or 
that are effective but too costly. ‘Too costly’ in this context means that a 
greater health benefit would have been generated had the money been 
spent on other interventions, or in other sectors. This is a classic area 
where an ‘on-paper’ Best Buy results in either a Contestable or Wasted 
Buy due to incomplete understanding of the cost-effectiveness criterion, 
pre-judgment and bias, inappropriate inferences about studies that have 
been done elsewhere and poor or incomplete implementation.
5.3.5 Low CE Threshold Used for Decision-Making
Even a threshold that is low by international standards of cost-
effectiveness can cause an intervention to be a Wasted Buy because a 
threshold that is not set sufficiently low will lead to more recommended 
additions to the benefits package than the budget can sustain. There 
are many ways of determining this threshold.29 The right threshold 
may be hard to discern but it should not be set arbitrarily. An ICER 
that admits more interventions than are affordable is too high, so the 
judgment of affordability (i.e., what the budget will support) is very 
important. It is much more common for thresholds, whether explicit or 
implicit, to be set too high than too low. One way of judging the right 
level of the threshold is to model the likely consequence of (a) small 
rises or falls in it and (b) small rises or falls in the healthcare budget 
allocation. Such experimentation ought to indicate clearly whether the 
threshold should be set higher or lower.30 The tendency to set thresholds 
too high encourages Wasted Buys and may cause true Best Buys to be 
crowded out by interventions that have a much lower impact on the 
public’s health. 
29  See Chapter 1.
30  Anthony J. Culyer, ‘Cost-Effectiveness Thresholds in Health Care: A Bookshelf 
Guide to Their Meaning and Use’, Health Economics, Policy and Law, 11.4 (2016), 
415–32, https://doi.org/10.1017/s1744133116000049
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5.4 Recommendations
Our goal has been to assist NCD managers and other stakeholders 
in navigating a pathway from Wasted to Best Buys in their own local 
context. But what ought one to do to correct past commitments to Wasted 
Buys that are still present in the system? The science of ‘reversing’ 
such commitments is evolving, but the intellectual guidance provided 
in this Wasted-Buy chapter still holds. To avoid future Wasted Buys, 
or to reverse an existing one, requires similar analysis and a similar 
commitment. There needs to be:
• due deliberation about the additional31 considerations; 
• collective acknowledgment of the existence of Wasted 
Buys — that they may entail sunk costs but nevertheless are 
diverting resources from higher-value applications; 
• an awareness that it is critical to generate good will — political, 
professional and social — for broader stakeholder support 
and the process of carrying out reform, involving ongoing 
stakeholder consultation and participation; 
• a high-level commitment to ensure that priority-setting is 
part of an explicit, formal and well-resourced policy agenda 
beyond short-term political timelines; 
• transparent decision-making frameworks removed from 
vested interests; 
• clear objectives and nomenclature, articulating an ethic of 
waste reduction and minimizing opportunity costs rather 
than rationing; 
• and finally, substantial new resources for data collection, 
monitoring, analysis and sharing.32
Further, and to conclude, we recommend the following principles when 
considering any intervention:
31  See Chapter 4.
32  Adam G. Elshaug et al., ‘Levers for Addressing Medical Underuse and Overuse: 
Achieving High-Value Health Care’, The Lancet, 390.10090 (2017), 191–202, https://
doi.org/10.1016/s0140-6736(16)32586-7
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• follow the step-by-step SEED Tool for considering whether to 
implement an intervention or not. Not all preventive measures, 
even those recommended in international guidelines, can 
be assumed to be Best Buys — their health impact (relative 
to other opportunities) may not be worth the investment, 
depending on a variety of contextual factors;
• develop agendas and policies in a participatory and systematic 
way with adequate checks and balances and involvement of all 
relevant stakeholders, to increase policy scrutiny and reduce 
the likelihood of ‘policy-based evidence’;
• consider whether the reason why an intervention might 
be cost-ineffective, and therefore a Wasted Buy, could be 
related to the cost and outcome components. For example, the 
intervention cost may be higher in the implementation setting 
compared to the study setting;
• seek ways of turning an intervention into a Best Buy, such 
as cutting or minimizing high-cost items without adversely 
affecting effectiveness. Identify the factors affecting outcomes 
and whether there are contextual circumstances that limit the 
impact of the intervention; 
• consider whether there is a tenable case for a selective 
intervention even though, based on evidence, it should be 
coupled with other interventions as part of a package to 
address the outcome; 
• lastly, if the intervention has a relatively low ICER but remains 
cost-ineffective according to the average thresholds used in 
the literature, consider whether the average threshold is even 
roughly appropriate for your setting.

6. Assessing the Transferability of 
Economic Evaluations:  
A Decision Framework
David D. Kim, Rachel L. Bacon and Peter J. Neumann
6.1 Introduction
As the field of economic evaluation has grown, questions have arisen 
about how ‘transferable’ or ‘generalizable’ studies are across settings. 
Part of the answer may lie in improving standards for economic 
evaluation. Various organizations and groups have proposed standard 
practices (‘reference case analyses’) to ensure transparency, high quality 
and comparability across cost-effectiveness analyses.1 Over the past 
decade, many high-income countries have also developed their own 
standards and guidelines.2 On the other hand, despite increasing use of 
1  Tessa-Tan-Torres Edejer et al., ‘Making Choices in Health: WHO Guide to Cost-
Effectiveness Analysis’, 2003, (Geneva: World Health Organization), https://www.
who.int/choice/publications/p_2003_generalised_cea.pdf; Gillian D. Sanders et 
al., ‘Recommendations for Conduct, Methodological Practices, and Reporting of 
Cost-Effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and 
Medicine’, JAMA, 316.10 (2016), 1093–103, https://doi.org/10.1001/jama.2016.12195; 
Thomas Wilkinson et al., ‘The International Decision Support Initiative Reference 
Case for Economic Evaluation: An Aid to Thought’, Value Health, 19.8 (2016), 921–28, 
https://doi.org/10.1016/j.jval.2016.04.015
2  Randa Eldessouki and Marilyn Dix Smith, ‘Health Care System Information 
Sharing: A Step toward Better Health Globally’, Value in Health Regional Issues, 1.1 
(2012), 118–20, https://doi.org/10.1016/j.vhri.2012.03.022; Yot Teerawattananon, 
‘Thai Health Technology Assessment Guideline Development’, Journal of the 
Medical Association of Thailand, 91.6 (2011), 11; Pharmaceutical Benefits Advisory 
Committee, Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory 
© Chapter’s authors, CC BY 4.0  https://doi.org/10.11647/OBP.0195.06
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economic evaluations for priority-setting and reimbursement decisions,3 
local guidelines have only recently emerged among low- and middle-
income countries (LMICs).4 To fill the gap, the international Decision 
Support Initiative (iDSI), with the support of the Bill and Melinda Gates 
Foundation, has provided a ‘reference case’ for economic evaluations 
to reflect best practices and guidelines that could apply to different 
contexts, particularly in LMICs.5
Still, questions about transferability remain. In recent years, the 
number of available CEAs employing disability-adjusted life-years 
(DALYs) has grown rapidly (Fig. 6.1). These analyses typically reflect 
the context and health systems of a particular country or region. Ideally, 
local authorities in other areas, seeking to understand their own locally 
relevant Best or Wasted Buys and lacking an economic evaluation 
applied to their own jurisdictions, would conduct a new study to 
generate localized evidence. However, such authorities, particular in 
LMICs, often lack expertise and resources for producing such evidence.6 
As shown in Figure 6.2,7 many LMICs have few or no economic studies 
available, thus highlighting the opportunity for decision-makers in 
these jurisdictions to apply economic evaluations conducted elsewhere. 
Committee (PBAC) Version 5.0 (Canberra: Department of Health; 2016); Michael D. 
Rawlins and Anthony J. Culyer, ‘National Institute for Clinical Excellence and Its 
Value Judgments’, BMJ: British Medical Journal, 329.7459 (2004), 224–27, https://doi.
org/10.1136/bmj.329.7459.224; Health Intervention and Technology Assessment 
Program (HITAP), Guide to Health Economic Analysis and Research (GEAR) Online 
Resource: Guidelines Comparison, 2019, http://www.gear4health.com/gear/
health-economic-evaluation-guidelines
3  Catherine Pitt et al., ‘Foreword: Health Economic Evaluations in Low- and Middle-
Income Countries: Methodological Issues and Challenges for Priority Setting’, 
Health Econ, 25 Suppl 1 (2016), 1–5, https://doi.org/10.1002/hec.3319
4  Health Intervention and Technology Assessment Program (HITAP); Benjarin 
Santatiwongchai et al., ‘Methodological Variation in Economic Evaluations 
Conducted in Low-and Middle-Income Countries: Information for Reference Case 
Development’, PLoS One, 10.5 (2015), e0123853, https://doi.org/10.1371/journal.
pone.0123853
5  Wilkinson et al. 
6  Michael F. Drummond et al., ‘Issues in the Cross-National Assessment of Health 
Technology’, International Journal of Technology Assessment in Health Care, 8.4 (1992), 
670–82; M. Drummond, F. Augustovski et al., ‘Challenges Faced in Transferring 
Economic Evaluations to Middle Income Countries’, International Journal of 
Technology Assessment in Health Care, 31.6 (2015), 442–48, https://doi.org/10.1017/
s0266462315000604
7  Center for the Evaluation of Value and Risk in Health (CEVR) Tufts Medical Center, 
Global Health CEA Registry, 2018, http://healtheconomics.tuftsmedicalcenter.org/
ghcearegistry/
Fig. 6.1  The growth of cost-per-DALY-averted studies. Source: Author’s analysis 
of Tufts Medical Center Global Health Cost-Effectiveness Analysis (CEA) 
Registry (www.ghcearegistry.org). 
Fig. 6.2  Geographic distributions of available cost-per-DALY-averted studies for 
non-communicable diseases. Source: Author’s analysis of Tufts Medical 
Center Global Health CEA Registry (www.ghcearegistry.org).
Note: DALY = disability-adjusted life-year.
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When applying economic evidence generated elsewhere to local settings, 
researchers and decision-makers need to consider potentially important 
differences in factors such as population characteristics, epidemiology, 
relative prices, religion and culture, and health systems. For example, 
the economic value of implementing national breast cancer screening 
may vary substantially by the regional or local population risks of 
developing breast cancer; the feasibility of workplace health and safety 
measures will depend upon the work patterns that prevail and the risks 
to which workers are exposed; the costs and benefits associated with 
investing or disinvesting in fertility services or clinics for pregnancy 
terminations are likely to vary greatly according to predominant 
national religious affiliations. 
 For this chapter, we define ‘transferability’ as the extent to which 
particular study findings can be applied to another setting or context. 
Results from highly transferable studies could thus be used in various 
decision-making contexts without further adjustment. 
Despite the importance of transferability in global health priority-
setting, several major guidelines and reports, including the Disease 
Control Priorities Third Edition, do not explicitly address a process for 
evaluating transferability or list the factors to consider for local relevance.8 
This chapter provides a decision-making framework and a checklist for 
the field, to help local decision-makers and practitioners who wish to 
apply existing economic evaluation results to their own settings. 
The chapter starts by reviewing the existing literature on the 
transferability of economic evaluations (Section 6.2). We then 
summarize critical factors for consideration and provide a decision-
making framework to help determine whether local decision-makers 
should accept the external evidence without further adjustment, modify 
it to reflect local data, or reject it altogether (Section 6.3). Section 6.4 
provides a worked example to provide a step-by-step illustration of 
how to perform the transferability assessment using our framework. 
We also discuss the use of an ‘Impact Inventory’ to aid decision-makers 
who wish to conduct for themselves original economic evaluations and 
identify Best and Wasted Buys in local settings (Section 6.5). The final 
section (Section 6.6) provides conclusions and future steps. 
8  Wilkinson et al.; S. Horton, ‘Cost-Effectiveness Analysis in Disease Control 
Priorities’, in Disease Control Priorities, ed. by D. Jamison et al. (Washington, DC: 
World Bank, 2017), 3rd edn., IX, pp. 145–56.
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6.2 Review of the Literature
A growing literature discusses issues surrounding the transferability 
of economic evaluations. Previous studies identified factors such as 
epidemiology, demography, relative prices, capacities of health systems, 
political and cultural conditions, affordability and others. These studies 
also suggested that the transferability of results to other settings was 
sometimes feasible, though a lack of transparency in the original 
research often made a judgment impossible. Several case studies have 
also been conducted to assess transferability empirically, for example, in 
physical activities among children, breast cancer treatment and smoking 
cessation.9 Despite the substantial growth of studies on this topic, 
systematic literature reviews and national guidelines have highlighted 
variations in approaches regarding the transferability of data from one 
setting to another.10 Here, we briefly summarize the contributions of 
major papers identified through Google Scholar, PubMed and cited 
references. Online Appendix 6A provides the search strategy in detail. 
In 1992, Drummond and co-authors first highlighted important 
considerations for extrapolating economic evaluation results using 
a case study of a multi-country evaluation of the prophylactic use of 
misoprostol vs. no prophylaxis for patients with abdominal pain.11 The 
paper suggested that a standard methodology used for all studies and 
9  Saskia Knies et al., ‘The Transferability of Economic Evaluations: Testing the 
Model of Welte’, Value Health, 12.5 (2009), 730–38, https://doi.org/10.1111/j.1524-
4733.2009.00525.x; Katharina Korber, ‘Potential Transferability of Economic 
Evaluations of Programs Encouraging Physical Activity in Children and Adolescents 
across Different Countries — a Systematic Review of the Literature’, International 
Journal of Environmental Research and Public Health, 11.10 (2014), 10606–21, https://doi.
org/10.3390/ijerph111010606; Brigitte A. B. Essers et al., ‘Transferability of Model-
Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment 
of HER2-Positive Early Breast Cancer in the Netherlands’, Value Health, 13.4 (2010), 
375–80, https://doi.org/10.1111/j.1524-4733.2009.00683.x; Marrit Berg et al., ‘Model-
Based Economic Evaluations in Smoking Cessation and Their Transferability to 
New Contexts: A Systematic Review’, Addiction, 112.6 (2017), 946–67, https://doi.
org/10.1111/add.13748
10  Ron Goeree et al., ‘Transferability of Health Technology Assessments and Economic 
Evaluations: A Systematic Review of Approaches for Assessment and Application’, 
Clinicoeconomics and Outcomes Research, 3 (2011), 89–104, https://doi.org/10.2147/
CEOR.S14404; M. Angel Barbieri et al., ‘What Do International Pharmacoeconomic 
Guidelines Say about Economic Data Transferability?’, Value Health, 13.8 (2010), 
1028–37, https://doi.org/10.1111/j.1524-4733.2010.00771.x
11  M. F. Drummond et al., Issues in the Cross-National Assessment of Health Technology.
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the application of local data may facilitate the extrapolation process. In 
1997, O’Brien summarized concerns about the transferability of cost-
effectiveness data, underscoring six significant issues: demographics 
and the epidemiology of diseases; local clinical practice and conventions; 
incentives and regulations for providers; relative prices; patient 
preferences; and the opportunity costs of resources.12 
Since the publication of these papers, several other investigators 
have suggested overarching frameworks, further explored key factors, 
and have begun to provide an empirical basis for understanding 
transferability. For example, Sculpher et al. systematically reviewed 
factors underlying variability in economic evaluations and recommended 
strategies for improving the generalizability of results.13 Welte et al. 
developed a transferability decision chart that included ‘knock-out’ 
criteria and offered a transferability factor checklist as well as methods 
for improving transferability.14 Boulenger et al. provided the European 
Network of Health Economics Evaluation Databases (EURONHEED) 
transferability information checklist.15 Manca and Willan proposed 
algorithms to choose an appropriate methodology to address between-
country differences.16 Goeree et al. identified seventy-seven factors 
affecting transferability, which they grouped into five categories: 
the patient; the disease; the provider; the healthcare system; and 
methodological conventions.17 In an attempt to improve the evaluation 
12  Bernie J. O’Brien, ‘A Tale of Two (or More) Cities: Geographic Transferability of 
Pharmacoeconomic Data’, Am J Manag Care, 3 Suppl (1997), S33–9.
13  Mark J. Sculpher et al., ‘Generalisability in Economic Evaluation Studies in 
Healthcare: A Review and Case Studies’, Health Technology Assessment, 8.49 (2004), 
https://doi.org/10.3310/hta8490 
14  Robert Welte et al., ‘A Decision Chart for Assessing and Improving the Transferability 
of Economic Evaluation Results between Countries’, Pharmacoeconomics, 22.13 
(2004), 857–76, https://doi.org/10.2165/00019053-200422130-00004
15  Stephanie Boulenger et al., ‘Can Economic Evaluations Be Made More 
Transferable?’, European Journal of Health Economics, 6.4 (2005), 334–46, https://doi.
org/10.1007/s10198-005-0322-1; John Nixon et al., ‘Guidelines for Completing the 
EURONHEED Transferability Information Checklists’, European Journal of Health 
Economics, 10.2 (2009), 157–65, https://doi.org/10.1007/s10198-008-0115-4
16  Andrea Manca and Andrew R. Willan, ‘‘Lost in Translation’: Accounting 
for Between-Country Differences in the Analysis of Multinational Cost-
Effectiveness Data’, Pharmacoeconomics, 24.11 (2006), 1101–19, https://doi.
org/10.2165/00019053-200624110-00007
17  Ron Goeree et al., ‘Transferability of Economic Evaluations: Approaches 
and Factors to Consider When Using Results from One Geographic Area for 
Another’, Current Medical Research Opinion, 23.4 (2007), 671–82, https://doi.
org/10.1185/030079906x167327
 976. Assessing the Transferability of Economic Evaluations
process, researchers have developed transferability indices to quantify 
the degree of transferability of economic evaluations.18 An International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
Task Force Report reviewed national guidelines on transferability 
and made several recommendations for improvement.19 A regional-
specific assessment of transferability was conducted for middle-income 
countries,20 Eastern Europe21 and Latin America.22 
Despite previous work to identify key factors and suggest frameworks 
for assessing transferability, existing tools may not be suited for local 
authorities due to the technical and complex nature of the assessment. 
Building upon past literature, we sought to develop a new decision 
framework and checklist for assessing the transferability of economic 
evidence to local settings (Section 6.3). Decision-makers and program 
managers often require rapid answers to complex questions. Our step-
by-step guideline is a practical tool to compensate for the scarcity of 
locally-relevant economic evidence in many LMICs and to help assess 
the transferability of external evidence. 
6.3 A Decision Framework for Identifying  
Locally-Relevant Best and Wasted Buys
6.3.1 Background
In Chapter 3, the authors describe a decision pyramid (the Systematic 
thinking for Evidence-based and Efficient Decision-making [SEED] 
Tool), which suggests exploring the transferability of economic 
18  Boulenger et al.; Fernando Antonanzas et al., ‘Transferability Indices for Health 
Economic Evaluations: Methods and Applications’, Health Economics, 18.6 (2009), 
629–43, https://doi.org/10.1002/hec.1397
19  Michael J. Drummond et al., ‘Transferability of Economic Evaluations across 
Jurisdictions: ISPOR Good Research Practices Task Force Report’, Value in Health, 
12.4 (2009), 409–18, https://doi.org/10.1111/j.1524-4733.2008.00489.x
20  Michael Drummond et al., ‘Challenges Faced in Transferring Economic Evaluations 
to Middle Income Countries’, International Journal of Technology Assessment in Health 
Care, 31.6 (2015), 442–48, https://doi.org/10.1017/s0266462315000604
21  Olena Mandrik et al., ‘Transferability of Economic Evaluations To Central and 
Eastern European and Former Soviet Countries’, Value in Health, 17.7 (2014), A443-4, 
https://doi.org/10.1016/j.jval.2014.08.1172
22  G. Stewart et al., ‘A Systematic Review of Economic Evaluations in Latin America: 
Assessing the Factors That Affect Adaptation and Transferability of Results’, Value 
in Health, 18.7 (2015), A813, https://doi.org/10.1016/j.jval.2015.09.218
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evidence (Consideration 3 of the SEED Tool) as part of a process for 
identifying Best and Wasted Buys. In this chapter, we provide a decision 
framework and assessment checklist to assess transferability objectively 
and transparently in a practical manner. 
 Before applying the framework and checklist, we recommend that 
evaluators, like NCD program managers, proceed only after identifying 
the following types of information: economic evaluations relevant 
for disease areas of interest (e.g., Best Buy interventions identified in 
Chapter 4); and local guidelines on economic evaluation to be used as 
a point of reference during assessment (if unavailable, we recommend 
international guidelines, such as the iDSI reference case).23 Because 
assessments can be complex, we suggest convening a technical review 
panel that involves, if possible, a variety of stakeholders, such as 
epidemiologists, clinicians, disease program managers and analysts 
(e.g., decision scientists or modeling experts). A variety of expertise 
in the review panel can provide diverse perspectives on how best to 
determine the transferability of the evidence to the local context. 
6.3.2 A Decision Framework and  
a Transferability Assessment Checklist 
The process starts with an initial assessment to determine whether 
the existing study warrants further evaluation (Step 1), followed by a 
data transferability assessment (Step 2). Using the flowchart (Fig. 6.3), 
four options regarding transferability exist: 1) applying the external 
evidence without further adjustment; 2) modifying the economic 
evidence based on local data; 3) using the evidence with caution when 
the economic evidence is not necessarily highly transferable, but still 
deemed informative to the decision problem; and 4) rejecting the 
evidence altogether. Table 6.1 provides a transferability checklist tool. 
The case study (Section 6.4 in this chapter) illustrates how to apply 
our framework and conduct the transferability assessment by using 
the example of Best Buy interventions for diabetes prevention and 
management for Kenya.
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Step 1: Initial Assessment of Study Design 
A foundational starting point is to examine whether the study under 
consideration is a suitable candidate for the transferability assessment. 
Previous literature also describes this process as the minimal 
methodology standard or the set of ‘knock-out’ criteria.24 The initial 
assessment consists of five components relevant to study design: A) 
perspective; B) intervention and its comparator(s); C) time horizon; 
D) discounting; and E) study quality. If any of these components do 
not meet the minimum criteria — which are subject to the evaluator’s 
judgment — the study conclusion cannot be applied to local settings. 
However, when the original study results are judged as potentially 
useful (e.g., through sensitivity analyses reporting how Incremental 
Cost-Effectiveness Ratios [ICERs] vary by different perspectives), the 
evaluator may either apply the original findings with caution or proceed 
further to the data transferability assessment. We discuss each of the 
five components for minimum study standards in detail: 
A. Study Perspective
Practice guidelines for economic evaluation emphasize the importance 
of the analytic perspective (or viewpoint) because it determines which 
costs and benefits to include in the analysis.25 Analytic perspectives may 
reflect a specific payer (e.g., Ministry of Health or local government), 
the healthcare sector as a whole, or the broader society. Depending 
on the choice of perspective, an intervention may be more cost-
effective (i.e., have a lower ICER) or less cost-effective. For example, 
pharmacotherapy for patients with alcohol use disorder is more cost-
effective from a societal perspective than a healthcare sector perspective 
24  Welte et al.; D. K. Heyland et al., ‘Economic Evaluations in the Critical Care 
Literature: Do They Help Us Improve the Efficiency of Our Unit?’, Critical Care 
Medicine, 24.9 (1996), 1591–98; Helmut Spath et al., ‘Analysis of the Eligibility of 
Published Economic Evaluations for Transfer to a Given Health Care System. 
Methodological Approach and Application to the French Health Care System’, 
Health Policy, 49.3 (1999), 161–77.
25  Michael F. Drummond et al., Methods for the Economic Evaluation of Health Care 
Programmes (Oxford: Oxford University Press, 2015); Peter J. Neumann et al., Cost-
Effectiveness in Health and Medicine (New York: Oxford University Press, 2017).
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because of improved outcomes that go beyond the healthcare sector, 
such as improved productivity or reduced alcohol-related motor-
vehicle accidents.26 We recommend that evaluators assess whether the 
study perspective aligns with their own decision-making preferences in 
their local setting.
B. Intervention and its Comparator(s)
Economic evaluation should reflect the specific decision problem 
that each individual decision-making group faces (e.g., interventions 
in routine use in the local setting). As a summary measure, the ICER 
represents the relative value between an intervention, which might 
already be available or considered for introduction in the local setting, 
and a comparator, which could be the standard of care, a comparable 
intervention, or the absence of an intervention. If the intervention or 
comparator(s) in the original study are not available or are not relevant 
in the local settings, results may not be easily transferable. Inadequate 
description of the intervention and comparator(s) in the original study 
may also limit transferability. 
C. Time Horizon
The time horizon used in CEAs can substantially affect the estimated 
value of an intervention.27 Standard guidelines recommend using a time 
horizon long enough to capture all relevant costs and health benefits.28 
When assessing interventions targeted for NCDs, such as cardiovascular 
diseases, cancer and diabetes, a lifetime horizon is recommended. Lifetime 
horizons can capture all of the important differences in consequences 
over time. For example, evaluators who wish to understand the economic 
26  David D. Kim et al., ‘Worked Example 1: The Costeffectiveness of Treatment for 
Individuals with Alcohol Use Disorders: A Reference Case Analysis’, in Cost-
Effectiveness in Health and Medicine, ed. by Peter J. Neumann et al. (New York: 
Oxford University Press, 2017), pp. 385–430.
27  David D Kim et al., ‘The Influence of Time Horizon on Results of Cost-Effectiveness 
Analyses’, Expert Review of Pharmacoeconomics Outcomes Research, 17.6 (2017), 615–
23, https://doi.org/10.1080/14737167.2017.1331432.
28  Wilkinson et al.; Michael F Drummond et al., Methods for the economic evaluation of 
health care programmes; Neumann et al. 
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evidence on cardiovascular disease prevention may want to exclude 
studies conducted from a short-term horizon. 
D. Discounting
Practice guidelines recommend discounting all future costs and health 
outcomes so that ICERs represent the ‘present value’ of the intervention, 
adjusting for the differential timing of costs and benefits.29 In other 
words, discounting makes near-term consequences (e.g., immediate 
costs and health benefits) more valuable than long-term consequences 
(e.g., costs and health benefits occurring in distant future). This is 
because of the opportunity costs to spend money now and to experience 
immediate benefits instead of those in the future. The use of higher 
discounting rates (i.e., strongly devaluing distant costs and benefits) 
tends to underestimate the value of preventive interventions. 
 A discount rate reflects society’s (or a specific decision-maker’s) time 
preference (i.e., how much they are willing to trade off consumption 
today vs. tomorrow). Thus, guidelines sometimes suggest using the real 
rates of government bonds as a proxy. Despite the common use of 3% 
or 3.5% for discounting both costs and health outcomes (per guideline 
recommendations, such as iDSI reference case, designed to promote 
comparability across studies),30 local evaluators may wish to select a 
time preference suitable for their country or context, or there may be 
standard rules set for all public-sector investment decisions. 
E. Study Quality
When considering transferability, evaluators may understandably 
wish to exclude economic evaluations of low quality. The question is 
how to determine quality. Despite various guidelines and checklists 
on conducting and reporting CEAs,31 challenges remain because these 
29  Michael F. Drummond et al., Methods for the economic evaluation of health care 
programmes; Neumann et al.
30  Wilkinson et al.
31  Wilkinson et al.; Michael F. Drummond et al., Methods for the Economic Evaluation 
of Health Care Programmes; Sanders et al.; Don Husereau et al., ‘Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) Statement’, BMJ, 346 
(2013), f1049, https://doi.org/10.1186/1741-7015-11-80; M. F. Drummond and T. O. 
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instruments are not designed to guide decision-makers on how to 
differentiate high- and low-quality studies. The quality of the study can 
be assessed based on adherence to the economic evaluation guidelines 
(the iDSI reference case or the Second Panel’s recommendations) or via a 
formal quality assessment tool.32 One source for such information is the 
Tufts Medical Center Global Health CEA Registry (www.ghcearegistry.
org), which includes detail on the degree to which published cost-per-
DALY-averted studies adhere to the iDSI reference case.33 
Step 2: Data Transferability Assessment 
After an initial screening, evaluators can determine, depending on data 
availability, whether the original evidence can be directly applied to 
their local setting. Despite a long list of items to be considered for data 
transferability, we focus on five major factors most often referred to in 
the literature: baseline risk, treatment effects, unit costs/prices, resource 
utilization and health-state preference weight. We will also briefly 
describe the other possible items for consideration.34 
During the data assessment for each of the five factors, the evaluator 
will determine whether or not to progress to the next stage by doing a 
separate analysis in three key aspects. These aspects are: 1) the need for 
further adjustment; 2) the availability of local data; and 3) the possibility 
of adjustment based on information from the original study (e.g., in 
sensitivity analysis) or access to the original model (or authors) for 
further modification. In certain instances, evaluators may determine 
Jefferson, ‘Guidelines for Authors and Peer Reviewers of Economic Submissions 
to the BMJ. The BMJ Economic Evaluation Working Party’, BMJ, 313.7052 (1996), 
275–83; Alan Williams, ‘The Cost-Benefit Approach’, Br Med Bull, 30.3 (1974), 
252–56; Zoë Philips et al., ‘Good Practice Guidelines for Decision-Analytic 
Modelling in Health Technology Assessment: A Review and Consolidation 
of Quality Assessment’, Pharmacoeconomics, 24.4 (2006), 355–71, https://doi.
org/10.2165/00019053-200624040-00006
32  Sanders et al.; Wilkinson et al.; Joshua J. Ofman et al., ‘Examining the Value and 
Quality of Health Economic Analyses: Implications of Utilizing the QHES’, J Manag 
Care Pharm, 9.1 (2003), 53–61, https://doi.org/10.18553/jmcp.2003.9.1.53
33  Center for the Evaluation of Value and Risk in Health (CEVR) Tufts Medical Center; 
Joanna Emerson et al., ‘Adherence to the IDSI Reference Case among Published 
Cost-per-DALY Averted Studies’, PLOS ONE, 14.5 (2019), e0205633, https://doi.
org/10.1371/journal.pone.0205633
34  Barbieri et al.; O’Brien; Sculpher et al.; Welte et al.; Boulenger et al.; Goeree et al. 
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that the original study is still informative to the local context even when 
the local data are not available or appropriate adjustment is not possible.
A. Baseline Risk (Disease Profile)
Variation in underlying population risk factors across countries is linked 
to different inherent baseline risk characteristics, such as differences in 
disease incidence, prevalence and background mortality. Differences in 
baseline risk may influence both an intervention’s effects and its costs 
in terms of actual resource utilization. For example, implementing a 
nation-wide screening program for type 2 diabetes may generate more 
favorable ICERs for countries with a higher prevalence of undiagnosed 
type 2 diabetes.35 Thus, the evaluator must determine whether the 
baseline risk in the original study is relevant to the local context. 
B. Treatment Effects (Clinical Information)
Treatment effects (i.e., measured as an intervention’s relative efficacy) 
are generally considered more transferable than other data inputs as the 
estimate is less likely to depend upon the practices and competencies 
of local professionals in LMICs and the incentive embodied in the local 
health system.36 An estimate of the absolute treatment effect from a 
multinational, randomized controlled trial would presumably have 
high transferability. An estimate of the relative treatment effect may also 
be used from country-specific studies after an appropriate adjustment 
in local baseline risk. 
C. Unit Costs/Prices
Adjusting for unit costs or prices relevant to the local context will 
typically be required for data transferability. Because of its importance,37 
35  Thomas J. Hoerger et al., ‘Screening for Type 2 Diabetes Mellitus: A Cost-
Effectiveness Analysis’, Annals of International Medicine, 140.9 (2004), 689–99, https://
doi.org/10.7326/0003-4819-140-9-200405040-00008
36  Barbieri et al. 
37  Barbieri et al.; Sculpher et al.; Welte et al.
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economic evaluations often conduct sensitivity analyses on the prices of 
the intervention/comparator(s) as well as the prices for other services. 
Assuming that all other data inputs are relevant to the local setting, if 
the original study provides results from sensitivity analyses for a range 
of intervention prices, evaluators could extract the ICERs relevant to 
their local settings without re-analyzing the data. For example, when 
the price of a drug is $100 in the local setting, instead of $500 in the 
original study, an ICER from a sensitivity analysis (e.g., $1000/quality-
adjusted life-years [QALY] gained at the drug price of $100) can be used 
as the locally relevant evidence, rather than the original evidence (e.g., 
$5000/QALY at the drug price of $500). 
D. Resource Utilization
Similar to the case for unit costs, the application of locally-relevant 
resource use data (e.g., on hospital days, physician office visits, or 
medications) may be required for the estimation of overall costs 
associated with the intervention and comparator(s). Many international 
guidelines consider resource use data from external locations as 
inappropriate sources and strongly encourage the use of locally-relevant 
resource data.38 
E. Health-State Preference Weight
Health-state preference weights, used as inputs into calculations of 
QALYs, represent the relative desirability for being in different health 
states. Guidelines generally recommend using generic preference 
measures (e.g., EQ-5D, SF-6D, or HUI) that assign a specific value to 
each health state, including zero for dead and one for perfect health.39 
Because of social and cultural factors, individuals in different countries 
38  Barbieri et al.; Sculpher et al.; Boulenger et al.; Goeree et al.; Michael Drummond 
et al., ‘Increasing the Generalizability of Economic Evaluations: Recommendations 
for the Design, Analysis, and Reporting of Studies’, International Journal of 
Technology Assessment in Health Care, 21.2 (2005), 165–71, https://doi.org/10.1017/
s0266462305050221
39  Michael F. Drummond et al., Methods for the economic evaluation of health care 
programmes; Neumann et al. 
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may assign different values to similar health states.40 Previous studies 
have demonstrated that the valuations of health states can be different 
for US and UK residents and, as a result, cost-effectiveness ratios were 
doubled when adjusted to US-specific weights.41 
For health-related quality of life measures used to calculate 
QALYs, thirty-two country-specific preference weights for EQ-5D 
(valuation sets) are currently available and the number continues to 
grow.42 Disability weights, which are used to calculate DALYs, have 
been estimated from international survey participants. Although they 
may not reflect the preference for health states among specific target 
populations, disability weights may be more readily transferable 
across different countries.43 
Once the data transferability assessment is completed, a final 
decision is required on whether local decision-makers should: 1) 
apply the external evidence without further adjustment, 2) modify the 
evidence based on local data, 3) use the evidence with caution because 
it is not highly transferable, but still deemed informative, or 4) reject 
the evidence altogether. In addition to the five major factors listed 
above, previous literature has described additional factors that may 
be relevant for assessing transferability.44 The list includes variation in 
local clinical practice, healthcare infrastructure, cultural background, 
implementation costs and the valuation of productivity and other non-
health benefits. When appropriate, evaluators may include additional 
factors for their data transferability assessments. 
40  Francis Guillemin et al., ‘Cross-Cultural Adaptation of Health-Related Quality 
of Life Measures: Literature Review and Proposed Guidelines’, Journal of Clinical 
Epidemiology, 46.12 (1993), 1417–32, https://doi.org/10.1016/0895-4356(93)90142-n; 
Roger T. Anderson et al., ‘A Review of the Progress towards Developing 
Health-Related Quality-of-Life Instruments for International Clinical Studies 
and Outcomes Research’, Pharmacoeconomics, 10.4 (1996), 336–55, https://doi.
org/10.2165/00019053-199610040-00004
41  Jeffrey A. Johnson et al., ‘Valuations of EQ-5D Health States: Are the United States 
and United Kingdom Different?’, Medical Care, 43.3 (2005), 221–28, https://doi.
org/10.1097/00005650-200503000-00004; Katia Noyes et al., ‘The Implications of Using 
US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation’, Medical 
Decision Making, 27.3 (2007), 327–34, https://doi.org/10.1177/0272989X07301822 
42  ‘EQ-5D Instruments — EQ-5D’, https://euroqol.org/eq-5d-instruments/
43  Joshua A. Salomon et al., ‘Disability Weights for the Global Burden of Disease 
2013 Study’, Lancet Glob Health, 3.11 (2015), e712–23,  https://doi.org/10.1016/
S2214-109X(15)00069-8
44  Sculpher et al.; Welte et al. 
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6.4 Worked Example: Assessing Transferability of 
Best Buy Interventions for Diabetes Prevention and 
Management in Kenya
6.4.1 Background and Rationale
To provide a step-by-step illustration of how to perform a transferability 
assessment using our framework and checklist, we offer a worked 
example from Kenya. We evaluated the transferability of seven studies 
for diabetes prevention and management,45 which included fourteen 
interventions deemed Best Buys based on the WHO definition (i.e., 
cost-saving or ICER ≤ $100 international dollars (I$)/DALY averted). 
These interventions mostly include screening or interventions targeting 
behavioral changes (Table 6.2).
 This worked example should be viewed as a stylized application, 
in order to provide an illustrative case study, rather than a definitive 
analysis for Kenya. Thus, throughout the example, we assume the role of 
a program manager for a hypothetical national diabetes prevention and 
control program in Kenya. The primary responsibility of the manager 
is to determine whether the identified Best Buy interventions for 
45  Shukri F. Mohamed et al., ‘Prevalence and Factors Associated with Pre-Diabetes 
and Diabetes Mellitus in Kenya: Results from a National Survey’, BMC Public 
Health, 18.Suppl 3 (2018), 1215, https://doi.org/10.1186/s12889-018-6053-x; Sanjay 
Basu et al., ‘Comparative Effectiveness and Cost-Effectiveness of Treat-to-Target 
versus Benefit-Based Tailored Treatment of Type 2 Diabetes in Low-Income and 
Middle-Income Countries: A Modelling Analysis’, Lancet Diabetes & Endocrinology, 
4.11 (2016), 922–32, https://doi.org/10.1016/s2213-8587(16)30270-4; Elliot Marseille 
et al., ‘The Cost-Effectiveness of Gestational Diabetes Screening Including 
Prevention of Type 2 Diabetes: Application of a New Model in India and Israel’, 
Journal of Maternal-Fetal & Neonatal Medicine, 26.8 (2013), 802–10, https://doi.org/10.
3109/14767058.2013.765845; N. Lohse et al., ‘Development of a Model to Assess the 
Cost-Effectiveness of Gestational Diabetes Mellitus Screening and Lifestyle Change 
for the Prevention of Type 2 Diabetes Mellitus’, International Journal of Gynaecology 
& Obstetrics, 115 Suppl (2011), S20–5, https://doi.org/10.1016/s0020-7292(11)60007-6; 
Melanie Y. Bertram et al., ‘Assessing the Cost-Effectiveness of Drug and Lifestyle 
Intervention Following Opportunistic Screening for Pre-Diabetes in Primary Care’, 
Diabetologia, 53.5 (2010), 875–81, https://doi.org/10.1007/s00125-010-1661-8; Stephen 
Colagiuri and Agnes E. Walker, ‘Using an Economic Model of Diabetes to Evaluate 
Prevention and Care Strategies in Australia’, Health Affairs (Millwood), 27.1 (2008), 
256–68, https://doi.org/10.1377/hlthaff.27.1.256; Dana Goldman et al., ‘The Value of 
Elderly Disease Prevention’, Forum Health Economics Policy, 9.2 (2006), https://doi.
org/10.2202/1558-9544.1004
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diabetes prevention and management can be transferrable to Kenya and 
recommended as part of the country’s essential health benefits package. 
We selected Kenya as the target country for two reasons: 1) Kenya’s 
recent move to Universal Health Coverage (UHC);46 and 2) the rising 
burden of diabetes in the country.47 Kenya’s efforts to reform its health 
and finance system to achieve UHC have been the subject of media 
coverage.48 However, barriers remain to achieving UHC in Kenya, 
specifically for NCD coverage, as infectious disease remains the focus 
of the government’s funding and coverage expansions.49 The burden 
of NCDs in Kenya has been rapidly increasing, accounting for 13,200 
DALYs [36% of the country’s overall disease burden in 2017, up from 
25% in 1990). The prevalence of diabetes in Kenya was 2.4% in 2015,50 
and its burden is growing, accounting for 1.7% of total DALYs in 2017, 
up from 0.83% in 1990.51 
6.4.2 Evaluator’s Guideline on Economic Evaluation
To our knowledge, Kenya does not have local guidelines for conducting 
economic evaluations. For this stylized example, we selected the iDSI 
reference case as our hypothetical economic evaluation guideline for 
Kenya for the purpose of the transferability assessment.52 Again, we 
note that the assumptions should be considered as illustrative and may 
not reflect actual context or preferences in Kenya.
46  Jemimah W. Mwakisha and O. K. A. Sakuya, Building Health: Kenya’s Move to 
Universal Health Coverage (WHO Africa, 2018), https://www.afro.who.int/news/
building-health-kenyas-move-universal-health-coverage
47  Global Burden of Disease Collaborative Network, Global Burden of Disease Study 
2017 (Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 
2019), http://ghdx.healthdata.org/gbd-results-tool
48  Jemimah W. Mwakisha and O. K. A. Sakuya; ‘Focus on Infrastructure, Staffing 
as Kenya Rolls out Universal Healthcare’, Business Daily, 2018, https://www.
businessdailyafrica.com/datahub/Kenya-rolls-out-universal-healthcare/3815418-
4889486-6tmjej/index.html; Elizabeth Merab, ‘Road to UHC: What It Will Take to 
Achieve Health for All’, Daily Nation (Nairobi City, Kenya, 2018), https://www.
nation.co.ke/health/Road-to-UHC-what-it-will-take--to-achieve-health-for-
all/3476990-4655230-jtp203z/index.html
49  Fredrick Nzwili, ‘Kenya To Launch Universal Health Coverage Pilot Of Free 
Healthcare,’ (Health Policy Watch, 2018), https://www.healthpolicy-watch.org/
kenya-to-launch-universal-health-coverage-pilot-of-free-healthcare/
50  Mohamed et al. 
51  Global Burden of Disease Collaborative Network.
52  Wilkinson et al. 
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For the initial assessment of study design (Step 1), our baseline 
decision making criteria were the following: 1) Study perspective: a 
societal perspective preferred, but healthcare payer (or government) 
perspective is acceptable; 2) Intervention and its comparator(s): the 
intervention under consideration should be available in the local 
setting; 3) Time horizon: a lifetime horizon is strongly preferred, 
but results from a shorter time horizon may also be considered with 
caveats; 4) Discounting: a 3% annual discount rate for both costs and 
health outcomes is preferred but results using different discounting 
rates may also be considered with a caveat; and 5) Study quality: poor 
study quality, which can be assessed based on adherence to the iDSI 
reference case guidelines,53 is a reason for excluding a study from 
further assessment. 
For the data transferability assessment (Step 2), considering 
our hypothetical role of a program manager for a national diabetes 
prevention and control program in Kenya, we assume that local data 
on baseline risk (i.e., disease profiles), unit costs/prices and resource 
utilization are readily available. Data on treatment effects or other 
relevant clinical information (e.g., diabetes risk prediction) are assumed 
to be transferable to Kenya in the absence of locally-relevant clinical 
data. Finally, we assume that use of disability weights, or health-related 
quality of life weights measured from local participants and valued using 
a local valuation set, is preferred, but measures or valuation sets from 
elsewhere can be used with a caveat. A summary of the hypothetical 
economic evaluation guideline for Kenya, on which our assessment is 
based, is available in the Online Appendix 6B.
53  Ibid. 
6.4.3 Transferability Assessment Process
We conducted a transferability assessment as follows. Three evaluators 
on our research team with experience in cost-effectiveness analysis (a 
senior investigator and two junior researchers) formed our ‘evaluation 
committee’ to simulate the kind of transferability assessment that might 
occur in Kenya. The evaluation consisted of first reviewing: 1) the 
decision chart for assessing transferability (Fig. 6.3); 2) the transferability 
assessment checklist (Table 6.1); and 3) the hypothetical economic 
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evaluation guideline for Kenya (Online Appendix 6B). After an initial 
training session, each of the three committee members independently 
conducted a transferability assessment for one of the seven articles54 and 
then convened to review and discuss questions or challenges that arose 
during the assessment. 
Once the two junior evaluators completed the basic training, they 
were ‘commissioned’ to evaluate the transferability of the remaining 
six articles independently. Next, they convened a consensus meeting to 
discuss whether the original study warranted further data assessment 
and, if so, whether the original evidence could be transferable to Kenya. 
Although each of the evaluators was encouraged to assess specific 
questions pertaining to the individual study characteristics and data 
inputs listed in Table 6.1, the final decision corresponded to one of four 
options: 1) apply the external evidence without further adjustment; 2) 
modify the evidence based on local data; 3) use the evidence with caution 
because the economic evidence was not necessarily highly transferable; 
and 4) reject the evidence altogether. During the consensus meeting, 
each of the members shared their individual decision and comments and 
the group discussed conflicting opinions to reach a consensus. Finally, 
the group made consensus recommendations for the transferability of 
the external evidence.
6.4.4 Transferability Assessment Results 
Among seven studies evaluated, only one was deemed directly 
transferable to Kenya. In that case, the country of the original study, 
Ghana, was deemed sufficiently similar to Kenya in terms of disease 
prevalence and its economic profile.55 The study found that a benefit-based 
tailored treatment, a strategy to reduce the composite risk of developing 
CVD in the next ten years or a microvascular disease risk over a lifetime 
for patients with type 2 diabetes, was a cost-saving strategy (i.e., lower 
costs with greater health benefits), compared to a treat-to-target strategy, 
which aimed to achieve target levels of specific biomarkers. 
Our committee also decided that another study was not transferable 
due to its failure to meet the minimum criteria for the study design 
54  Basu et al. 
55  Ibid.
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evaluation.56 For example, although the original study reported that 
effective control of hypertension could avoid 75 million DALYs and 
reduce healthcare spending by $890 billion, the study did not examine 
any specific intervention to achieve effective hypertension control. The 
study’s low-quality score (it neither stated its discount rate nor listed 
a specific intervention to be targeted) contributed to the committee’s 
decision to reject the use of this evidence for Kenya. 
For most of the other cases, study findings were deemed not directly 
transferable due to differences in key data inputs and an inability to 
adjust the original findings. However, the committee believed that the 
external evidence may still provide useful insight for how resources 
for diabetes prevention and management might best be allocated for 
Kenya, though caveats and caution were in order. 
The initial assessment of the study design (Step 1) reached consensus 
with no disagreement. However, evaluation committee members were 
often unsure about the data transferability assessment (Step 2). Some 
of the assessment questions required knowledge about the availability 
of local data inputs and the accessibility of the models, which was not 
readily grasped by the committee members. During the consensus 
meeting, the evaluation committee resolved conflicts and ambiguity 
based on our guideline of transferability assessment designed for Kenya 
(the Online Appendix 6B). Table 6.2 provides our committee’s consensus 
recommendations for the seven studies. The Online Appendix 6C 
provides the individual transferability assessment forms completed by 
the two evaluators for all of the studies. 
Our worked example revealed a few challenges in assessing 
transferability. First, the lack of transparency in the reporting of 
existing economic evaluations, particularly on data inputs (e.g., unit 
costs/prices), often constrained the ability to determine transferability. 
The use of the online appendix to provide analytic approaches, and to 
model assumptions and data inputs in detail, would be valuable. More 
comprehensive deterministic and probabilistic sensitivity and scenario 
analyses in published economic evaluations may also help to improve 
transferability of the external evidence. 
Another issue was the inaccessibility of the original models needed to 
generate results with locally-relevant data inputs. In practice, evaluators 
56  Goldman et al.
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may reach out to study author(s) to obtain the original model. Access 
to an original model allows evaluators to revise the analysis, reflecting 
local data and adapting the model structure or assumptions to be more 
context-specific. The open-source model would thus be valuable in 
LMIC settings.57
 Finally, when assessing interventions and their comparator(s), the 
feasibility and scalability for Kenya frequently arose as a concern. For 
example, although many interventions involving diet and exercise 
counseling are found to be cost-saving or very cost-effective for managing 
diabetes,58 it was challenging to assess the availability, feasibility and 
scalability of such interventions in Kenya without input from a local 
expert. In actual practice, a diverse set of experts in the evaluation 
committee, such as epidemiologists, clinicians, disease-program 
managers and analysts, may help to alleviate some of these concerns. 
6.5 Using the Impact Inventory
In previous sections, we sought to provide a framework for decision-
makers and practitioners to assess the transferability of economic 
evaluation to local settings. When possible, analysts should conduct 
original economic evaluations to identify relevant Best and Wasted 
Buys in local settings. For these cases, we recommend using an 
‘Impact Inventory’, a structured table listing an intervention’s health 
and non-health consequences, developed by the Second Panel on 
Cost-Effectiveness in Health and Medicine.59 The Impact Inventory is 
intended to ensure that all the consequences of interventions, including 
those falling outside the formal healthcare sector, are considered 
regularly and comprehensively (Online Appendix 6D).
Because of the substantial impact of NCDs on non-healthcare sectors, 
it is essential to consider the potential consequences of interventions 
for NCDs as much as possible. Ideally, analyses will consider factors, 
such as health effects on caregivers among Alzheimers patients or the 
impact of some interventions (e.g., alcohol-use-disorder treatment) on 
the criminal justice system. Even if decision-makers disagree over how 
57  Joshua T. Cohen et al., ‘A Call for Open-Source Cost-Effectiveness Analysis’, Annals 
of Internal Medicine, 167.6 (2017), 432–33, https://doi.org/10.7326/l17-0695
58  Marseille et al.; Lohse et al.; Bertram et al.; Colagiuri and Walker.
59  Neumann et al. 
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to value those consequences and do not incorporate them into formal 
assessments, they should be aware of the potential implications outside 
the originally intended outcomes in determining an intervention’s 
value. The Impact Inventory provides an approach that allows these 
components to be considered along with local needs and priorities.
6.6 Conclusion and Next Steps
Identifying locally-relevant Best or Wasted Buys often requires 
adapting economic evaluations conducted in one country to local 
settings elsewhere. The process is challenging and requires careful 
examinations of data inputs, local data availability and other contextual 
factors relevant to specific settings. The framework and checklist 
provided in this chapter are intended to be used to assess transferability 
objectively and transparently in a practical manner. We recognize that 
others could expand the checklist to include other factors that may 
be relevant in particular circumstances and we would encourage this 
tool development. We hope that these tools serve as a useful guide to 
identifying locally-relevant Best or Wasted Buys.
Improving transparency and reporting in original studies would 
help an evaluator’s ability to assess the transferability of available 
evidence. Future areas for improving transferability across countries 
may include multi-national economic evaluations, international cost 
catalogues (https://ghcosting.org/) and an open-source platform to 
share decision-analytic models to which local data can be applied. 
Additionally, future research may examine whether each element of 
the checklist is equally important for assessing transferability and in 
what situations it is worthwhile to conduct a thorough transferability 
assessment considering the resources required for the task.

7. Finding the Best Evidence
Thunyarat Anothaisintawee
7.1 Determining the Impact of Behavior Change on 
NCDs Through Research
Knowledge changes constantly. For this, if for no other reason, non-
communicable disease (NCD) managers must be able to find up-to-date 
evidence and to interpret and integrate that evidence into their local 
decision-making. One example is the effect on health of low-calorie 
sweeteners, as seen in Case Study 7.1.1. Evidence about effectiveness 
and cost-effectiveness usually come from research findings, so 
understanding the characteristics, advantages and disadvantages of 
various types of study design is important for NCD managers if they 
are to use evidence to good effect in their local contexts. 
Case Study 7.1.1 Knowledge growth: A case study of  
low-calorie sweeteners
Sugar is one of the unhealthiest diet ingredients. Consumption of 
excessive amounts of sugar can cause diseases like obesity, type 2 
diabetes mellitus (T2DM) and heart disease. Despite this knowledge, 
current intake level is very high. In 2012 the average intake among U.S. 
adults was 77 grams per day, equal to 19 teaspoons or 306 calories.1 
For this reason, the American Heart Association Nutrition Committee 
recommended a decrease in added sugar in sweetened products. By 
1  Elyse S. Powell et al., ‘Added Sugars Intake Across the Distribution of US Children 
and Adult Consumers: 1977–2012’, Journal of the Academy of Nutrition and Dietetics, 
116.10 (2016), 1543–50.e1, https://doi.org/10.1016/j.jand.2016.06.003
© Thunyarat Anothaisintawe, CC BY 4.0  https://doi.org/10.11647/OBP.0195.07
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contrast, low-calorie sweeteners (LCSs) contain few or even no calories 
while providing an intensely sweet taste. In addition, LCSs do not cause 
the same metabolic responses in the human body as sugars. These 
desirable properties make LCSs an attractive substitute for sugar from 
a public health perspective. LCSs are usually recommended for obese 
people and T2DM patients in order to reduce their weight and control 
their blood sugar levels.
However, after using LCSs as substitute for sugar for many years, 
the shocking evidence from several observational studies was that using 
LCSs was associated with weight gain and increased the risk of T2DM. 
These findings were the very opposite of the original belief that LCSs 
were safe. Despite this evidence, the potential harmful effect of LCSs is 
debated thanks to inconsistencies in the findings between observational 
studies and intervention trials. The American Heart Association has 
recommended against the consumption of LCS beverages by children 
and encourages the use of water (plain, carbonated and unsweetened) 
rather than LCSs as an alternative to sugar-sweetened beverages.2 Based 
on the available evidence, the potential adverse effects of LCSs are still 
inconclusive and further research on the association between LCSs and 
risk of CVDs and cardio-metabolic risk factors is needed.
7.2 Types of Study Design
There are two main types of study design: quantitative and qualitative3. 
A quantitative study is useful for assessing the burden of diseases, 
exploring the association between potential risk factors and diseases and 
estimating the benefit of the intervention for the prevention and treatment 
of diseases. A qualitative study is useful for understanding the process of 
implementing an intervention, how the intervention works and what the 
obstacles are to implementing the intervention in practice. 
There are several subtypes of quantitative studies4 as presented 
in Figure 7.1. Two broad types are experimental and observational. 
Experimental studies usually allocate subjects randomly into 
intervention and non-intervention groups (arms of the trial). Such 
2  Rachel K. Johnson et al., ‘Low-Calorie Sweetened Beverages and Cardiometabolic 
Health: A Science Advisory From the American Heart Association’, Circulation, 
138.9 (2018), e126–40, https://doi.org/10.1161/cir.0000000000000569
3  Leon Gordis, Epidemiology, 5th ed. (Philadelphia, US: Elsevier, 2013).
4  Ibid.
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studies are called randomized-controlled trials (RCTs). Studies using 
non-random methods, as when patients are allocated to the arms of a 
trial according to their birth dates, are called quasi-experimental studies. 
Observational studies investigate the relationship between exposures 
and outcomes. Common types are case-control, cohort and analytic cross-
section.5 If researchers select cases (for example, subjects having interested 
outcomes) and controls (subjects not having interested outcomes) and 
compare the odds of exposure between cases and controls, we have a case-
control study. If researchers select an interesting group or cohort of the 
population, measure its exposure or treatment and follow the subjects up 
until there are outcomes, we have a cohort study. A cohort study usually 
quantifies the effect of exposure as relative risk, or the probability of the 
outcome in the exposed group compared with that in the non-exposed 
group. In analytic cross-sectional studies, researchers select a group of 
the population, as in a cohort study, but with no follow-up. Exposure and 
outcome in a cross-sectional study are measured at the same time.
An observational study may be analytical or non-analytical. An 
analytical study is one that measures a relationship between two 
variables, like the relationship between interventions or exposures and 
outcomes. A non-analytical study typically describes characteristics 
of the population, such as the burden of disease and changes in it, by 
measuring prevalence and incidence. Descriptive studies commonly 
consist of case reports, case-series and cross-sectional studies. Analytical 
studies can be divided into experimental studies, in which researchers 
assign interventions or exposures to subjects, and observational studies, 
in which exposure and occurrence of disease are measured as they 
occur, without experimental controls. 
7.3 Quality Assessment of Studies/Evidence
Different study designs have different advantages and disadvantages. 
RCTs are most free from bias, especially selection bias, because the 
subjects are assigned to intervention or control groups randomly so that 
other determinants (confounders) are also randomized.6 This yields 
5  Ibid.
6  Michael Walsh et al., ‘Therapy (Randomized Trials)’, in Users’ Guides to the Medical 
Literature: A Manual for Evidence-Based Clinical Practice, ed. by Gordon Guyatt, 
Maureen O. Meade and Deborah J. Cook, 3rd ed. (New York: McGraw-Hill 
Education, 2015).
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greater certainty that any difference in outcomes between intervention 
and control groups is attributable to the intervention rather than other 
factors. RCT is the most appropriate design for assessing treatment 
efficacy. However, RCT is not suitable for investigating disease risk 
factors because it is unethical to allocate subjects randomly to potential 
harmful exposures. For such investigations, an observational study 
design is more appropriate. Findings from RCTs cannot always be 
generalized to non-experimental settings, because the confounding 
factors controlled for in the trial may be important determinants of 
the link between causes and consequences in real-world settings. The 
RCT is highly suited to testing hypotheses about cause and effect, 
but not so suited to making predictions about outcomes in normal 
practice. This test is sometimes termed ‘internal validity’. Studies that 
attempt to predict consequences in real-world settings seek ‘external 
validity’.
Fig. 7.1 Types of study design.
Note: Outcome = O and Exposure = E.
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Observational studies are liable to suffer from confounding bias.7 This 
occurs when the measured association between exposure and outcome 
is distorted by the presence of other factors. These other factors are 
termed confounding factors or confounders. 
Amongst observational studies, the cohort design has the highest 
validity, because it allows cause to precede effect, so that a temporal 
relationship between intervention and outcome can be claimed. These 
studies are, however, time-consuming because of the need to follow 
subjects up until the outcomes occur. This design is not suitable for rare 
diseases or for those with a long latent period, such as most cancers.
Case-control and cross-sectional studies can overcome some of the 
problems with cohort studies because measurements of intervention/
exposure and outcome occur at the same time but the temporal 
relationship cannot then be understood. Moreover, the case-control 
design is prone to recall bias because participants are asked to think 
back to whether or not they received the intervention. People with the 
disease tend to remember more of the exposure than those without it.
7.4 Types of Evidence Synthesis
Due to the huge and increasing volume of evidence, its synthesis 
integrates types and sources of evidence into a coherent review. This 
is called evidence synthesis. These reviews are of two main types, 
narrative and systematic, as illustrated in Figure 7.2. Systematic reviews 
have higher validity since its review processes (scope of the review, 
inclusion/exclusion criteria, selection of studies, data analysis, resolution 
of disagreements between reviewers) are explicit, transparent and have 
to be reproducible by other researchers. 
Not only have the number of primary researches increased hugely, but 
the number of systematic reviews has also risen. Many are published every 
day,8 so it is impossible for NCD managers or policy-makers to remain 
up to date with specific topics. Systematic reviews also usually focus on 
7  Raj S. Bhopal, ‘Error, Bias, Confounding and Risk Modification/Interaction in 
Epidemiology’, in Concepts of Epidemiology: Integrating the Ideas, Theories, Principles 
and Methods of Epidemiology, 2nd ed. (Oxford: Oxford University Press, 2008).
8  Hilda Bastian et al., ‘Seventy-Five Trials and Eleven Systematic Reviews a Day: 
How Will We Ever Keep Up?’, PLoS Medicine, 7.9 (2010), e1000326, https://doi.
org/10.1371/journal.pmed.1000326
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a specific topic to answer a specific question and so may not provide a 
comprehensive picture or perspective on complex conditions or problems, 
which is the usual situation in policy decision-making. For these reasons, 
umbrella reviews, or overviews of reviews, have been developed. These 
are tertiary researches that combine data from several systematic reviews 
that are relevant to a particular health problem.9 Umbrella reviews apply 
similar methods to those of systematic reviews but aim to provide a more 
comprehensive evidence synthesis, by including, for example, evidence of 
the effectiveness of different interventions for the same condition, or the 
same intervention for different conditions or populations. The umbrella 
review is useful for providing a general idea of research in a specific area 
and also for providing information when the existing evidence about a 
given topic is inconsistent or contradictory. An example of the umbrella 
review is presented in Case Study 7.4.1.
A further benefit of umbrella reviews is the speed with which they 
can be done. For pragmatic reasons, reviews that can synthesize the 
evidence quickly are likely to be most attractive to NCD managers and 
policy-makers. Umbrella reviews that consider previous systematic 
reviews rather than primary researches can save time in work and 
rapidly provide evidence to inform policy decision-making.
Fig. 7.2 Hierarchy of evidence synthesis.
9  Lisa Hartling et al., ‘Systematic Reviews, Overviews of Reviews and Comparative 
Effectiveness Reviews: A Discussion of Approaches to Knowledge Synthesis’, A 
Cochrane Review Journal, 9.2 (2014), 486–94, https://doi.org/10.1002/ebch.1968
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Case Study 7.4.1 Efficacy of lifestyle interventions and effect 
of lifestyle factors on the risk of type 2 diabetes mellitus, 
cardiovascular diseases and hypertension: An umbrella review
Health-harmful behavior such as eating a poor diet, physical inactivity, 
inadequate sleep time, use of tobacco and alcohol, all increase the risk 
of NCDs. Health-harmful behavior also increases the burden of NCDs 
by increasing their metabolic risk factors, including being overweight/
obese, abnormal blood pressure and unhealthy glucose and lipid 
levels. To prevent and control NCDs, these metabolic risk factors 
should be reduced by modification of harmful lifestyle behavior. This 
is an umbrella review of the efficacy of lifestyle interventions for the 
primary prevention of type 2 diabetes mellitus (T2DM), hypertension 
and cardiovascular disease (CVD), and the risk effect of harmful 
behavior (poor diet, physical inactivity, smoking, alcohol drinking and 
inadequate sleep time) on T2DM, hypertension and CVD. The methods 
used are in the Online Appendix 7.
Two-hundred and sixty-seven systematic reviews and meta-
analyses (SRMAs) of interventions for T2DM, hypertension and CVD 
met our inclusion criteria and are included in the umbrella review. Of 
these, 70 were on T2DM, 127 on hypertension and 70 on CVD. Lifestyle 
interventions considered in the review were diet, physical activity, 
combined diet control and physical activity interventions, smoking 
cessation, alcohol drinking and sleep interventions. The effects of each 
intervention are summarized below. 
• Food patterns (e.g., Mediterranean, DASH and diets with high 
HEI and AHEI scores) reduced the risk of T2DM, CVD and 
high blood pressure, while the evidence on food groups and 
food nutrients show conflicting results.
• The findings from this review were similar to those of other 
reviews and confirm the benefit of moderate and high 
intensity physical activity in the prevention of T2DM and 
CVD. However, our review found that low intensity physical 
activity, such as walking, could also lower the risk of each 
condition.
• Evidence from systematic reviews and meta-analyses (SRMAs) 
of RCTs strongly supports the advantage of several lifestyle 
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interventions in the prevention of T2DM and lowering blood 
pressure. However, the RCTs showed no significant benefit of 
lifestyle interventions in the case of CVD.
• There was a J-curve association between alcohol and risk 
of CVD: moderate but not high alcohol intake significantly 
decreased the risk of CVD, when compared with non-alcohol 
intake. However, alcohol reduction in people who regularly 
drank reduced the risk of T2DM and blood pressure level. 
• Sleep is one of the lifestyle factors that was associated with 
a risk of NCD. People who sleep less than 7 hours/day had 
significant higher risk of T2DM, CVD and hypertension than 
people who sleep 7–8 hours/day.
7.5 Role of Environmental Interventions  
in Changing Health Behavior
The findings from the umbrella review show that health-promoting 
behavior significantly reduces the risk of developing T2DM. However, 
encouraging people to change their long-term unhealthy habits 
and maintain the new behavior for months or years is challenging. 
Lifestyles are not determined only by individual preferences, but also 
by sociocultural determinants (i.e., social norms and networks) and 
environmental influences (e.g., workplace and school environments, 
city plan and public transport).10 Motivating people to change their 
unhealthy lifestyles using only individual-based or health-system 
strategies might therefore be insufficient to achieve broad success, 
though applying policy- or population-based approaches by modifying 
social and environmental factors are likely to be important. 
Policy- or population-based interventions target the entire 
population. These interventions are usually classified into six types: 
• behavior-change communication and mass media campaigns,
• front-of-pack labeling and consumer information,
• taxation subsidies and other economic incentives,
10  Johannes Brug, ‘Environmental Determinants of Healthy Eating: In Need of Theory 
and Evidence’, The Proceedings of the Nutrition Society, 67.3 (2008), 307–16.
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• school and workplace interventions,
• local environmental changes and 
• direct restrictions and controls.11 
Policy interventions that are cost-effective by the WHO-recommended 
cost-effectiveness ratio of ≤100 I$ per DALY averted12 include: reducing 
exposure to risk factors such as unhealthy diets and physical inactivity 
through front-of-pack labelling of salt content, establishment of a 
supportive environment for lower-sodium options to be provided in 
public workplace cafeterias and implementing wide public education 
and awareness of the benefits of physical activity through mass-media 
campaigns. The status of these measures as Best or Wasted Buys is 
discussed in Chapters 4 and 5, respectively. Problems in evaluating their 
cost-effectiveness include the limited nature of the behavior changes 
actually induced and the time taken for effects to emerge. Additionally, 
several policy interventions (sugar tax is one) cannot be randomly 
assigned at the population level, so experimental research designs like 
RCTs are inappropriate and one needs to turn to natural experimental 
methods. 
Natural experimental studies are called for when an RCT is 
impractical or unethical, the intervention in question is likely to have a 
significant health impact but there is uncertainty about its effect size and 
there is the potential for replication or generalizability of the study.13 
This study design is more susceptible to error through omitted variable 
bias, loss to follow-up and misclassification of exposure and outcomes. 
Since the intervention cannot be randomly assigned in the population, 
this study design affords less protection against selection bias or 
confounding resulting from selective exposure to the intervention. 
Explicit multivariate modelling, with accurate measurement of 
11  Dariush Mozaffarian et al., ‘Population Approaches to Improve Diet, Physical 
Activity, and Smoking Habits: A Scientific Statement from the American 
Heart Association’, Circulation, 126.12 (2012), 1514–63, https://doi.org/10.1161/
cir.0b013e318260a20b
12  World Health Organization, ‘Best Buys and Other Recommended Interventions for the 
Prevention and Control of Non-communicable Diseases’, 2017, https://www.who.int/
ncds/management/WHO_Appendix_BestBuys.pdf 
13  Peter Craig, ‘Using Natural Experiments to Evaluate Population Health 
Interventions: New Medical Research Council Guidance’, Journal of Epidemiology and 
Community Health, 66.12 (2012), 1182–86, https://doi.org/10.1136/jech-2011-200375
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exposures, outcomes and potential confounders, in addition to using a 
large sample size to detect the expected effect, are crucial. 
7.6 Conclusion
This chapter has reviewed the armory of research designs that may be 
called into use in understanding causes and effects in NCD prevention 
and treatment. The SEED Tool in Chapter 3 recommends systematic 
reviews or umbrella reviews as useful in answering the fundamental 
question concerning the theoretical basis of an intervention’s effect, 
which helps to identify both causative variables and potential 
confounders. 
We used an umbrella review of systematic reviews to demonstrate the 
process of evidence synthesis on the efficacy of lifestyle interventions on 
health-harming behavior for T2DM, CVD and hypertension. The review 
process and data synthesis took a long time and required an enormous 
effort from the review team. Whenever possible, therefore, methods 
should be modified to accelerate the review process and provide the 
information to the decision-makers in a timely fashion. In addition, the 
umbrella review cannot replace policy monitoring and evaluation, since 
the evidence synthesis is used to inform policy development to identify 
the most effective intervention. However, monitoring and evaluation 
of policy implementation remains the key component for ensuring the 
Best Buy policy.
8. Cross-Sectoral Policies to Address 
Non-Communicable Diseases
Melitta Jakab and Peter C. Smith
8.1 Introduction
It is well-established that many — if not the majority — of the 
determinants of health lie outside the immediate control of the health 
system.1 The WHO Commission on the Social Determinants of Health2 
collected a vast body of evidence showing that the risk factors associated 
with poor health arise overwhelmingly from behavioral and social 
circumstances that cannot be addressed by the health system alone. This 
insight has led to movements such as ‘Health in All Policies’, which seek 
to ensure that health outcomes are given full consideration in all policy 
areas, including education, housing, transport, environment and fiscal 
policy. The link between social determinants and non-communicable 
diseases (NCDs) is especially strong and well-documented.3
The importance of other sectors for health-related outcomes has led 
to a growing interest in the development of cross-sectoral policies to 
1  Melita Jakab et al., ‘Health Systems Respond to Non-communicable Diseases: 
Time for Ambition’, Health Systems Respond to Non-communicable Diseases: Time 
for Ambition., 2018, http://www.euro.who.int/__data/assets/pdf_file/0009/380997/
Book-NCD-HS.pdf?ua=1
2  World Health Organization, Closing the Gap in a Generation: Health Equity through 
Action on the Social Determinants of Health (Geneva, 2008), https://apps.who.int/iris/
bitstream/handle/10665/43943/9789241563703_eng.pdf?sequence=1
3  Michael Marmot and Ruth Bell, ‘Social Determinants and Non-Communicable 
Diseases: Time for Integrated Action’, BMJ (Online), 394 (2019), 1251, https://doi.
org/10.1136/bmj.l251
© M. Jakab and P. C. Smith, CC BY 4.0  https://doi.org/10.11647/OBP.0195.08
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address health objectives. We define the concept of ‘sector’ broadly, to 
include both governmental and non-governmental parts of the economy. 
The only requirement for cross-sectoral working should be that the 
non-health sector is capable of developing and implementing policies 
in pursuit of its own sectoral objectives and is prepared to enter into a 
dialogue with the health sector on matters of mutual interest. Examples 
include joint working between health and education ministries to 
improve child health and educational progress, or public-private 
partnerships to improve the health and productivity of the workforce. 
It is noteworthy that many reported experiments with cross-sectoral 
programs seek to target disadvantaged groups and specifically address 
health inequalities, for which underlying social determinants might be 
especially important.4 
The WHO defines intersectoral action as ‘actions affecting health 
outcomes undertaken by sectors outside the health sector, possibly, 
but not necessarily, in collaboration with the health sector’.5 Using 
this definition, responsibility for implementing the actions lies outside 
the health sector, although of course the health sector may be the 
driving force behind the program and may finance part or all of it. 
In this chapter we adopt a broader view of collaboration between 
sectors, which might include but is not limited to the WHO concept of 
intersectoral actions. Specifically, our definition also includes actions 
led by the health sector that either have benefits for other sectors 
beyond health improvement, or where collaboration with another 
sector is essential for success. An example might be an occupational 
health intervention that is undertaken by a health system, partly with 
the aim of improving health per se, but also offering potential benefits 
for employers and the broader economy. We therefore use the term 
cross-sectoral actions in this chapter to describe joint working, whether 
or not implementation is led by the health sector. This definition of 
multisectoral actions captures the active collaboration of two or more 
sectors that deliberately seeks to promote some of the objectives of the 
health sector.
4  Public Health Agency of Canada and World Health Organization, Health Equity 
Through Intersectoral Action: An Analysis of 18 Country Case Studies, 2008, https://
www.who.int/social_determinants/resources/health_equity_isa_2008_en.pdf
5  World Health Organization, Intersectoral action, 2019, https://www.who.int/
social_determinants/thecommission/countrywork/within/isa/en/
 1318. Cross-Sectoral Policies to Address Non-Communicable Diseases
In many cases, cross-sectoral policies are intended to promote the 
objectives of all the sectors involved and not just those of the health 
system. For example, an educational policy to promote healthy diets 
amongst schoolchildren may have an immediate objective for the 
education sector of improving attendance and performance at school, 
but may have the additional objective of improving health (and 
reducing health inequalities) amongst young people. Such effects are 
sometimes referred to as ‘spillovers’ of the educational policy. However, 
the use of this term suggests an incidental (or accidental) benefit for the 
health sector, with an implication that the education sector would have 
implemented the program regardless of its effects on health-system 
objectives. In contrast, in this chapter we are mainly concerned with 
purposefully designed programs offering joint benefits that might not 
be implemented without active cross-sectoral collaboration. In such 
circumstances, the fact that one particular sector may have ultimate 
responsibility for implementing a program should not disguise its 
essential cross-sectoral nature.
Many of the NCD interventions discussed elsewhere in this book 
can be implemented successfully only with the involvement of other 
(non-health) sectors. It will often be the case that — from a health 
perspective — such cross-sectoral policies address the risk factors 
associated with ill-health, rather than specific NCDs. Broad areas of 
concern include nutrition, sanitation and water quality, air quality, 
alcohol and drugs, exercise and smoking.6 The diversity of important 
risk factors associated with NCDs is an indication of the wide variety of 
potential cross-sectoral collaborations that might be considered, often 
addressing the social determinants of health. Note that cross-sectoral 
work is considered central to the achievement of the United Nations 
Sustainable Development Goals.7 
Yet, notwithstanding the manifest importance of cross-sectoral 
projects for controlling the rise of NCDs, the health sector in many 
6  Jeffrey D. Stanaway et al., ‘Global, Regional, and National Comparative Risk 
Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic 
Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic 
Analysis for the Global Burden of Disease Study 2017’, The Lancet, 392.10159 (2018), 
1923–1994, https://doi.org/10.1016/S0140-6736(18)32225-6
7  Frank Pega et al., ‘The Need to Monitor Actions on the Social Determinants of 
Health’, Bulletin of the World Health Organization, 95.11 (2017), 784–87, https://doi.
org/10.2471/blt.16.184622
132 Non-Communicable Disease Prevention
countries has found it difficult to initiate and sustain such working. As 
we shall discuss, this is in part because of the administrative complexity 
of managing cross-sectoral projects. But the difficulties are also due 
in part to limitations in the traditional approach towards evaluating 
projects that rely on cross-sectoral working. In short, it will usually be 
the case that cross-sectoral projects need to take account of the objectives 
of the partner sectors as well as the health sector. We argue that this is 
not in principle difficult, but does require a reorientation of the cost-
effectiveness analysis traditionally applied in the health sector. 
The purpose of this chapter is therefore to offer a framework for 
thinking about the implementation and evaluation of cross-sectoral 
work to address NCDs. The next section examines the reasons why cross-
sectoral work has in many circumstances proved challenging. We then 
offer a simple analytic framework for assessing the cost-effectiveness 
of cross-sectoral projects. The fourth section examines the institutional 
requirements for managing cross-sectoral work and we then briefly 
present two successful case studies. We conclude by underlining the 
need for progress in this area if the rise of NCDs is to be successfully 
moderated.
8.2 Why Are Cross-Sectoral Policies So Challenging?
There is widespread evidence that countries are not exploiting all the 
opportunities that exist for effective cross-sectoral action to promote 
health-system objectives.8 There are many reasons for this. First, it is 
often extremely difficult to formulate persuasive policies relating to 
cross-sectoral working. Successful design requires knowledge of all the 
sectors involved, often requiring novel methods of policy development 
and knowledge sharing. The various sectors will have different 
objectives, different budgetary, legal and other constraints and different 
metrics of success. Reconciling these differences and creating a unified 
policy is likely to be more challenging than remaining in the ‘comfort 
zone’ of single-sector programs.
8  Kumanan Rasanathan et al., ‘Governing Multisectoral Action for Health in Low- 
and Middle-Income Countries’, PLoS Medicine, 14.4 (2017), e1002285, https://doi.
org/10.1371/journal.pmed.1002285; David Mcdaid, ‘Institutionalising Inter-Sectoral 
Action: A Time for Leaping and Pole-Vaulting. Eurohealth. 24.1, 13–15.
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Second, the institutions of public administration often militate 
against successful cross-sectoral working. Within government, 
ministries are usually given discrete budgets, sometimes further 
constrained by ‘budget lines’ dedicated to specific services or functions. 
It is often extremely difficult, or even impossible, to introduce a degree 
of flexibility into how the budgets are spent. There may in any case be 
a reluctance to cede some part of a ministry’s budget to another sector, 
as it may be seen to be a signal that the current budget allocation was 
unnecessarily generous. By spending on cross-sectoral projects, the 
ministry may fear that in future years its current level of finance will 
come under threat. 
Third, in the same vein, a ministry will usually be judged according 
to an accountability system that focuses on a narrow set of objectives 
specific to its own sector. Pursuit of cross-sectoral projects may appear 
to be diluting its focus on those objectives. Furthermore, if a ministry 
transfers some of its budget to cross-sectoral activities, it may feel 
that it loses some degree of control over how the money is spent and 
the outcomes to be pursued. Existing monitoring systems may be ill-
suited to tracking the use of resources and outcomes. Even if good 
results can be demonstrated, the health ministry may find it difficult 
to argue that those results are attributable to its own efforts. In short, 
if cross-sectoral projects appear to sacrifice some degree of control 
over resources and performance, there may be a reluctance to pursue 
them. The accountability problem becomes particularly acute when 
the goals of the partner sector are in direct conflict with those of the 
health sector — for example, a trade ministry responsible for promoting 
economic growth may be reluctant to implement taxes on alcohol that 
could have an adverse impact on (say) the brewing industry. 
Finally, implementation of cross-sectoral projects can be especially 
challenging. Compared with conventional single-sector projects, which 
have well-established and simple lines of command, a cross-sectoral 
project may require commitment of resources and authorization from 
a variety of sources. There may, moreover, be no arbiter to resolve 
disagreements or accelerate implementation. A potentially effective cross-
sectoral project may therefore languish unimplemented, or be poorly 
implemented, because there is neither the commitment nor the authority 
amongst the participating sectors to overcome challenges and see the 
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project through to a successful conclusion. In short, the administrative 
transaction costs associated with cross-sectoral projects may be very high 
compared to those associated with more conventional projects.
As argued by Rasanathan and colleagues,9 the fundamental difficulty 
associated with cross-sectoral projects is one of governance. They argue 
that ‘effective governance is key to the development of shared policy 
visions and, even more critically, the effective implementation of 
programs and policies that require coordination across different sectoral 
agencies and different levels of government’.10 From the health sector 
perspective, there has often been a failure to learn from the insights of 
disciplines such as political economy and public administration, which 
can offer important lessons for how cross-sectoral working can be 
pursued successfully. In broad terms, the key requirement for successful 
cross-sectoral working is what has become known as ‘collaborative 
governance’, relying on characteristics such as mutuality, trust and 
leadership amongst autonomous partners.11 Such methods are in stark 
contrast to the conventional ‘command and control’ models adopted 
within many ministries.
This chapter is principally concerned with the choice of cross-sectoral 
interventions to address the prevention of non-communicable diseases. 
We shall argue that — with minor amendments — cross-sectoral 
projects can be evaluated using the same cost-effectiveness principles 
as are customarily used elsewhere. However, it is important to keep 
in mind the context of governance when considering cross-sectoral 
projects and to take their feasibility and the costs of implementation 
fully into account.
8.3 Analytic Framework
The normative principle underlying this book is that cost-effectiveness 
analysis should form a central pillar for guiding priorities in the 
prevention of NCDs. As discussed elsewhere, CEA involves estimating 
the incremental costs to the health system of a proposed intervention 
9  Rasanathan et al. 
10  Ibid.
11  Kirk Emerson, ‘Collaborative Governance of Public Health in Low- and Middle-
Income Countries: Lessons from Research in Public Administration’, BMJ Global 
Health, 3.Supplement 4 (2018), e000381 https://doi.org/10.1136/bmjgh-2017-000381
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and comparing them to the health benefits that would arise, with 
adjustments for equity considerations if needed. Health benefits will 
usually be measured in terms of QALYs or their DALY counterparts. 
Projects should then be ranked according to the chosen cost-effectiveness 
criterion and any projects with a cost per QALY that is less than the 
health system’s cost-effectiveness threshold should be funded. We 
assume that the health system’s threshold value indicates the maximum 
the health system is willing to pay for an additional QALY, given its 
current level of funding. 
There has been a great deal of debate in the economics literature 
concerning the appropriate ‘societal’ perspective to adopt for evaluating 
health projects that have consequences (costs or benefits) beyond the 
health sector.12 In this chapter we argue that each sector involved in a 
cross-sectoral project should assess its maximum willingness to pay 
(WTP) for the project according to its usual evaluation criterion, given 
the benefits of the project that would accrue to that sector. Then, if the 
aggregate willingness to pay across the sectors involved exceeds the 
project costs, the project should go ahead. For the health sector, this 
means that, when considering contributing to a cross-sectoral project, 
the same cost-effectiveness principle can be applied to the use of health 
system funds as is used for conventional single sector projects. 
If we know each sector’s WTP for the project, based on its specific 
outcome measures, then we can add these up to obtain the maximum 
joint WTP for the cross-sectoral project across all the collaborating sectors. 
If this exceeds the costs of the project, then it should in principle be 
implemented. The precise funding contribution of each sector to the project 
will be determined by bargaining and agreement, but the contribution of 
each sector should be no more than its maximum WTP. In that way, each 
sector will be participating in a cross-sectoral project that contributes in a 
cost-effective way to its own objectives. Of course, the bargaining over the 
precise magnitude of each sector’s funding contribution will determine 
what sort of a Buy (Best, Wasted or Contestable) the project turns out to 
be for the sector. Fuller details are given in the analytical appendix. This 
approach is consistent with the ‘extended impact inventory’ approach 
12  Bengt Jönsson, ‘Ten Arguments for a Societal Perspective in the Economic Evaluation 
of Medical Innovations’, European Journal of Health Economics, 10.4 (2009), 357–59, 
https://doi.org/10.1007/s10198-009-0173-2
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described by Walker et al.,13 which presents the effects of an intervention 
across a number of sectoral dimensions, and applies societal values to 
each dimension to see if the intervention is worthwhile.
Notwithstanding its conceptual simplicity, the usual challenges 
associated with undertaking persuasive CEA remain when adopting 
this approach, principally those associated with modelling and 
quantifying all the relevant health outcome consequences of the 
initiative.14 Furthermore, compared with conventional applications 
of CEA, the benefits of many cross-sectoral NCD initiatives are likely 
to be distributed across a wide population over a long period, with 
considerable associated uncertainty. In many cases there is likely to 
be a need for country-specific epidemiological modelling to identify 
the impact of NCD initiatives. The need for contextual modelling and 
the high levels of uncertainty are therefore challenging, However, the 
principle of using CEA to assess health-sector actions is not altered, 
even though some of the benefits and costs accrue to other sectors.
The outcomes for one of the partners may be negative for some cross-
sectoral projects. This is particularly the case when the health sector 
seeks collaboration with another sector to create infrastructure that will 
improve health outcomes. For example, a public-transport initiative 
might improve access to healthcare facilities and the associated health 
outcomes. The principle remains the same — the health sector must be 
prepared to reimburse the transport sector for the necessary opportunity 
cost this project would impose. However, if the WTP of the health sector 
exceeds the opportunity cost to the transport sector, then the project 
should be viable and it should in principle be possible to calculate a 
financial transfer between the sectors that satisfies both parties.
Some commentators have argued that cost-benefit analysis may be 
a more appropriate framework than CEA for assessing cross-sectoral 
projects.15 Under CBA, the full range of societal benefits and costs arising 
13 Simon Walker et al., ‘Striving for a Societal Perspective: A Framework for Economic 
Evaluations When Costs and Effects Fall on Multiple Sectors and Decision 
Makers’, Applied Health Economics and Health Policy, 17.5 (2019), 577–90, https://doi.
org/10.1007/s40258-019-00481-8
14  Michael F. Drummond et al., Methods for the Economic Evaluation of Health Care 
Programmes (Oxford: Oxford University Press, 2015).
15  Michelle Remme et al., ‘Financing Structural Interventions: Going beyond HIV-Only 
Value for Money Assessments’, AIDS, 28.3 (2014), 424–34, https://doi.org/10.1097/
qad.0000000000000076
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from a project would be estimated and monetized. This is a legitimate 
(though analytically demanding) approach that will demonstrate 
whether or not — in principle — the project should be implemented from 
a societal perspective. However, CBA ignores the institutional reality that 
society has organized much of the economy into discrete sectors (often 
in the form of government ministries), allocated budget constraints to 
each sector and attached distinct objectives to the use of those budgets. 
Furthermore, many cross-sectoral projects entail the involvement of 
the private (for-profit and not-for-profit) sectors, which may have 
quite different evaluation criteria from those in the government sector. 
These institutional constraints in themselves create the need for cross-
sectoral delivery of certain projects, because the design of society and 
government is not aligned with the organizational needs of the project. 
In these circumstances, CEA is not only a useful device — it is the most 
appropriate tool for assessing cross-sectoral projects, because it takes into 
account the financial constraints and missions of each separate sector.
8.4 Institutional Requirements
Once the case for pursuing a cross-sectoral project has been established 
in principle, an organizational structure for delivering and monitoring 
the project must be established. As noted above, almost by definition, 
existing structures of accountability will often be inadequate for this 
purpose and so some feasible and administratively efficient governance 
structure must be identified. The design of project governance is mainly 
beyond the scope of this chapter, but it is important to offer a brief 
outline of the issues involved in order to give some context to the cross-
sectoral case studies that follow.
There are a number of possible models of collaboration for cross-
sectoral projects16. They include:
• The health sector is the lead actor, but receives support in the 
form of funding or other resources from an external partner to 
support the project. The principal governance requirements 
are proper accountability to the partner for the use of resources 
and the outcomes achieved.
16  Rasanathan et al.
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• The mirror image organizational structure, in which the external 
partner is the lead actor, but receives support from the health 
sector. Here the need is for proper accountability to the health 
sector for the use of resources and the outcomes achieved.
• The health sector is a partner with one or more other sectors to 
implement projects with joint benefits across the sectors, with 
a new delivery entity created under the governance of a joint 
board of control, representing the interests of all partners.
• The health sector is not a formal partner. There is no 
contribution of resources to the implementing sector, but 
the health system seeks to influence the implementation and 
performance of the project in order to promote health system 
goals (in the spirit of ‘health in all policies’).
Such modes of working have become quite widespread in some higher 
income countries and have led to the development of innovative models 
of management and control, known as ‘collaborative governance’.17 
However, such working is less familiar in many LMICs and may require 
new models of leadership and accountability. For example, a common 
failing in cross-sectoral projects is a lack of incentives to prioritize 
the project and a lack of accountability mechanisms to ensure that it 
is delivered in line with expectations. Although willing to participate, 
the individual partners may fail to give the project adequate priority 
because it falls outside their traditional lines of business. Therefore, 
whatever approach to collaborative governance is adopted, it is likely 
that the cross-sectoral project will need sustained leadership, often from 
a very high level of government, to ensure that momentum is sustained 
and that the outcomes promised by the project are fully realized. 
McDaid18 suggests a number of ways in which incentives can 
be introduced to strengthen the chosen governance and leadership 
arrangements. For example:
• the national government (in the form of the finance ministry) 
can make funds available only if an effective cross-sectoral 
partnership is put in place;
17  Emerson.
18  Mcdaid.
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• the national government could introduce a competitive 
process for funding cross-sectoral projects;
• continued funding of such projects could be conditional on 
demonstration of successful implementation and evaluation; or
• government ministries could be required to ‘ring-fence’ part 
of their budgets for cross-sectoral projects.
Each of these approaches has shortcomings and risks and cannot succeed 
without appropriate governance and leadership. However, they might 
serve to underline the importance of cross-sectoral collaboration and 
emphasize the commitment of the government to such working. 
To support the chosen model of governance, there will be a need 
for information and analysis, in order to monitor implementation 
and to check that expected outcomes are being secured. This is often 
challenging because it may be necessary to integrate information systems 
and reporting requirements from the different sectors. Moreover, it 
can often be analytically complex to identify the incremental impact of 
cross-sectoral interventions on expected outcomes. A specific concern 
in many low-income countries is the large range of often incompatible 
reporting requirements required by different donor organizations and 
the preference of such organizations to work in independent ‘silos’ 
rather than collaboratively. 
Although there have been examples of successful intersectoral 
projects, few countries have succeeded in institutionalizing cross-sectoral 
working as a routine undertaking. The UK government experimented 
with a range of cross-sectoral ‘public-service agreements’ as a basis for 
setting ministerial targets and monitoring progress.19 Under Tony Blair’s 
leadership, a Prime Minister’s Delivery Unit was established to drive 
forward cross-sectoral programs such as childhood obesity reduction.20 
However, this cross-sectoral approach generally failed to take account 
of its inherent institutional complexity and it lost momentum under 
subsequent prime ministers. In contrast, the Netherlands has established 
19  Peter C. Smith, ‘Performance Budgeting in England: Public Service Agreements’, in 
Performance Budgeting: Linking Funding and Results, ed. by M Robinson (Washington, 
DC:, 2007), pp. 211–33, https://doi.org/10.1057/9781137001528_12
20  Audit Commission / Healthcare Commission, ‘Tackling Child Obesity  — First Steps’, 
2006, https://publications.parliament.uk/pa/cm200607/cmselect/cmpubacc/157/157.
pdf
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a Centre for Healthy Living that seeks to promote health by adopting 
a systematic approach to the evaluation of cross-sectoral policies. An 
evaluation concluded that the Centre’s approach had been ‘instrumental 
in advancing intersectoral health promotion policy and practice across 
the country’.21 Finland has an especially successful and long-standing 
tradition of cross-sectoral health promotion, using instruments such as 
legislation and administrative reforms at both the national and local 
level.22 Even there, however, it has at times proved difficult to nurture 
a sustained commitment to collecting the evidence necessary to design 
and evaluate cross-sectoral projects. 
8.5 Types of Cross-Sectoral Policies
Whilst it is rare to find cross-sectoral working institutionalized, there are 
a number of examples of successful cross-sectoral policies in countries 
at all levels of development. The types of initiatives designed — at least 
in part — to address NCDs might include, but are not limited to:
• commissioning of non-health infrastructure (e.g., public 
transport);
• adaptation of non-health programs (e.g., changes to school 
curriculum);
• sharing delivery platforms (e.g., health sector use of a postal 
delivery network);
• legislation/regulation affecting non-health sectors (e.g., food 
labelling);
• taxation or subsidy incentives (e.g., alcohol taxes);
• integrated cross-sectoral programs for specific population 
groups (e.g., child development programs).
A report of eighteen case studies by the Public Health Agency of Canada 
and the WHO, albeit focusing on health equity rather than NCDs 
21  Nicoline Tamsma et al., Centre for Healthy Living in The Netherlands: Building 
Sustainable Capacity and Alliances for Effective Health Promotion (Copenhagen, 2018), 
http://www.euro.who.int/__data/assets/pdf_file/0005/365612/gpb-healthy-living-
nl-eng.pdf?ua=1
22  Tapani Melkas, ‘Health in All Policies as a Priority in Finnish Health Policy: A 
Case Study on National Health Policy Development’, Scandinavian Journal of Public 
Health, 41.Supplement 11 (2013), 3–28, https://doi.org/10.1177/1403494812472296
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explicitly, illustrates the wide scope of possible cross-sectoral working 
and the range of possible institutional arrangements.23 In this section 
we present two additional case studies from Hungary and Croatia that 
entailed legally binding commitments to promote the longevity and 
effectiveness of the cross-sectoral program.
Case Study 8.5.1. The public catering decree in Hungary: 
Intersectoral public-health action to improve nutrition and 
address social inequalities with a binding legal instrument24
Context 
Addressing obesity, particularly among children, has been a major 
public-health concern in Hungary to reduce premature NCD mortality 
and morbidity. Having recognized that voluntary actions alone have not 
been successful to change unfavorable nutritional outcomes, a complex 
set of mandatory legal actions have been launched by the Hungarian 
Government. School catering policies have become the target of action. 
Because children spend most of their daytime in preschools and schools 
and 35–65% of their daily energy consumption takes place there, schools 
have a central role in providing access to healthy nutrition and shaping 
children’s health behavior.
Instrument
A binding legal instrument in the form of a Ministerial Decree was 
used to increase vegetable/fruit intake and to reduce fat, salt and sugar 
consumption among school children. The decree came into force on 1 
January 2015. Its scope covered pre-schools, primary and secondary 
schools and other educational settings, inpatient care facilities and 
certain types of services providing social care and child protection.
The decree gives a definition of nutritious and healthy meals 
appropriate for age and physiological status and it considers special 
dietary needs. The decree puts special emphasis on equity by guaranteeing 
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healthy meals free of charge for children in socially disadvantaged 
families, with the cost covered by public funds. The regulation obliges 
caterers to provide adequate information to consumers by displaying 
the amount of nutrients and presence of allergens. A special chapter is 
dedicated to the mandatory training of caterers.
Making It Happen
The preparatory intersectoral work was led by the Ministry of Human 
Capacities, a supra ministry covering the areas of health, social 
affairs, education, youth and sport. Having these various government 
competencies under one roof facilitated more efficient cooperation, 
more effective alignment of intersectoral cooperation and a strong 
social and equity focus included in the decree. The decree was widely 
and thoroughly negotiated with all relevant stakeholders, including 
governmental bodies, professional and public organizations (such as 
caterer associations, parental associations, patient associations and 
local governments) and with the food industry. Robust communication 
activities ensured good understanding of public health goals.
Impact 
Preliminary evaluations show that between 2013–2017, meals in primary 
schools became healthier: there was increased consumption of milk and/
or dairy products, fruits and vegetables and whole-grain products and 
cereals and reduced intake of salt and saturated fatty acids. An impact 
on the food industry was detected in the form of increased willingness 
to reformulate food with respect to fat and salt content.
Case Study 8.5.2. Employing people with disabilities in Croatia: 
intersectoral public health action for an inclusive labor market25
Context 
In Croatia, as in many other countries, people with disabilities are an 
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on their welfare, including their health status, and exacerbates social 
inequalities in society. People with disabilities account for about 12% of 
the total population or about half a million people, of which 48% are in 
the working age group of 19–64 years. 
Strengthening employment opportunities for people with disabilities 
has received growing attention as a civil rights issue and as an under-
appreciated growth opportunity for businesses and government 
budgets. For people with disabilities, employment means greater 
economic self-sufficiency, an opportunity to use their skills and more 
active participation in community life. Employment in this group is 
particularly important because having a disability often means being 
socially isolated, which negatively influences health outcomes over 
time.
Instrument
To address this, Croatia implemented a Law on Vocational Rehabilitation 
and Employment of Disabled Persons in 2013 with the aim of increasing 
the number of employed people with disabilities. 
The 2013 Law focused on regulatory mechanisms including i) quotas 
related to the number of people with disabilities to be employed, ii) 
incentives for employers, iii) the development of integrative workshops 
and working centers which seek to match the abilities of people with 
disabilities to employment opportunities. The Law also regulates 
reasonable accommodations to be made at the workplace, including the 
adaptation of physical barriers and provision of working equipment 
and personal assistance as needed.
The 2013 law was not an isolated instrument but one component of 
concerted policy action to support the welfare of people with disabilities, 
based on prominent regulatory activity developed over 15 years and 
including more than 250 laws, sub-acts and decisions.
Making It Happen
The role of the Public Health Institute was essential in the development 
of the 2013 Law and related intersectoral action. It produced evidence-
based briefings on the impact of employment policies on the health of 
people with disabilities and presented them to various working groups 
that were established to implement the process. The role of producing 
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and presenting actionable evidence proved critical in catalyzing 
intersectoral action. The Institute also coordinated preparatory action 
between the various stakeholders to highlight the importance of civil 
rights and health issues relating to people with disabilities.
Impact 
The 2013 Law serves as an effective incentive for employers to hire, 
recruit and retain people with disabilities. Around 11,000 people with 
disabilities have been newly employed since the implementation of the 
Law.
8.6 Conclusions
Many NCD interventions rely on cross-sectoral collaboration 
for implementation. This chapter has shown that cross-sectoral 
interventions can — in principle — be analyzed from the perspective of 
the health sector in the same way that conventional health interventions 
are assessed, by applying CEA to the health benefits and the costs to 
the health sector associated with the project. However, cross-sectoral 
interventions are, by their nature, complex. The evidence to support 
the analysis will often be in short supply, somewhat speculative 
or of poor quality. Partner sectors are likely to encounter analogous 
difficulties when assessing the project from their own perspectives. 
Therefore, cross-sectoral projects will often need to negotiate serious 
analytic hurdles before they can even be considered. From the health 
sector perspective, the role of public health institutes might therefore 
be crucial in assembling and presenting evidence relevant to the 
development of cross-sectoral NCD policies.
We have argued that it is difficult to ensure successful 
implementation of cross-sectoral projects without paying attention 
to their leadership and governance. To some extent, governance 
requirements can be met by the suitable design of institutional 
arrangements, including the specification of the organization 
responsible for the project, the basis on which it will be held to 
account and the means of assuring satisfactory performance. Models 
of collaborative governance are emerging to address such issues, but 
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these are at an early stage of development. There is ample evidence 
to suggest that any collaborative arrangements must usually be 
buttressed by a very high level of authority, for example through 
legislation, or the direct interest of the prime ministerial office. 
Notwithstanding these challenges, the importance of the social 
determinants of health is so great that — without concerted efforts to 
engage non-health sectors in health promotion — societies will not 
be able to address the rising burden of NCDs with any effectiveness. 
Policy-makers therefore need to put in place arrangements for designing 
appropriate cross-sectoral interventions, assessing their feasibility and 
performance from the perspective of all the sectors involved, designing 
appropriate governance arrangements, monitoring the implementation 
and performance of the initiatives and holding all relevant parties 
properly to account. This is a major undertaking, especially for the many 
countries with little experience of such working. However, the potential 
gains from carefully targeted policies are likely to be very large and 
the necessary investment in analytic capacity and policy commitment 
has the potential to transform a health system’s approach to health 
improvement.
8.7 Analytical Appendix
Consider two sectors (say health H and education E) considering a joint 
project with costs C and joint outputs bH > 0 for health and bE > 0 for 
education. 
First assume that each sector is concerned only with outputs relevant 
to its own sector. These can be measured in composite measures relevant 
to the sector, such as (say) additional QALYs for health and additional 
quality-adjusted years of schooling for education. 
Then health would implement the project on its own if and only if 
C/bH ≤ kH, where kH is the cost-effectiveness threshold for the health 
sector;
and education would implement the project on its own if and only if 
C/bE ≤ kE, where kE is the cost-effectiveness threshold for the education 
sector.
In either case, the non-implementing sector would ‘free-ride’ on the 
cost-effective project for the other sector.
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Suppose now that the project, although producing joint benefits, 
is not cost-effective for either sector on its own. That is, C/bH > kH and 
C/bE > kE. There might nevertheless still be scope for proceeding if the 
costs of the project can be shared between the sectors. Given its cost-
effectiveness threshold, health should be willing to pay the education 
sector a side-payment SH of up to bH*kH to implement, given the 
magnitude of the health-related benefits. Education would in turn be 
prepared to implement if (C-SH)/bE ≤ kE; that is if the side-payment 
is adequate to make the project cost-effective from the education 
perspective.
Rearranging, this implies SH ≥ C - bE*kE to assure implementation, 
with equality to ensure that the project is (just) acceptable to education. 
A similar argument can be advanced to assess the circumstances under 
which health would implement the project, subject to a side-payment 
from education. 
Therefore, there is always scope for implementation so long as the 
project costs C satisfy C ≤ bE*kE + bH*kH, the joint willingness to pay for 
the project. This requires that health makes a co-funding contribution SH 
to education satisfying bH*kH ≥ SH ≥ C - bE*kE. Alternatively, the project 
could be implemented by health if education makes a co-funding 
contribution SE to health satisfying bE*kE ≥ SE ≥ C - bH*kH. This concept 
can be extended to multiple sectors, or even the general public, when 
assessing whether a cross-sectoral project can be a Best Buy. Without 
extending the analysis beyond the health sector, however, we may 
misinterpret from a societal perspective whether a cross-sectoral project 
is a Best Buy, a Wasted Buy or a Contestable Buy. Note that in either 
case the upper limit of the inequality indicates the maximum payment 
the co-funder would be prepared to make to secure implementation, 
whilst the lower limit indicates the minimum payment that the recipient 
would be prepared to receive in order to proceed with the project. The 
actual choice of S would be a matter for bargaining between the two 
sectors. 
Note that there is no scope for joint implementation if project costs 
C are such that C > bE*kE + bH*kH. This means that this cross-sectoral 
project is a Wasted Buy, even when a broader societal perspective is 
adopted.
9. Deliberative Processes in Decisions 
about Best Buys, Wasted Buys and 
Contestable Buys:  
Uncertainty and Credibility1
Kalipso Chalkidou and Anthony J. Culyer
9.1 Introduction
Deciding whether a prospective buy in the field of Non-Communicable 
Disease is likely to be a Best Buy is a tricky business. It is tricky for at 
least the following reasons:
• the criteria for deciding what is a Best or Wasted Buy may not 
be agreed;
• the alternative best uses of resources (the opportunity costs) 
are rarely obvious and may lie outside the health sector;
• the health benefits of NCD interventions are often in the long 
rather than the short term;
• the evidence upon which the appraisal is based is rarely 
complete, accurate, locally applicable, or entirely relevant and 
may even be wholly absent;
• the processes through which a decision or a recommendation 
about a possible Best Buy are made may be secretive, 
1  This chapter draws extensively on Anthony J. Culyer and Jonathan Lomas, 
‘Deliberative Processes and Evidence-Informed Decision Making in Health Care—
Do They Work and How Might We Know’, Evidence & Policy: A Journal of Research, 
Debate and Practice, 2 (2006), 357–71, https://doi.org/10.1332/174426406778023658; 
and Anthony J. Culyer, ‘Deliberative Processes in Decisions about Health Care 
Technologies’, OHE Briefing, No. 48 (2009), https://papers.ssrn.com/sol3/papers.
cfm?abstract_id=2640171 
© K. Chalkidou and A. J. C ulyer, CC BY 4.0  https://doi.org/10.11647/OBP.0195.09
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dominated by specific interest groups and incomprehensible 
to outsiders;
• many of the interventions require collaboration with other 
sectors and non-health organizations;
• the implementation of any decision is hindered by absent 
or underfunded delivery mechanisms and organizational 
weaknesses.
As a result of the foregoing, a decision may lack credibility and generate 
a mistrust of the professional scientists, clinicians and others involved in 
the process and bring the use of cost-effectiveness analysis and kindred 
methods into disrepute.
Each of the recommendations we shall be making can be interpreted 
as implying the use of deliberative processes in decision making 
because there will be so much to discuss: the diseases in questions are 
often insidious in their onset and complex in their manifestation over 
time; the mix of politics, social value judgments and science is thorough; 
the disciplines required to understand the interventions and the genesis 
and treatment of NCDs are in many cases non-medical; the professions 
involved in diagnosis and treatment are likewise many and include non-
medical ones; technical understanding and experience is often limited 
and needs nurturing with opportunities and support to enable local 
people to become both competent and confident. There is considerable 
public interest in finding ways to control the NCD epidemic but less 
understanding of why the apparent priorities are as they are; in many 
cases there are vested interests that could be threatened by effective 
NCD policies but that might be reassured or even brought on side by 
sympathetic initiatives.
9.2 Criteria, Opportunity Costs and  
Social Value Judgments: A Role for Deliberation2
Everyone involved in NCD prevention and treatment needs to be aware 
that social values permeate all aspects of both. Decisions are not merely 
‘technical’, let alone scientific. Moreover, since uncertainty abounds, 
2  Culyer (2009) offers a series of charachteristics of ‘good’ deliberative processes; 
Presidential Commission for the Study of Bioethical Issues, Deliberation for Better 
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all decisions require the exercise of judgment — judgment about the 
quality of the evidence, the difficulty of implementation, the value of 
the outcome, the value of what is forgone as resources are committed 
to specific purposes, the merits of openness and transparency, 
the worthwhile nature of reaching outside the health and finance 
ministries, etc. Any criterion for what constitutes a Best Buy embodies 
value judgments. For example, the commonly encountered ‘threshold’ 
criterion, which a technology must meet to be adopted, states that the 
incremental cost-effectiveness ratio (ΔC/ΔE) must not exceed a stated 
monetary sum, thereby making two social value judgments: that cost 
ought to be a factor and that effectiveness ought to be another. In 
addition, the threshold criterion embodies an assumption (other things 
being equal) that more effectiveness is good. Further analysis reveals 
that effectiveness is typically (though not invariably) indicated by a 
specific measure such as the Quality-Adjusted Life-Year (QALY) or 
averted Disability-Adjusted Life-Year (DALY), which may or may not be 
good proxies for ‘health’. Moreover, other things are not always equal, 
so additional criteria may be required. Two common criteria concern 
the distribution of health benefits (QALYs or DALYs) and the impact the 
intervention has on exposure to out-of-pocket costly healthcare needs. 
Other value-laden issues include how much risk or uncertainty about 
the evidence can be tolerated; whether future costs and benefits ought 
to be discounted (reduced in current value) at the same general rate as 
is used elsewhere in the public sector; how much information (some of 
which may be claimed to be commercially confidential) should be shared 
with stakeholders, including journalists and the general public; whether 
the right technologies have been selected for investigation to start with 
and for use as comparators; how to negotiate clashes between criteria 
when they occur; where to look to find out what values the public and 
its constituents have; and a host of social value judgments regarding 
the processes of decision-making such as: choice of stakeholders; the 
nature of their involvement, if any, in decision-making; opportunities to 
appeal against decisions; the public nature and openness of committee 
and other meetings and the accessibility of their minutes; the frequency 
of revisiting past decisions as circumstances and knowledge change. 
Health, Science, and Technology Policy: Five Steps for Effective Deliberation 1 (2006) sets out 
five steps for effective deliberative approaches for decision-making in health science and 
technology policy. 
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This list merely elaborates the commonplace observation that ‘one size 
(or recommendation) does not fit all (circumstances)’. 
Deliberation is a thoughtful and careful way of reaching a conclusion 
or deciding something. It is not precipitous and discourages rushed 
judgments. It involves the focused evaluation of alternatives, weighing 
their pros and cons. Deliberation can be a learning process — learning 
about the evidence and learning from other people about perspectives 
on the question that had not previously occurred to one. In deciding or 
advising on matters of NCD policy it requires a kind of ‘round table’ 
at which significant interests and expertise are represented. A major 
political value judgment must be made when deciding what counts as 
‘significant’.
Deliberation can be a means of suppressing the arbitrary and 
subjective self-interest of the participants in a decision-making process. 
It should be a means of achieving an impartial state of mind in which 
people of good will restrain their more selfish personal and professional 
concerns in pursuit of a wider, or deeper, idea of the social good: one 
that is not simply the sum of the preferences, prejudices (admirable 
or not, well-informed or not, representative or not, based on mature 
reflection or not) of those participating in the debate. Deliberation 
enables decision-makers to reflect on, discuss openly and possibly 
revise their beliefs about a problem. Is this our top priority? Who loses 
most if we do such-and-such? Do we believe the scientists? Can we trust 
the economists? Have we got the balance between rival assertions right? 
Have we inferred correctly from the evidence? 
9.3 Deliberation Contrasted with Algorithms
In stark contrast to the deliberative process stands the algorithm. An 
algorithm is a systematic mathematical process sequentially linking 
various strands in a decision problem to an outcome. A good example 
of an algorithm for present purposes is the EQ-5D version of the QALY, 
which combines a set of pre-defined characteristics of good health, 
measurable at a variety of intensities and weighted in a pre-set fashion 
in order to measure a health outcome such as the difference between a 
person’s health with and without, or before and after, an intervention or in 
comparison with an alternative intervention. The algorithm can be made 
as complicated as one likes, at least in principle, by adding characteristics, 
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breaking it into social subgroupings, refining intensities, changing the 
weights, including probabilities and uncertainty, discounting future 
health changes and so on; and every element of the algorithm can even 
be moderated by the results of consultative engagement with patients, 
say, for their values, and public health doctors, say, for their beliefs about 
the transitional probabilities. The process remains, however, mechanical, 
unidirectional and, if used without interaction between decision-makers, 
not conducive to learning. Rather than enabling the exercise of judgment 
about the merits and interpretation of evidence, it can conceal important 
conclusions that have already been reached. These may (as with EQ-5D) 
have been reached in earlier (which may even have been deliberative) 
stages of preparation for a decision, but the nature of dispute resolution, 
the character of value judgments, the extent of agreement about them, 
the adequacy of the information base available and so on, all become 
subsumed in the algorithmic solution. The use of algorithms is likely to be 
perceived as impenetrable to those not involved in the decision-making 
process but who may nonetheless have significant stakes in its outcome. 
The effective use of an algorithm requires there to be sufficient expertise 
within the decision group for its members as a whole to have confidence 
that no unacceptable short cuts have been taken. It may often be useful to 
adopt and then adapt someone else’s algorithm. For example, to ensure 
localization and context sensitivity, several countries have developed 
their own QALY weighting system.3
The same may be said about the use of computerized models to 
simulate decision-making processes. Computers are good at storing, 
retrieving, manipulating and communicating information but they 
cannot exercise judgement. A chair or facilitator and members of 
the decision-making unit must perform that function: formulating 
problems, locating those deemed most important, identifying key issues, 
considering risk and uncertainty about the future, forming preferences, 
making judgments of subjective value, establishing goals and objectives, 
appraising the quality of evidence and assessing trade-offs among 
objectives whilst also incorporating algorithms (and explaining them) 
into the decision-making process.
3  Richard Norman et al., ‘International Comparisons in Valuing EQ-5D Health 
States: A Review and Analysis’, Value in Health, 12.8 (2009) 1194–200, https://doi.
org/10.1111/j.1524-4733.2009.00581.x; EuroQol Research Foundation, ‘EQ-5D-3L | 
Valuation’, 2019, https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/valuation/
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9.4 Evidence
Box 9.1 Categories of Evidence
Defined by method of collection, discipline or theoretical framework:
• observational, experimental, quasi-experimental, extrapolated, survey, 
experiential; 
• administrative;
• quantitative, qualitative, economic, ethical/philosophical; 
• narrative review, systematic review, meta-analysis;
• legal, epidemiological, clinical;
• clinical epidemiology, decision science, expected utility theory.
Defined by general purpose:
• problem identification, description or scoping;
• cost-containment, efficacy, effectiveness, cost-effectiveness, 
implementability;
• cultural, leadership, measurement; philosophical-normative, practical-
operational; academically driven by discipline (clinical, biostatistics, 
economics, sociology, etc.).
Defined by source:





• local managerial experience;
• professional (scientific, theoretical, practical, expert, judicial, ethical).
Evidence can be classified in a variety of ways, as summarized in Box 
9.1.4 The first type is based on the method of collection used for the evidence; 
for example, whether it was experimental or from a survey. A second 
4  Source adapted from Jonathan Lomas et al., Conceptualizing and Combining Evidence 
for Health System Guidance, Canadian Health Services Research Foundation (CHSRF), 
(2005).
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focuses on the general purpose to which the evidence would contribute, 
such as identifying a problem or measuring the effectiveness of an 
intervention. A third emphasizes source, usually distinguishing research 
by professional researchers from unsystematic forms of evidence such 
as ‘clinical experience’. 
When people in the clinical, management or policy worlds are asked 
what they consider to be evidence, they tend to think of a medley of 
scientifically verifiable and locally idiosyncratic types of information, 
which Lomas et al. call ‘colloquial’ interpretations, drawing on a wide 
range of experiences and using a broad definition of evidence.5 Thus, 
clinical effectiveness data compete with expert assertion, cost-benefit 
calculations are balanced against political acceptability and public- 
or patient-attitude data are combined with the recollection of recent 
personal encounters with strong personalities. The evidence-informed 
decision-making movement has, however, engendered for many of 
them a greater regard for the more scientific forms of evidence than 
would have been usual thirty years ago and there is an increasing 
tendency to ‘dress up’ the conclusions of a decision-making process in 
the language of science. 
By contrast, the research community’s view of evidence, both 
in clinical subjects and the social sciences, tends to be restricted to 
information generated through a prescribed set of processes and 
procedures recognized as scientific. In this case, both scientific tradition 
and more modern influences from the philosophy of science determine 
what is evidence, which can be summarized as knowledge that is 
explicit (that is, codified and propositional); systematic (that is, uses 
transparent and explicit methods) and replicable (that is, it can be 
tested to see whether others following the same methods with the same 
samples arrive at the same results).
At a basic level, the general notion of evidence concerns actual or 
asserted facts (a fact is defined as a ‘thing certainly known to have occurred 
or be true’ [Oxford English Dictionary] intended for use in support of 
a conclusion. Most decision-makers view evidence colloquially and 
eclectically as anything that increases their degree of belief in a fact (Fig. 
9.1). They define it by its resonance with experience and relevance to the 
5  Ibid.
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kinds of decisions they have to make. This is the first form: colloquial 
evidence. The second and third forms are two versions provided by 
scientists. Scientists’ views on the role of evidence divide into those 
who emphasize context-free universal truths (identified closely with 
evidence-based medicine) and those who emphasize a context-sensitive 
role for evidence in a particular decision process (identified more with 
the applied social sciences).
Fig. 9.1 Three different forms of evidence. 
The appropriate methods for obtaining scientific evidence about context 
factors are not the same as those for obtaining evidence related to the 
testing for the validity of bioscientific hypotheses. Though the research 
designs may be very different, the scientific principles are, however, 
the same. Hypothesis testing is common to both, as is the control of 
‘confounding’ variables. But both the phenomena hypothesized about 
and the method required to do the testing differ. The intent when using 
context-free evidence is to ensure ‘internal validity’ of evidence, that is, 
evidence that is free from bias. The intent when using context-sensitive 
evidence is to ensure ‘external validity’ of evidence, that is, evidence that 
the intervention will work under conditions likely be met in a practical 
context. Thus, whereas the gold standard procedure for controlling for 
confounding variables in clinical sciences might be a form of prospective 
randomized trial, where randomization does much of the work of 
removing bias from confounders, the gold standard for quantitative 
social scientists in assessing the resource consequences of adopting a 
technology is more likely to be a retrospective multivariate econometric 
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study with contextual elements specifically modelled as determinants. 
Scientific evidence on context must, in addition, be more than merely 
medical and can embrace professional attitudes, ease of implementation, 
organizational capacity, competences of workforce, forecasting future 
burdens of sickness, economics or finance and ethics. Not all will always be 
relevant, but some will always be relevant (given the context). Colloquial 
evidence will typically embrace the resources likely to be available, 
expert and professional opinion on a matter, political judgment, values, 
habits and traditions, lobbyists and pressure groups and the particular 
pragmatics and contingencies of a situation. In healthcare decisions, all 
three kinds of evidence are more or less constantly in play.
These three different forms of evidence — colloquial, context-
free scientific and context-sensitive scientific — will not combine 
of themselves to determine Best or Wasted buys. Combining and 
interpreting them requires a process and the most suitable process may 
be deliberative through, for example, what has recently been described 
as qualitative Multi-criteria Decision Analysis.6 Regardless of which of the 
three types of evidence one is considering, any suitable process needs to 
address a common set of complexities: 
• all evidence needs to be interpreted;
• its relevance needs to be assessed;
• its quality needs to be assessed;
• its applicability in the current context, as compared with that 
in which it was generated or collected, needs to be assessed;
• its completeness needs to be assessed;
• qualitative evidence needs to be weighed alongside 
quantitative;
• any technical controversy over its standing needs to be settled;
• the precision of estimates of effectiveness needs to be assessed;
• the robustness of the results needs to be tested by sensitivity 
analyses;
6  Rob Baltussen et al., ‘Multicriteria Decision Analysis to Support HTA Agencies: 
Benefits, Limitations, and the Way Forward’, Value in Health 22.11 (2019), 1283–1288, 
https://doi.org/10.1016/j.jval.2019.06.014
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• the evidence, of whatever kind, needs to be considered on the 
basis of values to determine priorities, ‘worthwhileness’ and 
to specify what ought to be done and by whom.
Facts do not ‘speak for themselves’ and any single piece of evidence, 
whether of the scientific or colloquial type, is rarely complete 
enough to enable guidance to be created without further evidence 
and assessment. To be useful, a deliberative process must therefore 
facilitate the combination and interpretation of the evidence for the 
purpose intended and enable those engaged in it to explain why they 
decided as they did. 
Maintaining a common understanding of what constitutes evidence 
is likely to become increasingly difficult as further interest groups or 
stakeholders are added in any procedure for determining Best Buys. 
Conversely, the more homogeneous the group in terms of professional 
background and level of responsibility, the less tension and disagreement 
is likely to exist about what constitutes permissible evidence. However, 
it seems unlikely that the object ought ever to be to maximize the 
homogeneity merely for the sake of achieving a common understanding. 
It is convenient if a common understanding can be reached but, if it cannot 
be reached, then the differences and the reasons for them are worth facing 
up to explicitly and should not be obscured through selection bias. 
In short, the decision-making process ought to provide a means 
through which the preferences of participants can be transformed 
rather than merely aggregated; it should be a process that allows 
participants to change their minds; it should allow the three kinds 
of evidence to be assessed and combined — colloquial (e.g., from 
professional experience, case-studies, other gossip); context-free science 
with high internal validity (such as evidence from explanatory RCTs); 
context-specific science with high external validity (such as evidence 
from cost-effectiveness analyses, pragmatic trials,7 most budget impact 
analyses) — and it should enable such things that people bring to the 
deliberation to count (such as their own values, experience, attitudes to 
risk and degrees of understanding and knowledge).
7  BOLDER research group, ‘Better Outcomes through Learning, Data, Engagement, 
and Research (BOLDER) ? A System for Improving Evidence and Clinical Practice 
in Low and Middle Income Countries’, F1000Research, 5 (2016) 693, https://doi.
org/10.12688/f1000research.8392.1 
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Some of the problems posed by evidence that might be resolvable 
through deliberation include situations where:
• evidence from more than one expert discipline is involved;
• evidence from more than one profession is involved;
• some stakeholders’ interests are threatened by evidence;
• there are technical disputes to resolve;
• evidence is scientifically controversial;
• evidence is incomplete;
• evidence is lacking;
• evidence gathered in one context is to be applied in another;
• issues of outcome, benefits and costs go beyond the 
conventional boundaries (of concept and end-point) of 
medical research design;
• there is substantial uncertainty about key values; 
• there are risks (quantified or unquantified) to patients that 
need to be assessed and weighed;
• there are risks (e.g., of malpractice suits) to professionals that 
need to be assessed and weighed;
• there are other social and personal values not taken into 
account in the scientific evidence;
• there are issues of equity and fairness of treatment (e.g., of 
patients similar in many respects but differing in their capacity 
to benefit);
• there are issues of implementability and operational feasibility;
• there are issues of short-term financial feasibility;
• there are reasons to suppose that implementation may 
seriously destabilize local strategies and priorities;
• wide professional ‘ownership’ is desired;
• public credibility is desired;
• political ‘trust’ is involved (e.g., no unpleasant surprises for 
ministers; help on how to handle unwelcome or embarrassing 
evidence).
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When there is evidence from more than one expert discipline, issues 
can easily arise about language. ‘Cost’ and ‘outcome’ are unlikely to 
mean the same to a clinician, a sociologist or an economist. Confusion 
may arise through failing to distinguish between statistical, clinical and 
policy significance. Views about the relative virtues of cross-sectional 
and time-series data are not shared. Bayesians and frequentists do not 
always see eye to eye. Equilibrium gets confused with equipoise. There 
are a lot of conventions that are manifestly different between disciplines 
and these can easily become barriers to communication. Many such 
issues can be resolved only by talking and, moreover, by frequent 
engagements of a deliberative character. 
Feeling threatened is something that is dangerous, not only for the 
person threatened but also for the whole decision-making process. A 
deliberative process can be one in which people’s interests are exposed 
and the character of the risks to which they are exposed is assessed. That 
in itself may be sufficient protection, for example, through enabling 
those affected to take preliminary steps to minimize adverse impacts, 
or for further analysis of the size of the threat and for exploration of any 
more extensive protection or compensation that might be warranted. 
But further protection may be required if, say, the revelation that a 
member of a committee espoused an unpopular political position were 
to lead them to subsequent discrimination and harm.
Deliberation is likely to be useful when there are technical disputes 
to resolve in connection with evidence. These are endemic and non-
trivial. Some relate to the evidence itself, some to its generation and 
some to the methodology used to summarize it.
Complex problems will often benefit from deliberation. Examples 
include issues concerning outcomes, benefits or costs, any or all of 
which might go well beyond someone’s conventional boundaries 
of concept (for example, when the principal beneficiary is a family 
member rather than the patient); issues of metric (biological proxy 
measures of outcome like blood pressure in comparison to the clinical 
or social consequences of such indicators); issues of end point (end of 
trial versus remainder of expected life); issues of uncertainty about 
the importance attached to different elements in a decision; and lots of 
other types of issue too.
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9.5 Uncertainty
Uncertainty is all-pervading, both that which is formally measured 
through conventions about statistical significance (for example, less 
precision in an estimate is usually indicated by a larger standard error) 
and that which is qualitatively expressed, for example, via a Likert scale 
of ‘more or less’ likelihood. There can be uncertainty about the right 
methodology (should benefits be discounted by the same factor as costs? 
Was the sample large enough to make statements with confidence about 
the experience of subgroups of patients? Was the measurement of other 
social and personal values, which are not normally taken into clinical 
account, appropriate? Ought such effects be taken into account at all?) It 
seems plausible to suppose that open discussion about matters of which 
one is uncertain may help to locate more precisely the reason for the 
uncertainty and whether, for example, it is the sort of uncertainty that 
can be resolved by having more, or better, data; or that needs greater 
investigation of analytical methods; and whether there is a comfort in 
agreeing on a course of action about which there is a consensus, even 
though everyone is uncertain. When taking politically controversial 
decisions, it may be helpful for the minister to be able to explain in 
Parliament and to the public that there has been extensive consultation, 
much deliberation, full consideration of expert opinion and the ample 
weighing of the values of those most affected by the decision. At a 
minimum, the case becomes easier to make that the decision was not 
arbitrary and its rationale becomes communicable. This will take on 
specific significance if the decision is an unpopular one. Both the process 
and its outcome help to make a decision credible and to legitimize it. 
9.6 Credibility
Decisions taken on behalf of other people need to be credible. That 
is, the ‘other people’ in NCDs, typically the public at risk and the 
professionals who care for them, want to know that decisions taken 
were taken for good and understandable reasons (especially when 
controversial); that they were taken in a way consistent with generally 
accepted social values; and that they were informed by the best quality 
evidence available. This is true not only of decisions regarding Best Buys 
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but also, and perhaps especially, of buys judged likely to be Wasted, 
especially if such buys have powerful political or commercial backing. 
If the public is going to be able to judge the credibility of the decisions 
made on its behalf, it needs to be able to penetrate the decision-making 
process to discover whether the reasoning was sound (and other 
possible decisions considered); the value judgments were acceptable; 
and whether the evidence was appropriately identified and interpreted. 
The public will want to be satisfied that those involved in the process 
were competent (for example, that the scientists were men and women 
of unimpeachable scientific authority and integrity); that they sought to 
promote the public interest and not a narrow selfish interest (whether 
personal, professional or commercial); and that those who were there to 
represent the public were appointed in a fair way and could be held to 
account. Credibility is further served if all stakeholders (i.e., any group 
likely to be affected for good or ill by the decision) have had a reasonable 
opportunity to comment before a final decision is taken.
Deliberative processes often include, but are not the same as, 
consultation or comment. A famous example of consultation was 
the Oregon experiment to help determine which clinical procedures 
ought to be included in that state’s Medicare program. It was not a 
deliberative process, but a process of consultation in which there were 
forty-seven community meetings, twelve public hearings and fifty-four 
panel meetings for healthcare providers. All the data thereby gathered 
was fed into a committee (the Oregon Health Services Commission) 
for prioritization of procedures.8 Thus, many were consulted prior 
to the decision but relatively few participated in its making. The 
Commission itself doubtless engaged in much deliberation but the 
participation of all those people who were consulted was not part of 
the decision-making.
Nor are opportunities to comment the same as deliberation. The 
National Institute for Health and Care Excellence in England and Wales 
(NICE) provides opportunities for people to comment on technologies 
that are under appraisal, alongside consultation and deliberation. The 
public in general might be invited to comment (say, via a website) and 
8  Michael Garland, ‘Rationing in Public: Oregon’s Priority-Setting Methodology’, in 
Rationing America’s Medical Care: The Oregon Plan and Beyond. Brookings Institution, 
ed. by M. A. Strosberg et al. (Washington, DC: Brookings Institution, 1992).
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some individuals or organizations may receive specific invitations. Like 
consultation, commenting can be a part of a deliberative process, but 
it is not to be equated with one. Neither consulting nor commenting 
involves mutual deliberation. There is limited interchange, there is 
restricted participation and neither is an arrangement for the actual 
taking of decisions, whereas deliberative processes can embody all 
three. This is what makes deliberative processes different.
One approach that embraces the whole range of comment, 
consultation and deliberative participation is the Cooperative 
Discourse Model.9 This entails the elicitation of values and criteria from 
stakeholder groups, the provision of policy options by expert groups 
and the evaluation and design of policies by randomly selected citizens. 
This was a model that seems to have been used to good effect by the UK 
Committee on Radioactive Waste Management, which is an independent 
committee established by the UK Government in November 2003 to 
develop recommendations for the long-term management of higher 
level radioactive wastes and which faced a classic set of issues of science 
and of value. Its terms of reference explicitly required that the review 
be carried out in an open, transparent and inclusive manner […] 
must engage members of the UK public, and provide them with the 
opportunity to express their views. Other key stakeholder groups 
with interests in radioactive waste management […] [had also] to be 
provided with opportunity to participate. The objective of the review 
[was] to arrive at recommendations which can inspire public confidence 
and [were] practicable in securing the long-term safety of the UK’s 
radioactive wastes. It must therefore listen to what people say during the 
course of its work and address the concerns that they raise.10 
The use of the Cooperative Discourse Model seems to have been a 
success — at least as judged by the criterion that the client knows best. 
The Government’s response to the report included this: 
The reflection of a wide range of viewpoints, and a basis in sound science 
is key to providing recommendations which inspire public confidence 
for managing the wastes in the long term, providing protection for 
9  Ortwin Renn, ‘A Model for an Analytic−Deliberative Process in Risk Management’, 
Environmental Science & Technology, 33.18 (1999), 3049–55.
10  Committee on Radioactive Waste Management, Managing Our Radioactive Waste 
Safely (London, 2006).
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people and the environment. The open and transparent manner in 
which CoRWM has conducted its business has been ground breaking. 
Accordingly, Government welcomes CoRWM’s report and believes it 
provides a sound basis for moving forward. Most recommendations 
can be acted on immediately; others require us to undertake more 
work.11
The production of evidence itself will often have embodied deliberative 
processes as, for example, in scientific discussions of the design of a 
research project, clinical trial or systematic review. The typical scientific 
evidence on (context-free) efficacy is summarized in the form of 
narrative reviews, systematic reviews or meta-analyses (each of which 
will themselves have involved a lot of ‘judgment’) and each of which in 
itself will have often embodied mini-deliberative processes. Thus, within 
deliberative processes lie further deliberative processes. ‘Artificial’ 
evidence, such as evidence from economic/epidemiological models that 
extrapolate beyond experimental time periods, is particularly suited 
to deliberation, as is the evidence that comes up through colloquial 
processes like public meetings, hearings from special witnesses and 
survey material. 
No evidence is totally authoritative; it all involves judgments by 
people in its creation, assembly and presentation. Some of the judgments 
are technical and scientific (was the most efficient estimating procedure 
used?). Some are scientific but also interpretive (are the trial results 
applicable in another setting?). Some are scientific and judgmental 
(were the scientists at risk of bias from their funding sources?). Some 
have the character of social value judgments (was the outcome measure 
an appropriate indicator of health?). Moreover, these are all questions 
about which it is perfectly possible for both scientifically trained and 
lay people to disagree amongst themselves. To be credible, therefore, 
all these judgments need to be seen to have been reasonable under the 
prevailing circumstances.
11  UK Government, Response to the Report and Recommendations from the Committee 
on Radioactive Waste Management (CoRWM) by the UK Government and the Devolved 
Administrations (London, 2006).
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9.7 Some Characteristics of Deliberative Processes
The table below12 offers some specific practical examples of how some 
common features of deliberative processes can be given a practical form. 
Table 9.1 Principles of good governance for HTA.
Principles Examples of how bodies can adhere to these principles 
Independence Maintain arm’s length from government, payers, industry 
and professional groups; 
Strong and enforced conflict of interest policies. 
Transparency Meetings are open to the public; 
Material placed online; decision criteria and rationale for 
individual decisions made public.
Consultation Wide and genuine consultation with stakeholders; 
Willingness to change decision in light of new evidence. 
Scientific basis Strong, scientific methods and reliance on critically 
appraised evidence and information. 
Timeliness Decisions produced and published in a reasonable 
timeframe. 
Consistency The same technical and process rules are applied to all 
priority-setting channels. 
Regular review Regular updating of decisions and of methods, with 
review dates specified in final reports. 
Contestability The decision-making process can be challenged, through 
legal challenges or non-judicial appeal mechanisms. 
We are not advocating the indiscriminate use of deliberative processes. 
They are costly and may not be worth their cost. In LMICs, in particular, 
gaining credibility may present challenges that are hard to overcome, such 
as the availability of sufficiently qualified and independent individuals 
or the availability of evidence of direct local relevance. Under such 
12  Reproduced from Francis Ruiz, Kalipso Chalkidou and Laura Morris, ‘Process 
Matters for Priority Setting and Health Technology Assessment in Indonesia’, 
F1000Research, 8 (2019), https://doi.org/10.7490/f1000research.1116839.1
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circumstances, the transparency of the decision-making process becomes 
even more important, if the client population is to believe that what is 
claimed as a Best Buy is truly likely to be one and that interventions 
deemed to be Wasted Buys really are inferior to the alternatives.
In the early days of the life of an advisory or decision-making 
organization that is to determine Best Buys, in-camera sessions might be 
used more frequently than in its more mature days, because at least some 
members might feel intimidated by the presence of a public, or afraid of 
unpleasantness downstream should their support for a decision lead to an 
unwanted outcome, or simply wish to avoid looking indecisive because 
they have changed their mind about something. Other participants 
(local politicians, aggressive lobbyists, show-off clinicians) may play to 
the crowd. Plainly, such measures will militate against credibility, so 
conflict between the ideal and the practical should be minimized as much 
as possible. For example, minutes could record disagreements without 
naming names, meetings could be held with only a select group of public 
witnesses present and absent evidence could be replaced with the best 
possible local or international expert opinion.
9.7.1 Case Study: The (then) National Institute for Clinical 
Excellence (England and Wales)
NICE was created to be an authoritative foundation of ‘clinical 
governance’. This was (and is) a framework through which National 
Health Service (NHS) organizations are accountable for continually 
improving the quality of their services and safeguarding high standards 
of care by creating a local environment for managing accountability 
and the audit of clinical practice. From the beginning, it was decided 
that NICE’s procedures would be conducted with the highest degree of 
transparency possible and with much participation by ‘stakeholders’. 
These were categorically defined as patients, informal caregivers, clinical 
and other professional caregivers, healthcare managers, manufacturers, 
researchers and the public in general. NICE insisted on being located 
within the NHS rather than the Department of Health (ministry). It 
sought the respect of the overwhelming majority of the country’s 
clinical-and-health-service research community and the support of the 
Royal Colleges of Medicine and other bastions of professional life. The 
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royal colleges are the principal professional associations of the United 
Kingdom’s medical professions. They comprise: The Royal College of 
Anesthetists, The Royal College of General Practitioners, The Royal 
College of Obstetricians and Gynecologists, The Royal College of 
Pediatrics and Child Health, The Royal College of Pathologists, The 
Royal College of Psychiatrists, The Royal College of Radiologists, The 
Royal College of Surgeons of England, The Faculty of Public Health 
Medicine, The Faculty of Pharmaceutical Medicine and The Faculty of 
Occupational Medicine.
It was important to NICE that its guidance could not be dismissed as 
cranky, under-researched, or second rate. But it also had to be acceptable 
to the NHS’s users and fair to the inventors and manufacturers of the 
various interventions in a huge range of patient-management pathways. 
It also had to be deemed ‘do-able’ by the managers. There had to be lots 
of opportunities for skeptics and any who might feel threatened to air 
their concerns and for NICE to respond appropriately.
Some of the ways in which NICE sought to be a model of deliberative 
process were:
• there were open Board meetings that took place bi-monthly 
around England and Wales, accompanied by public receptions 
and ‘Question and Answer’ sessions with the chair;
• minutes were published on the NICE web pages before 
confirmation by the Board;
• there was a Partners’ Council. This had a statutory duty to meet 
once a year to review NICE’s annual report. In practice, in the 
early days it met more frequently as a source of advice and a 
forum for exchanging ideas and developing the future plans 
for the Institute. Its membership included representatives 
from organizations with a special interest in its work such 
as patient groups, health professionals, NHS management, 
quality organizations, industry and trade unions. Members 
were appointed by the Secretary of State for Health (English 
minister) and the Welsh Assembly Government. It was 
abolished after a few years having served a useful function in 
getting NICE respectably off the ground;
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• there was a Citizens’ Council. This was a form of ‘citizens’ 
jury’ that considered social-value-laden matters referred to it 
by the Institute’s Board. Its thirty members had no economic 
involvement in the healthcare system and were selected to 
representative of the regions and demographic characteristics 
of England and Wales. Members were paid £150 per day plus 
their travel and subsistence expenses. It met twice a year and 
adopted a deliberative approach and could call witnesses and 
commissions papers. It was managed at arm’s length from 
NICE by a company specializing in research and community 
consultation;
• the membership of the Technology Appraisals Committee 
was set broadly. The Committee was a standing advisory 
committee of the Institute, which had a very public profile since 
it was the source of NICE’s recommendations for the NHS. 
Members were appointed for a three-year term. They were 
drawn from the NHS, patient and care-giving organizations, 
relevant academic disciplines and the pharmaceutical and 
medical devices industries. Names of Appraisal Committee 
members were posted on the Institute’s website;
• there were extensive consultation exercises throughout the 
appraisals process;
• there was an appeals procedure. There were three grounds 
for appeal: that the Institute had failed to act fairly and 
in accordance with the Appraisal Procedure set out in its 
Guidance to Manufacturers and Sponsors; that it had prepared 
Guidance which was perverse in the light of the evidence 
submitted; and that it had exceeded its legal powers;
• there were consultative processes about process. For example, 
the process through which the procedures for health 
technology assessment were developed involved several 
committees with representation of experts from a variety of 
stakeholders. The outcome was a public document describing 
procedure;13
13  National Institute for Clinical Excellence, Guide to the Methods of Technology Appraisal 
(London, 2004).
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• there were extensive liaisons with eleven Royal Colleges, 
seven Independent Academic Centres and seven National 
Collaborating Centres. NICE created the National 
Collaborating Centres within consortia that consisted of 
the royal colleges, professional bodies and patient/carer 
organizations for developing clinical guidelines. They were: 
the National Collaborating Centres for Acute Care, Cancer, 
Chronic Conditions, Mental Health, Nursing and Supportive 
Care, Primary Care and Women and Children’s Health;
• there was considerable joint working with NHS R&D and 
the National Coordinating Centre for Health Technology 
Assessment. This was a part of the Wessex Institute for Health 
Research and Development at the University of Southampton. 
It coordinated the national HTA research program on behalf 
of NHS R&D.
Thus, it was determined that the process of technology appraisal was to 
be open, multi-disciplinary, multi-professional and multi-institutional 
and that it would have ‘lay’ participation. It was heavily dependent 
upon people’s willingness to serve pro bono. It was plain from the 
outset that very large numbers of people would be involved and the 
Institute itself would be largely a virtual organization.14
Several of these features have been modified since 1999, mainly on 
grounds of expense, and it is easy to see that NICE, as a ‘Rolls Royce’ of 
such institutes, cannot be a model to be adopted wholesale anywhere 
else, nor has it survived as such in England and Wales. Its features, 
however, facilitated deliberation in evidence-informed decision-making 
and can readily be adapted to suit different contexts.
9.8 Conclusions
A deliberative process for selecting Best Buys is likely to: 
• identify relevant clinical, social and political contexts for 
interpreting context-free scientific evidence about NCDs, 
14  Anthony J. Culyer, ‘NICE’s Use of Cost Effectiveness as an Exemplar of a 
Deliberative Process’, Health Economics, Policy, and Law, 1.Pt 3 (2006), 299–318, 
https://doi.org/10.1017/s1744133106004026
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simply by virtue of the fact that representative people and 
people who can interpret the scientific evidence on external 
validity are there at the table;
• generate guidance that is consistent with the context-free 
scientific evidence and its reasonable interpretation in 
particular contexts;
• command a wide credibility in professional circles and 
beyond, simply because respected professionals are there at 
the table; 
• result in a quality and power of residual opposition that is 
low. The prediction is that there will be less hurt, less offence 
and therefore less opposition if deliberation is used than 
without it;
• result in less alienation. If the process is one whose design was 
actually shaped by everybody with a stake in its outcome, so 
that they actually become parties to its design and committed 
to the nature of the process, stakeholders are much less likely 
to be alienated by its outcome. After all, it was a process that 
they helped to design and even approved, rather than some 
other arbitrary process that somebody else invented and 
thrust upon them. They are more likely to be able to live with 
the consequences of deliberation, even if on occasion the 
approved process produces results that are not their preferred 
ones;
• generate guidance whose implementation will be speedy;
• identify impediments to the implementation of guidance and 
to find solutions to those impediments: ways of leaping over 
or going around them;
• identify knowledge gaps that might be resolved by further 
enquiry and research.
Finally, deliberation is not about establishing consensus. There is a lot 
to be said, however, for discovering whether there is or is not consensus 
and, when there is disagreement, whether it is a matter of fact that might 
be resolved by further research and other factual enquiry, a matter 
of methodology or procedures which might be resolved by specialist 
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workshops, or a matter of value which may need a political resolution 
at a high level. The important principle to keep in mind is that of facing 
up to difficulties rather than burying them and of demonstrating 
reasonableness in the ways they are handled. Therein lies credibility.

10. Summing Up
Wanrudee Isaranuwatchai, Rachel A. Archer  
and Anthony J. Culyer
The global community has to reckon with the scourge of non-
communicable diseases (NCDs). 
In an ideal world, it would be easy and straightforward to prioritize 
and allocate resources to interventions that have the maximum impact 
on health, while ensuring fair distribution of resources to all and 
minimizing the risk of financial hardship from out-of-pocket payments. 
In the real world, however, things may be quite different. Some may 
be opposed to allocating healthcare resources according to impact and 
fairness (they have their own agendas); there is evidence but it is patchy 
and not always agreed by the experts; sometimes that evidence may not 
be suited to ‘our’ situation; sometime there is simply no evidence at all. 
There are other uncertainties: do we have the resources to make a real 
impact; are our methods good enough; can we train up enough people 
with the right skills; can we institutionalise the necessary expertise; and 
can we find ways of making complicated matters accessible to public 
understanding? In the real world, things may not be perfect, they may 
not be ideal but it is our world. It is the world that is continuously 
challenged by the burden of NCDs.
In this book, we have tried to bring the two worlds together. We have 
made a number of suggestions for mitigating some of these difficulties 
and enhancing the ability of societies to address the rising burden of 
NCDs more effectively and efficiently. We have provided definitions of 
commonly used terms and some basic theory drawn from the literature 
on effectiveness and cost-effectiveness encompassing the fields of 
© Chapter’s authors, CC BY 4.0  https://doi.org/10.11647/OBP.0195.10
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epidemiology and economics. Specifically, we have presented some 
ideas and tools to help decision-makers and NCD program managers 
in ‘NCD Units’ to navigate this complex landscape. These ideas include 
but are not limited to:
• creating organizational structures that facilitate multisectoral 
approaches (Chapter 2);
• creating authoritative guidance at the global level to impact 
effectively on political leadership and at the local level for 
NCD program managers (Chapter 2);
• introducing Systematic thinking for Evidence-based and 
Efficient Decision-making (SEED) as a tool for evaluating the 
evidence base — a thinking aid with step-by-step practical 
considerations to implementing Best Buys and avoiding 
Wasted Buys (Chapter 3);
• using a list of Additional Considerations to supplement cost-
effectiveness analysis and to complement SEED (Chapter 4);
• sharing real-world case studies of Best Buys, Wasted Buys and 
Contestable Buys (Chapters 4 and 5);
• working systematically and in a participatory manner with 
stakeholders (Chapter 5);
• providing a means of effective interrogation of claims that 
particular buys are Best Buys through descriptions of some 
common characteristics of inefficient spending (Chapter 5);
• using realistic thresholds and selective implementation 
strategies (Chapters 5 and 9);
• using the Transferability Framework and Checklist for 
assessing the applicability of research results obtained 
elsewhere (Chapter 6);
• cultivating awareness of the strengths and weaknesses of 
different research designs with real-world examples on the 
efficacy of lifestyle interventions on health harming behavior 
for type 2 diabetes, cardiovascular diseases and hypertension 
(Chapter 7);
 17310. Summing Up
• devising accountability and governance arrangements that 
match multisectoral requirements (Chapters 8 and 9); and
• understanding that one size seldom fits all in a health care 
system, especially across countries (throughout).
Key learnings and practical frameworks (the SEED Tool, transferability 
checklist, etc.) also have potential beyond NCDs and, indeed, across the 
whole fields of public and personal healthcare and of non-healthcare 
that impacts on health (the environment, education, housing and so on). 
These are topics for future research. While this book cannot solve all 
problems related to the political economy of NCDs, it does offer key 
considerations and guidance for assessing and implementing NCD 
interventions. We are not denying that there is a long road ahead and 
that universal problems may lack universal solutions. We know full 
well that prevention is often seen as the poor cousin of treatment and 
that budgets often have no room for it. Program managers usually find 
themselves navigating systems with inappropriate disease-focused 
structures and decisions frequently need to be made in the absence of 
good quality local evidence. However, there are also lessons we can 
learn from other countries and there are methods we can employ to 
assess the applicability of other countries’ evidence.
Buys, in the case of NCD prevention, are often complex, constantly 
changing and unique to each jurisdiction. There is no ‘one-stop shop’ 
for policy-makers, but there are positive steps we can take to continue 
our efforts to support NCD prevention. This work has been a guide to 
some of the more important ones.
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